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Abstract
Background
Early accurate detection of all skin cancer types is important to guide appropriate management, to reduce morbidity and to
improve survival. Basal cell carcinoma (BCC) is almost always a localised skin cancer with potential to infiltrate and damage
surrounding tissue, whereas a minority of squamous cell carcinoma (cSCC) and invasive melanoma are higher risk skin
cancers with the potential to metastasise and cause death. Dermoscopy has become an important tool to assist specialist
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clinicians in the diagnosis of melanoma, and is increasingly used in primary care settings. Dermoscopy is a precision-built
handheld illuminated magnifier that allows more detailed examination of the skin down to the level of the superficial dermis.
Establishing the value of dermoscopy over and above visual inspection for the diagnosis of BCC or cSCC in primary and
secondary care settings is critical to understanding its potential contribution to appropriate skin cancer triage, including
referral of higher risk cancers to secondary care, the identification of low risk skin cancers that might be treated in primary
care and to provide reassurance to those with benign skin lesions who can be safely discharged.
Objectives
To determine the diagnostic accuracy of visual inspection and dermoscopy, alone or in combination, for the detection of a)
BCC and b) cSCC, in adults. Studies were separated according to whether the diagnosis was recorded face-to-face (in-
person) or based on remote (image-based) assessment.
Search methods
We undertook a comprehensive search of the following databases from inception up to August 2016: Cochrane Central
Register of Controlled Trials; MEDLINE; Embase; CINAHL; CPCI; Zetoc; Science Citation Index; US National Institutes of
Health Ongoing Trials Register; NIHR Clinical Research Network Portfolio Database; and the World Health Organization
International Clinical Trials Registry Platform. We studied reference lists and published systematic review articles.
Selection criteria
Studies of any design that evaluated visual inspection and/or dermoscopy in adults with lesions suspicious for skin cancer,
compared with a reference standard of either histological confirmation or clinical follow-up.
Data collection and analysis
Two review authors independently extracted all data using a standardised data extraction and quality assessment form
(based on QUADAS-2). We contacted authors of included studies where information related to the target condition or
diagnostic threshold were missing. We estimated accuracy using hierarchical summary ROC methods. Analysis of studies
allowing direct comparison between tests was undertaken. To facilitate interpretation of results, we computed values of
sensitivity at the point on the SROC curve with 80% fixed specificity and values of specificity with 80% fixed sensitivity. We
investigated the impact of in-person test interpretation; use of a purposely developed algorithm to assist diagnosis; and
observer expertise.
Main results
A total of 24 publications reporting on 24 study cohorts were included, providing 27 visual inspection datasets (8805 lesions;
2579 malignancies) and 33 dermoscopy datasets (6855 lesions; 1444 malignancies). The risk of bias was mainly low for the
index test (for dermoscopy evaluations) and reference standard domains, particularly for in-person evaluations, and high or
unclear for participant selection, application of the index test for visual inspection and for participant flow and timing.
Concerns regarding the applicability of study findings were scored as ‘high’ or 'unclear' concern for almost all studies across
all domains assessed. Selective participant recruitment, lack of reproducibility of diagnostic thresholds and lack of detail on
observer expertise were particularly problematic.
The detection of BCC was reported in 28 datasets; 15 on an in-person basis and 13 image-based. Analysis of studies by
prior testing of participants and according to observer expertise was not possible due to lack of data. Studies were primarily
conducted in participants referred for specialist assessment of lesions with available histological classification. No clear
differences in accuracy were noted between dermoscopy studies undertaken in-person and those which evaluated images.
The lack of effect observed is likely due to other sources of heterogeneity, including variations in the types of skin lesion
studied, in dermatoscopes used, in the use of algorithms and varying thresholds for deciding on a positive test result.
Meta-analysis found in-person evaluations of dermoscopy (7 evaluations; 4683 lesions and 363 BCCs) to be more accurate
than visual inspection alone for the detection of BCC (8 evaluations; 7017 lesions and 1586 BCCs), with an RDOR of 8.2
(95% CI: 3.5 to 19.3; P < 0.001). This corresponds to predicted differences in sensitivity of 14% (93% vs 79%) at a fixed
specificity of 80% and predicted differences in specificity of 22% (99% vs 77%) at a fixed sensitivity of 80%. Very similar
results were observed for the image-based evaluations.
When applied to a hypothetical population of 1000 lesions, of which 170 are BCC (based on median BCC prevalence across
studies), an increased sensitivity of 14% from dermoscopy would lead to 24 fewer BCCs missed, assuming 166 false positive
results from both tests. A 22% increase in specificity from dermoscopy with sensitivity fixed at 80% would result in 183 fewer
unnecessary excisions assuming 34 BCCs missed for both tests. There was not enough evidence to assess the use of
algorithms or structured checklists for either visual inspection or dermoscopy.
Insufficient data were available to draw conclusions on the accuracy of either test for the detection of cSCC.
Authors' conclusions
Dermoscopy may be a valuable tool for the diagnosis of BCC as an adjunct to visual inspection of a suspicious skin lesion
following a thorough history-taking including assessment of risk factors for keratinocyte cancer. The evidence primarily
comes from secondary care (referred) populations and populations with pigmented lesions or mixed lesion types. There is no
clear evidence supporting the use of currently available formal algorithms to assist dermoscopy diagnosis.
Plain language summary
Does dermoscopy improve the accuracy of diagnosing basal cell or squamous cell skin cancer (BCC or cSCC)
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compared to using the naked eye alone?
What is the aim of the review?
We wanted to find out whether using a handheld illuminated microscope (dermatoscope or ‘dermoscopy’) is any better at
diagnosing basal cell carcinoma (BCC) or cutaneous squamous cell carcinoma (cSCC) compared to just looking at the skin
with the naked eye. We included 24 studies to answer this question.
Why is improving diagnosis of BCC or cSCC important?
There are a number of different types of skin cancer. BCC and cSCC are less serious than melanoma skin cancer because
they usually grow more slowly and BCC does not spread to other organs in the body. Making the correct diagnosis of BCC or
cSCC is still important because their treatment may differ. A missed BCC (known as a false negative result) can result in
disfigurement and the need for more major surgery. A missed cSCC can spread to other parts of the body. Diagnosing BCC
or cSCC when they are not actually present (a false positive result) may mean unnecessary treatment, e.g. surgical excision
which may result in a disfiguring scar, and worry to patients if the lesion is benign, or may result in wrong treatment, e.g. a
non-surgical therapy, being used if the lesion is misdiagnosed.
What was studied in the review?
A dermatoscope is a handheld magnifier that includes a light source. Dermoscopy is often used by skin specialists to help
diagnose skin cancer .It is also being used more by community doctors.
In addition to seeing whether dermoscopy added anything to visual inspection alone overall, we also wanted to find out
dermoscopy accuracy was different when used in a face-to-face consultation or when used on images of skin lesions sent to
specialists. We also tried to find out whether the accuracy of dermoscopy was improved by use of a checklist or if it was
better when used by a skin specialist compared to a non specialist.
What are the main results of the review?
The review included 24 studies reporting data for people with lesions suspected of skin cancer.
Diagnosis of BCC with the patient present
We found eleven relevant studies. Eight studies (including 7017 suspicious skin lesions) investigated the accuracy of visual
inspection on its own and seven studies (with 4683 suspicious skin lesions) investigated the accuracy of dermoscopy added
to visual inspection. The results suggest that dermoscopy is more accurate than visual inspection on its own both for
identifying BCC correctly and excluding things that are not BCC.
The results can be illustrated using a group of 1000 lesions, of which 170 (17%) are BCC. In order to see how much better
dermoscopy is in identifying BCC correctly when compared to just looking at the skin, we have to assume that both lead to
the same number of lesions being falsely diagnosed as BCC (we assumed that 166 of the 830 lesions without BCC would
have an incorrect diagnosis of BCC). In this fixed situation, adding dermoscopy to visual inspection would correctly identify
an extra 24 BCCs (158 compared with 134) that would have been missed by just looking at the skin alone. In other words,
more BCC cancers would be correctly identified.
In order to see how much better dermoscopy is in deciding if a skin lesion is not a BCC when compared to just looking at the
skin, we have to assume that both lead to the same number of BCCs being correctly diagnosed (in this case we assumed
that 136 out of the 170 BCCs would be correctly diagnosed). In this situation, adding in dermoscopy to visual inspection
would reduce the number of lesions being wrongly diagnosed as being BCC by 183 (a reduction from 191 in the visual
inspection group to 8 people in the dermoscopy group). In other words, more lesions that were not BCC would be correctly
identified and less people would end up being sent for surgery.
Image-based diagnosis of BCC 
Eleven studies concerning BCC diagnosis using either clinical photographs or magnified images from a dermatoscope were
included. Four studies, (including 853 suspicious skin lesions) used visual inspection of photographs and 9 studies (including
2271 suspicious lesions) used dermoscopic images. Results were very similar to the in-person studies.
Value of checklists and observer expertise
There was no evidence that use of a checklist to help visual inspection or dermoscopy interpretation improved diagnostic
accuracy. There was not enough evidence to examine the effect of clinical expertise and training.
Diagnosis of cSCC
There was not enough evidence to reliably comment on the accuracy of either test for the detection of cSCC.
How reliable are the results of the studies of this review?
In most of our studies a reliable final diagnosis was made by lesion biopsy and by following people up over time to make sure
the skin lesion remained negative for skin cancer. In some studies, absence of skin cancer was made by expert diagnosis
which is less reliable. Poor reporting of what was done in the studies made it difficult for us to judge how reliable they were.
Some studies excluded certain types of skin lesion and some did not describe how a positive test result to trigger referral to a
specialist or treatment was defined.
Who do the results of this review apply to?
Eleven studies were done in Europe (46%), and the rest in North America (n = 3), Asia (n = 5), Oceania (n = 2), or multiple
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countries (n = 2). People included in the studies were on average between 30 and 74 years old. The percentage of people
with BCC ranged between 1% and 61% for in-person studies and between 2% and 63% in studies using images. Almost all
studies were done with people referred from primary care to specialist skin clinics. Over half of studies considered the ability
of dermoscopy and visual inspection to diagnose any skin cancer, including melanoma and BCC, while 10 (42%) focused on
just BCC. Variation in the expertise of doctors doing the examinations and differences in the definitions used to decide when
a test was positive makes it unclear how dermoscopy should be carried out and what level of training is needed in order to
achieve the accuracy observed in studies.
What are the implications of this review?
When used by specialists, dermoscopy may be a useful tool to help diagnose BCC correctly when compared with visual
inspection alone. It is not clear whether dermoscopy should be used by general practitioners to correctly identify people with
suspicious lesions who need to be seen by a specialist. Checklists to help interpret dermoscopy don't seem to help improve
accuracy for BCC. Further research to see if dermoscopy is useful in primary care is needed.
How up-to-date is this review?
The review authors searched for and used studies published up to August 2016.
*In these studies biopsy, clinical follow up or specialist clinician diagnosis were the reference standards.
Background 
This review is one of a series of Cochrane Diagnostic Test Accuracy (DTA) reviews on the diagnosis and staging of
melanoma and keratinocyte skin cancers as part of the National Institute for Health Research (NIHR) Cochrane Systematic
Reviews Programme. Appendix 1 shows the content and structure of the programme.
Target condition being diagnosed
The commonest skin cancers in Caucasian populations are those arising from keratinocyte cells: basal cell carcinoma
(BCC) and cutaneous squamous cell carcinoma (cSCC) (Gordon 2013; Madan 2010). BCC is the more common of the
two keratinocyte carcinomas, and approximately one third of people with a BCC will subsequently develop a second (Flohill
2013). In 2003, the World Health Organization estimated that between two and three million ‘non-melanoma’ skin
cancers (of which BCC and cSCC are estimated to account for around 80% and 16% of cases respectively) and
132,000 melanoma skin cancers occur globally each year (WHO 2003).
Rather than defining BCC and cSCC by what they are not (i.e. non-melanoma skin cancer), we collectively refer
to these conditions using the preferred and more accurate term of 'keratinocyte carcinoma' in this diagnostic test
accuracy review (Karimkhani 2015 ). We define (a) BCC and (b) cSCC as the primary target conditions for this review.
We also examine accuracy for the target condition of (c) any skin cancer, including keratinocyte skin cancer,
melanoma or intraepidermal melanocytic variants and any other skin cancer. We have examined the accuracy of
visual inspection for the diagnosis of melanoma in a previous review (Dinnes 2018a) and in a further review,
examined the potential benefit of dermoscopy added to visual inspection for the diagnosis of melanoma (Dinnes 2018b).
Appendix 2 provides a glossary of terms used.
Basal cell carcinoma
BCC can arise from multiple stem cell populations, including from the follicular bulge and interfollicular
epidermis (Grachtchouk 2011). Growth is usually localised, but it can infiltrate and damage surrounding tissue, which if
left untreated can cause considerable destruction and disfigurement, particularly when located on the face (Figure 1
). The four main types of BCC are superficial, nodular, morphoeic (infiltrative), and pigmented. Lesions typically
present as slow-growing asymptomatic papules, plaques, or nodules, which may bleed or form ulcers that do not
heal (Firnhaber 2012). People with a BCC often present themselves to healthcare professionals with a non-healing
lesion rather than specific symptoms such as pain. Many lesions are diagnosed incidentally (Gordon 2013).
BCC most commonly occurs on sun-exposed areas of the head and neck (McCormack 1997) and are more common in
men and in people over the age of 40. A rising incidence of BCC in younger people has been attributed to increased
recreational sun exposure (Bath-Hextall 2007a; Gordon 2013; Musah 2013). Other risk factors include Fitzpatrick
skin types I and II (Fitzpatrick 1975; Lear 1997; Maia 1995); previous skin cancer history; immunosuppression; arsenic
exposure; and genetic predisposition, such as in basal cell naevus (Gorlin) syndrome (Gorlin 2004; Zak-Prelich 2004).
Annual incidence is increasing worldwide; Europe has experienced an average increase of 5.5% per year over the last
four decades, the USA 2% per year, while estimates for the UK show incidence appears to be increasing more steeply
at a rate of an additional 6 / 100,000 persons per year (Lomas 2012). The rising incidence has been attributed to
an ageing population, changes in the distribution of known risk factors, particularly ultraviolet radiation, and
improved detection due to the increased awareness amongst both practitioners and the general population (Verkouteren
2017). Hoorens 2016 points to evidence for a gradual increase in the size of BCCs over time, with delays in diagnosis
ranging from 19 to 25 months.
According to National Institute for Health and Care Excellence (NICE) guidance (NICE 2010), low-risk BCCs are
nodular lesions occurring in people older than 24 years old who are not immunosuppressed and do not have Gorlin
syndrome. Furthermore, lesions should be located below the clavicle; should be small (< 1 cm) with clinically well-
defined margins; not recurrent following incomplete excision or other treatment; and not in awkward or highly visible
locations (NICE 2010). Superficial BCCs are also typically low risk and may be amenable to medical treatments
such as cryotherapy, photodynamic therapy or topical immunomodulatory therapy, e.g. 5% Imiquimod cream (Kelleners-
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Smeets 2017). Assigning BCCs as low or high risk influences the management options (Batra 2002; Randle 1996).
Advanced locally destructive BCC can be found on the H-area of the face (Lear 2014), can arise from long-standing
untreated lesions, or from a recurrence of aggressive basal cell carcinoma after primary treatment (Lear 2012).
Very rarely, BCC may metastasise to regional and distant sites resulting in death; this is particularly true for large
neglected lesions in those who are immunosuppressed, or those with Gorlin syndrome (McCusker 2014). Rates of
metastasis are reported at 0.0028% to 0.55% with very poor survival rates (Lo 1991). It is recognised that
basosquamous carcinoma (more like a high risk SCC in behaviour and not considered a true BCC) is likely to have
accounted for many cases of apparent metastases of BCC, hence, the spuriously high reported incidence in some
studies of up to 0.55% which is not seen in clinical practice (Garcia 2009).
Squamous cell carcinoma of the skin
Primary cSCC arises from the keratinising cells of the epidermis or its appendages. cSCC typically presents with an
ulcer or firm (indurated) papule, plaque, or nodule (Griffin 2016) often with an adherent crust (Madan 2010) (Figure 1). cSCC
can arise in the absence of a precursor lesion, or may develop from pre-existing actinic keratosis or Bowen's disease
(considered by some to be cSCC in situ); the estimated annual risk of progression being < 1% to 20% for newly arising
lesions (Alam 2001) and 5% for pre-existing lesions (Kao 1986). It remains locally invasive for a variable length of
time, but has the potential to spread to the regional lymph nodes or via the bloodstream to distant sites, especially
in immunosuppressed individuals (Lansbury 2010). High risk lesions are those arising on the lip or ear, recurrent
cSCC, lesions arising on non-exposed sites, within scars or chronic ulcers, tumours more than 20 mm in diameter and
those with a histological depth of invasion exceeding 4mm, and poor differentiation status on pathological examination
(Motley 2009). Perineural nerve invasion (PNI) of at least > 0.1 mm in diameter is a further documented risk factor for
high risk cSCC (Carter 2013).
Chronic ultraviolet light exposure through recreation or occupation is strongly linked to cSCC occurrence (Alam 2001). It
is particularly common in people with fair skin and in less common genetic disorders of pigmentation, such as albinism,
xeroderma pigmentosum, and recessive dystrophic epidermolysis bullosa (RDEB) (Alam 2001). Other recognised
risk factors include immunosuppression; chronic wounds; arsenic or radiation exposure; certain drug treatments,
such as voriconazole and BRAF mutation inhibitors; and previous skin cancer history (Baldursson 1993; Chowdri 1996; 
Dabski 1986; Fasching 1989; Lister 1997; Maloney 1996; O'Gorman 2014). In solid organ transplant recipients,
cSCC is the most common form of skin cancer; the risk of developing cSCC has been estimated at 65 to 253 times
that of the general population (Hartevelt 1990; Jensen 1999; Lansbury 2010). Overall, local and metastatic
recurrence of cSCC at five years is estimated at 8% and 5% respectively. The five-year survival rate of
metastatic cSCC of the head and neck is around 60% (Moeckelmann 2018).
Treatment
Treatment options for BCC and cSCC include surgery, other destructive techniques such as cryotherapy or
electrodesiccation and topical chemotherapy. A Cochrane Review of 27 randomised controlled trials (RCTs) of
interventions for BCC found very little good quality evidence for any of the interventions used (Bath-Hextall 2007b).
Complete surgical excision of primary BCC has a reported five-year recurrence rate of < 2% (Griffiths 2005; Walker 2006
), leading to significantly fewer recurrences than treatment with radiotherapy (Bath-Hextall 2007b). After apparent
clear histopathological margins (serial vertical sections) after standard excision biopsy with 4mm surgical peripheral
margins taken there is a 5-year reported recurrence rate of around 4% (Drucker 2017). Mohs micrographic surgery,
whereby horizontal sections of the excised specimen are microscopically examined intraoperatively, and re-excision is
undertaken until the margins are tumour-free, can be considered for high risk lesions where standard wider excision
margins might lead to incomplete excision or considerable functional and/or cosmetic impairment (Bath-Hextall 2007b; 
Motley 2009; Lansbury 2010; Stratigos 2015). Bath-Hextall and colleagues (Bath-Hextall 2007b) found a single trial
comparing Mohs micrographic surgery with a 3mm surgical margin excision in BCC (Motley 2009), showing non-
significantly lower recurrence at 10 years with Mohs micrographic surgery (4.4% compared to 12.2% after surgical
excision, P = 0.10) (van Loo 2014).
The main treatments for high risk BCC are wide local excision, Mohs micrographic surgery and radiotherapy. For
low risk or superficial subtypes of BCC, or for small and/or multiple BCCs at low risk sites (Marsden 2010), destructive
techniques other than excisional surgery may be used (e.g. electrodesiccation and curettage or cryotherapy (Alam 2001; 
Bath-Hextall 2007b)). Alternatively, non-surgical (or non-destructive) treatments may be considered (Bath-Hextall 2007b; 
Kim 2014;Drew 2017), including topical chemotherapy such as imiquimod (Williams 2017), 5-fluorouracil (5-FU) (Arits 2013
), ingenol mebutate (Nart 2015) and photodynamic therapy (PDT) (Roozeboom 2016). Non-surgical treatments are
most frequently used for superficial forms of BCC, with one head to head trial suggesting topical imiquimod is
superior to PDT and 5-FU (Jansen 2018). Although non-surgical techniques are increasingly used, they do not allow
histological confirmation of tumour clearance, and their efficacy is dependent on accurate characterisation of the histological
subtype and depth of tumour and so a baseline diagnostic biopsy can be helpful. The 2007 systematic review of BCC
interventions found limited evidence from very small RCTs for these approaches (Bath-Hextall 2007b), which have only
partially been filled by subsequent studies (Bath-Hextall 2014; Kim 2014; Roozeboom 2012). Most BCC trials have
compared interventions within the same treatment class, and few have compared medical versus surgical treatments (Kim
2014).
Vismodegib, a first-in-class Hedgehog signalling pathway inhibitor is now available for the treatment of metastatic or
locally advanced BCC based on the pivotal study ERIVANCE BCC (Sekulic 2012). It is licensed for use in these
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patients where surgery or radiotherapy is inappropriate, e.g. for treating locally advanced periocular and orbital BCCs
with orbital salvage of patients who otherwise would have required exenteration (Wong 2017). However, NICE has
recently recommended against the use of vismodegib based on cost effectiveness and uncertainty of evidence (NICE 2017).
A systematic review of interventions for primary cSCC found only one RCT eligible for inclusion (Lansbury 2010). Current
practice therefore relies on evidence from observational studies, as reviewed in Lansbury 2013, for example. Surgical
excision with predetermined margins is usually the first-line treatment (Motley 2009; Stratigos 2015). Estimates of
recurrence after Mohs micrographic surgery, surgical excision, or radiotherapy, which are likely to have been
evaluated in higher risk populations, have shown pooled recurrence rates of 3%, 5.4% and 6.4%, respectively with
overlapping confidence intervals; the review authors advise caution when comparing results across treatments (Lansbury
2013)
Index test(s)
For the purposes of our series of reviews, each component of the diagnostic process, including visual inspection during
clinical examination, is considered a diagnostic or index ‘test', the accuracy of which can be established in comparison with a
reference standard of diagnosis, either alone or in combination with other available technologies that may assist the
diagnostic process. In this review, two index tests are under consideration, visual inspection and dermoscopy, both of which
can be undertaken in-person (in a face-to-face consultation) or image-based (remote diagnosis using images). As
dermoscopy is effectively added to visual inspection of a skin lesion when it is undertaken in-person, we effectively have
three index tests: visual inspection alone (in-person or using images), visual inspection plus dermoscopy (in-person
dermoscopy), and dermoscopy alone (image-based dermoscopy).
Visual inspection
Clinical history taking and visual inspection (and palpation) of the lesion, surrounding skin and comparison with other lesions
identified on complete examination of the body, is fundamental to the diagnosis of skin cancer. In the UK, clinical
examination is typically done at two decision points – first in primary care where a decision is made to refer, treat (if low risk
BCC is suspected), or reassure, and then a second time by a dermatologist or other secondary care clinician where a
treatment decision is made if appropriate.
Visual inspection of a lesion involves clinical reasoning based on both non-analytical and analytical pattern
recognition strategies (Norman 1989; Elstein 2002; Norman 2009). Non-analytical pattern recognition uses
subconscious intuitive processes, while analytical pattern recognition uses more explicit rules based on hypothetico-
deductive reasoning (Norman 2009). The balance between non-analytical and analytical reasoning varies between clinicians,
according to factors such as constitutional reasoning style preference, experience and familiarity with the diagnostic
question.
Unlike for melanoma where a number of diagnostic algorithms or checklists have been developed to help recognise
melanomas (Sober 1979; Friedman 1985; Steiner 1987; Pehamberger 1993; MacKie 1985; MacKie 1990; Nachbar 1994; 
Stolz 1994), visual inspection for keratinocyte skin cancers relies primarily on pattern recognition. Accuracy has been
demonstrated to vary according to expertise of the clinician. Primary care physicians have been reported to miss over
half of BCC (Offidani 2002) and to inappropriately diagnose one third of BCC (Gerbert 2000). In contrast, an Australian
study found that skin cancer specialists were able to detect 89% of BCC compared to 79% for GPs, with corresponding
specificities of 79% (specialists) and 83% (GPs) (Youl 2007a).
Visual inspection of a digital photograph or ‘macroscopic’ image of a suspicious skin lesion can also be undertaken
as part of a teledermatology consultation whereby clinical photographs, dermoscopic images, or both, are taken by
non-specialist clinicians and forwarded to a dermatologist, to obtain a specialist opinion (Chuchu 2018a). Images can
also be encompassed in a store-and-forward smartphone application whereby a photograph of a concerning lesion is
taken by the smartphone user and forwarded for an assessment of skin cancer risk by a specialist clinician (Chuchu 2018b
). Images are often accompanied by a summary of the medical history and demographic information as part of a
consultation package (Ndegwa 2010). According to UK guidelines, both clinical and dermoscopic images must be sent
for ‘full dermatology’, i.e. as a replacement for a face-to-face consultation, whereas for ‘triage teledermatology’
dermoscopic images should be sent where facilities permit (BAD 2013).
Dermoscopy
Dermoscopy (also referred to as dermatoscopy or epiluminescence microscopy or ELM) has become a widely used
tool for the specialist clinician and is also increasingly being used in primary care settings. It uses a hand-held
microscope and incident light (with or without oil immersion) to reveal subsurface images of the skin at increased
magnification of x 10 to x 100 (Kittler 2011) (Figure 2; Figure 3). It is particularly useful for the identification of
melanoma when used by specialists (Dinnes 2018b), but its role in the diagnosis of keratinocyte skin cancers is less clearly
established.
The visual nature of dermoscopic interpretation means that when used on an in-person basis, dermoscopy is
essentially added to visual inspection of a skin lesion and similar non-analytical and analytical pattern recognition
strategies are employed to reach a dermoscopic diagnosis. Dermoscopic histological correlations have been
established for the diagnosis of melanoma, allowing a number of diagnostic algorithms to be developed based on
lesion colour, aspect, pigmentation pattern, and skin vessels (Dinnes 2018b). However, the diagnosis of keratinocyte
skin cancers using dermoscopy again relies predominantly on subjective pattern recognition. Features of BCC on
dermoscopy include arborising (branching of) blood vessels, superficial fine telangiectasia (abnormally tortuous and
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dilated blood vessels), grey-blue ovoid nests and globules, in-focus dots, spoke wheels and maple-leaf-like areas,
concentric structures, ulceration, multiple small erosions, shiny white-red structureless areas, and short white streaks (
Apalla 2013). Features favouring cSCC on dermoscopy include the presence of keratin, white circles, radial
telangiectasia and blood spots (Rosendahl 2012; Zalaudek 2012).
In modern practice, dermoscopic images are frequently obtained for skin lesions that are recommended for excision
and are also obtained for lesions that have not yet met the diagnostic threshold for excision but are to be monitored
over time in case of any further suspicious changes. Dermoscopic images are also a key component of
teledermatology consultations, usually accompanied by digital photographs and other pertinent information (Chuchu 2018a),
as discussed above.
Clinical Pathway 
The diagnosis of skin lesions occurs in primary, secondary, and tertiary care settings by both generalist and specialist
healthcare providers. In the UK, people with concerns about a new or changing lesion will present to their general
practitioner rather than directly to a specialist in secondary care. If the general practitioner has concerns, then a
referral is usually made to a specialist in secondary care – usually a dermatologist but sometimes to a surgical
specialist such as a plastic surgeon or an ophthalmic surgeon. Suspicious skin lesions may also be identified in a
referral setting, for example by a general surgeon, and referred for a consultation with a skin cancer specialist (Figure 4).
Skin cancers identified by other specialist surgeons (such as an ear, nose, and throat (ENT) specialist or maxillofacial
surgeon will usually be diagnosed and treated without further referral.
Current UK guidelines recommend that all suspicious pigmented lesions presenting in primary care should be
assessed by taking a clinical history and visual inspection using the seven-point checklist (MacKie 1990); lesions
suspected to be melanoma or cSCC should be referred for appropriate specialist assessment within two weeks (Chao 2013; 
Marsden 2010; NICE 2015). Evidence is emerging, however, to suggest that excision of melanoma by GPs is not
associated with increased risk compared with outcomes in secondary care (Murchie 2017). In the UK, low risk BCC are
usually recommended for routine referral, with urgent referral for those in whom a delay could have a significant impact
on outcomes, for example due to large lesion size or critical site (NICE 2015). Appropriately qualified generalist care
providers increasingly undertake management of low risk BCC in the UK, such as by excision of low risk lesions (NICE
2010). Similar guidance is in place in Australia (CCAAC Network 2008).
For referred lesions, the specialist clinician will use history-taking, visual inspection of the lesion (in conjunction
with other skin lesions), palpation of the lesion and associated regional nodal basins in conjunction with
dermoscopic examination to inform a clinical decision. If melanoma is suspected, then urgent 2mm excision biopsy
is recommended (Lederman 1985; Lees 1991); for cSCC predetermined surgical margin excision or a diagnostic biopsy may
be considered. BCC and pre-malignant lesions potentially eligible for nonsurgical treatment may undergo a diagnostic biopsy
before initiation of therapy if there is diagnostic uncertainty. Equivocal melanocytic lesions for which a definitive clinical
diagnosis cannot be reached may undergo surveillance to identify any lesion changes that would indicate excision biopsy or
reassurance and discharge for those lesions that remain stable over a period of time.
Theoretically, teledermatology consultations may aid appropriate triage of lesions into urgent referral; non-urgent secondary
care referral (e.g. for suspected basal cell carcinoma); or where available, referral to an intermediate care setting, e.g. clinics
run by GPs with a special interest in dermatology. The distinction between setting and examiner qualifications and
experience is important as specialist clinicians might work in primary care settings (for example, in the UK, general
practitioners (GPs) with a special interest in dermatology and skin surgery who have undergone appropriate training), and
generalists might practice in secondary care settings (for example, plastic surgeons who do not specialise in skin cancer).
The level of skill and experience in skin cancer diagnosis will vary for both generalist and specialist care providers and will
also impact on test accuracy.
Prior test(s)
Although smartphone applications and community-based teledermatology services can increasingly be directly
accessed by people who have concerns about a skin lesion (Chuchu 2018b), visual inspection of a suspicious lesion by
a clinician is usually the first in a series of tests to diagnose skin cancer. In the UK this usually takes place in primary
care, however in many countries people with suspicious lesions can present directly to a specialist setting. Although
dermoscopy is frequently combined with visual inspection of a lesion in secondary care setting, it is also increasingly
used in primary care, particularly in countries such as Australia (Youl 2007).
Consideration of the degree of prior testing that study participants have undergone is key to interpretation of test
accuracy indices, as these are known to vary according to the disease spectrum (or case-mix) of included participants
(Lachs 1992; Moons 1997; Leeflang 2013; Usher-Smith 2016). Spectrum effects are often observed when tests that
are developed further down the referral pathway have lower sensitivity and higher specificity when applied in settings
with participants with limited prior testing (Usher-Smith 2016). Studies of individuals with suspicious lesions at the
initial clinical presentation stage ('test naïve') are likely to have a wider range of differential diagnoses and include a
higher proportion of people with benign diagnoses compared with studies of participants who have been referred for
a specialist opinion on the basis of visual inspection (with or without dermoscopy) by a generalist practitioner.
Furthermore, studies in more specialist settings may focus on equivocal or difficult to diagnose lesions rather than
lesions with a more general level of clinical suspicion. However this direction of effect is not consistent across tests
and diseases, the mechanisms in action often being more complex than prevalence alone and can be difficult to
identify (Leeflang 2013). A simple categorisation of studies according to primary, secondary or specialist setting therefore
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may not always adequately reflect these key differences in disease spectrum that can affect test performance.
Role of index test(s)
When diagnosing potentially life-threatening conditions, the consequences of falsely reassuring a person that they do not
have skin cancer can be serious and potentially fatal, as the resulting delay to diagnosis means that the window for
successful early treatment may be missed. To minimise these false-negative diagnoses, a good diagnostic test will
demonstrate high sensitivity and a high negative predictive value (NPV), i.e. so that very few of those with a negative test
result will actually have a malignant lesion. Giving falsely positive test results (meaning the test has poor specificity and a
high false-positive rate) resulting in the removal of lesions that turn out to be benign is arguably less of an error than missing
a potentially fatal lesion, but is not cost free. False-positive diagnoses not only cause unnecessary scarring from the biopsy
or excision procedure, but also increase anxiety (particularly during the time that people wait for results) and increase
healthcare costs as the number of lesions that need to be removed to yield one malignant diagnosis increases.
Delay in diagnosis of a BCC as a result of a false-negative test is not as serious as for melanoma because BCCs are
usually slow-growing and very unlikely to metastasise (Betti 2017). However, delayed diagnosis can result in a larger and
more complex excision with consequent greater morbidity. Very sensitive diagnostic tests for BCC however may compromise
on lower specificity leading to a higher false-positive rate, and an enormous burden of skin surgery, such that a balance
between sensitivity and specificity is needed. The situation for cSCC is more similar to melanoma in that the consequences
of falsely reassuring a person that they do not have skin cancer can be serious and potentially fatal given that removal of an
early cSCC is usually curative. Thus, a good diagnostic test for cSCC should demonstrate high sensitivity and a
corresponding high negative predictive value. A test that can also reduce false positive clinical diagnoses without missing
true cases of cSCC has patient and resource benefits.
Alternative test(s)
A number of other tests have been reviewed as part of our series of Cochrane DTA reviews on the diagnosis of
keratinocyte skin cancers, including, reflectance confocal microscopy (RCM) (Dinnes 2018c), computer-aided
diagnosis or artificial intelligence-based techniques using dermoscopic or spectroscopic images (Ferrante di Ruffano 2018a
), optical coherence tomography (OCT) (Ferrante di Ruffano 2018b), high frequency ultrasonography (Dinnes 2018d
) and exfoliative cytology (Ferrante di Ruffano 2018c). Evidence permitting, the accuracy of available tests will be compared
in an overview review, exploiting within-study comparisons of tests and allowing the analysis and comparison of commonly
used diagnostic strategies where tests may be used singly or in combination.
We also considered and excluded a number of tests from this review such as tests used for monitoring people (e.g. total
body photography of those with large numbers of pigmented lesions). We also did not assess histopathological confirmation
following lesion excision because it is the established reference standard for skin cancer diagnosis and will be one of the
standards against which the index tests are evaluated in these reviews.
Rationale
This series of reviews of diagnostic tests used to assist the clinical diagnosis of BCC and cSCC in clinical practice or
research settings, aims to identify the most accurate approaches to diagnosis and provide clinical and policy decision-makers
with the highest possible standard of evidence on which to base diagnostic and treatment decisions. With the increasing
availability of a wider range of tests, there is a need to differentiate and appropriately triage keratinocyte skin cancers to
avoid sending too many people with benign or low risk lesions for a specialist opinion whilst not missing those people who
have lesions that require treatment.
There is a lack of available systematic reviews in the field. A 2007 review of a range of tests for diagnosis of BCC
did not report the use of systematic methods for study inclusion or extraction and did not appear to apply any
quality assessment (Mogensen 2007). Critical questions of comparative test accuracy and the impact of examiner, prior
testing, and underlying risk status remain unanswered for the NHS. With the increasing availability of digital imaging systems
and computerised instruments, there is a further need for an up-to-date analysis of their accuracy in comparison with visual
inspection or dermoscopy.
This review follows a generic protocol which covers the full series of Cochrane DTA reviews for the diagnosis of
keratinocyte skin cancer (Dinnes 2015a). The Background and Methods sections of this review therefore use some
text that was originally published in the protocol (Dinnes 2015a) and text that overlaps some of our other reviews (Dinnes
2018a; Dinnes 2018b).
Objectives 
To determine the diagnostic accuracy of visual inspection and dermoscopy, alone or in combination, for the detection of BCC
in adults.
To determine the diagnostic accuracy of visual inspection and dermoscopy, alone or in combination, for the detection of
cSCC in adults.
For both visual inspection and dermoscopy, accuracy was estimated separately according to whether the diagnosis was
recorded based on a face-to-face (in-person) encounter or based on remote (image-based) assessment. We therefore aimed
to compare tests in the following way:
To estimate incremental accuracy for the diagnosis of BCC in adults, a) from dermoscopy added to in-person visual
inspection of a skin lesion, or b) from dermoscopic image-based assessment in comparison to visual inspection of a
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clinical photograph.
To estimate incremental accuracy for the diagnosis of cSCC in adults, a) from dermoscopy added to in-person visual
inspection of a skin lesion, or b) from dermoscopic image-based assessment in comparison to visual inspection of a
clinical photograph.
We also proposed to analyse data according to the prior testing undergone by study participants (comparing those with
limited prior testing with those referred for further evaluation of a suspicious skin lesion) however this was not possible due to
limited data.
Secondary objectives
For the identification of BCC (or cSCC):
i. To compare the accuracy of dermoscopy added to in-person visual inspection versus visual inspection alone, where
both tests have been evaluated in the same studies (direct test comparisons);
ii. To compare the accuracy of image-based dermoscopy versus visual inspection of digital photographs, where both tests
have been evaluated in the same studies (direct test comparisons);
iii. To determine the diagnostic accuracy of individual algorithms used to assist visual inspection;
iv. To determine the diagnostic accuracy of individual algorithms used to assist dermoscopy; and
v. To determine the effect of observer experience on diagnostic accuracy.
To assess an alternative target condition:
vi. To determine the diagnostic accuracy of visual inspection or dermoscopy, alone or in combination, for the detection of
any skin cancer, and to compare the accuracy of dermoscopy with that of visual inspection alone.
Investigation of sources of heterogeneity
We set out to address a range of potential sources of heterogeneity for investigation across our series of reviews, as
outlined in our generic protocol (Dinnes 2015a) and described in Appendix 3, however our ability to investigate these was
necessarily limited by the available data on each individual test reviewed.
The sources of heterogeneity that were investigated for this review were:
in-person versus image-based evaluations
use of a diagnostic algorithm: no algorithm reported versus any named algorithm used
disease prevalence: 0 to 25%; >25%
observer expertise.
Methods 
Criteria for considering studies for this review
Types of studies 
We included test accuracy studies that allow comparison of the result of the index test with that of a reference standard,
including the following:
studies where all participants receive a single index test and a reference standard;
studies where all participants receive more than one index test(s) and reference standard;
studies where participants are allocated (by any method) to receive different index tests or combinations of index tests
and all receive a reference standard (between-person comparative studies (BPC));
studies that recruit series' of participants unselected by true disease status (referred to as case series for the purposes of
this review);
diagnostic case-control studies that separately recruit diseased and non-diseased groups (see Rutjes 2005); however, we
did not include studies that compared results for malignant lesions to those for healthy skin (i.e. with no lesion present);
both prospective and retrospective studies; and
studies where previously acquired clinical or dermoscopic images were retrieved and prospectively interpreted for study
purposes.
We excluded studies from which we could not extract 2x2 contingency data or if they included less than five cases of basal
cell carcinoma (BCC) or cutaneous squamous cell carcinoma (cSCC), or less than five benign lesions. Although the size
threshold of five is arbitrary, such small studies are likely to give unreliable estimates of sensitivity or specificity, and may be
biased like small randomised controlled trials of treatment effects.
Participants
We included studies in adults with lesions suspicious for skin cancer. These could include participants:
with lesion characteristics suspicious for keratinocyte skin cancers, including BCC or cSCC
with lesion characteristics suspicious for any skin cancer, including melanoma (e.g. restricted to those with pigmented
lesions, only or including both pigmented and non-pigmented lesion types); or those
at high risk of developing BCC or cSCC.
We excluded studies that recruited only participants with malignant or benign final diagnoses.
We excluded studies conducted in children or which clearly reported inclusion of more than 50% of participants aged 16 and
under.
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Index tests
Studies reporting accuracy data for visual inspection or dermoscopy, or both, with diagnosis made either in-person (face-to-
face diagnosis) or image-based (diagnosis based on photographs or dermoscopic images, remotely from the study
participant) were eligible for inclusion. All established algorithms or checklists to assist diagnosis were included.
Studies developing new algorithms or methods of diagnosis (i.e. derivation studies) were included if they:
used a separate independent 'test set' of participants or images to evaluate the new approach, or
investigated lesion characteristics that had previously been suggested as associated with one of the BCC or cSCC and
the study reported accuracy based on the presence or absence of specific combinations of characteristics.
Studies were excluded if they:
used a statistical model to produce a data driven equation, or algorithm based on multiple diagnostic features, with no
separate test set.
used cross-validation approaches such as 'leave-one-out' cross-validation (Efron 1983)
evaluated the accuracy of the presence or absence of individual lesion characteristics or morphological features, with no
overall diagnosis of malignancy
reported accuracy data for ‘clinical diagnosis’ with no clear description as to whether the reported data related to visual
inspection alone or included dermoscopy in all study participants
were based on the experience of a skin cancer-specific clinic, where dermoscopy may or may not have been used on an
individual basis.
Although primary care clinicians can have a specialist interest in skin cancer, for the purposes of this review we considered
primary care physicians as generalist practitioners and dermatologists as specialists. Within each group, we extracted any
reporting of special interest or accreditation in skin cancer.
Target conditions
The primary target conditions were the detection of:
BCC, including all subtypes;
Invasive cSCC (we did not consider cutaneous SCC in situ such as Bowen’s disease, as disease positive)
An additional target condition was considered in secondary analyses, namely the detection of:
any skin cancer, including BCC, cSCC, melanoma or any rare skin cancer (e.g. Merkel cell cancer), as long as skin
cancers other than melanoma made up more than 50% of the disease positive group. Data from studies in which
melanoma accounted for more than 50% of skin cancers were included in our reviews of visual inspection and of
dermoscopy compared to visual inspection for the diagnosis of melanoma (Dinnes 2018a; Dinnes 2018b).
Reference standards
The ideal reference standard was histopathological diagnosis in all eligible lesions. A qualified pathologist or
dermatopathologist should perform histopathology. Ideally, reporting should be standardised detailing a minimum
dataset to include the type of skin cancer (BCC, cSCC) and subtype of BCC and may also refer to the TNM (tumour, node,
and metastasis) classification of staging for cSCC (Royal College of Pathologists 2014). We did not apply the reporting
standard as a necessary inclusion criterion, but extracted any pertinent information.
Partial verification (applying the reference test only to a subset of those undergoing the index test) was of concern given that
lesion excision or biopsy are unlikely to be carried out for all clinically benign skin lesions within a representative population
sample. Therefore, we accepted clinical follow-up of benign lesions as an eligible reference standard, whilst recognising the
risk of differential verification bias (as misclassification rates of histopathology and follow-up will differ).
Additional eligible reference standards included cancer registry follow-up and 'expert opinion' with no histology or clinical
follow-up. Cancer registry follow-up is considered less desirable than active clinical follow-up, as follow-up is not carried out
within the control of the study investigators. Furthermore, if participant-based analyses as opposed to lesion-based analyses
are presented, it may be difficult to determine whether the detection of a malignant lesion during follow-up is the same lesion
that originally tested negative on the index test.
All of the above are eligible reference standards with the following caveats:
all study participants with a final diagnosis of the target disorder must have a histological diagnosis, either subsequent to
the application of the index test or after a period of clinical follow-up, and
at least 50% of all participants with benign lesions must have either a histological diagnosis or clinical follow-up to confirm
benignity.
Search methods for identification of studies 
Electronic searches 
The Information Specialist (SB) carried out a comprehensive search for published and unpublished studies. A
single large literature search was conducted for the programme grant, covering all conditions and tests (Appendix 1
). This allowed for the screening of search results for potentially relevant papers for all reviews at the same time. A
MEDLINE scoping search combining disease-related terms with terms related to the test names, using both text
words and subject headings was formulated. As the majority of records were related to the searches for tests for
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staging of disease, a filter using terms related to cancer staging and to accuracy indices was applied to the staging
test search, to try to eliminate irrelevant studies, for example, those using imaging tests to assess treatment
effectiveness. A sample of 300 records that would be missed by applying this filter were screened and the filter
adjusted to include potentially relevant studies. The final search filter (Appendix 4) reduced the overall numbers retrieved
from MEDLINE by around 6000. The final search result was cross-checked against the list of studies included in five
systematic reviews; our search identified all but one of the studies, and this study is not indexed on MEDLINE. The
Information Specialist devised the search strategy, with input from the Trials Search Co-ordinator from the Cochrane Skin
Group. No additional limits were used.
We searched the following bibliographic databases to 29 August 2016 for relevant published studies:
MEDLINE via OVID (from 1946);
MEDLINE In-Process & Other Non-Indexed Citations via OVID; and
EMBASE via OVID (from 1980).
We searched the following bibliographic databases to 30 August 2016 for relevant published studies:
the Cochrane Central Register of Controlled Trials (CENTRAL) Issue 7, 2016, in the Cochrane Library;
the Cochrane Database of Systematic Reviews (CDSR) Issue 8, 2016 in the Cochrane Library;
Cochrane Database of Abstracts of Reviews of Effects (DARE) Issue 2, 2015;
CRD HTA (Health Technology Assessment) database Issue 3, 2016;
CINAHL (Cumulative Index to Nursing and Allied Health Literature via EBSCO from 1960).
We searched the following databases for relevant unpublished studies:
CPCI (Conference Proceedings Citation Index) via Web of Science™ (from 1990);
Zetoc (from 1993)
SCI Science Citation Index Expanded™ via Web of Science™ (from 1900, using the "Proceedings and Meetings
Abstracts" Limit function).
We searched the following trials registers:
The US National Institutes of Health Ongoing Trials Register (www.clinicaltrials.gov);
NIHR Clinical Research Network Portfolio Database (http://www.nihr.ac.uk/research-and-impact/nihr-clinical-research-
network-portfolio/);
The World Health Organization International Clinical Trials Registry Platform (apps.who.int/trialsearch/).
We aimed to identify all relevant studies regardless of language or publication status (published, unpublished, in press, or in
progress). No date limits were applied. Update searches will be time and resource dependent.
Searching other resources 
We have included information about potentially relevant ongoing studies in the 'Characteristics of ongoing studies' tables. We
have screened any relevant systematic reviews identified by the searches for their included primary studies, and have
included any missed by our searches. We have checked the reference lists of all included papers, and subject experts within
the author team have reviewed the final list of included studies. No citation searching has been conducted.
Data collection and analysis 
Selection of studies 
Titles and abstracts were screened by at least one author (JDi or NC), with any queries discussed and resolved by
consensus. A pilot screen of 539 MEDLINE references showed good agreement (89% with a kappa of 0.77)
between screeners. Primary test accuracy studies and test accuracy reviews (for scanning of reference lists) of any
test used to investigate suspected melanoma, BCC, or cSCC were included at initial screening. Inclusion criteria (Appendix
5) were applied independently by both a clinical reviewer (from one of a team of twelve clinician reviewers) and a
methodologist reviewer (JDi or NC) to all full text articles, disagreements were resolved by consensus or by a third party
(JDe, CD, HW, and RM). Authors of eligible studies were contacted when insufficient data were presented to allow for the
construction of 2x2 contingency tables.
Data extraction and management
One clinical (as detailed above) and one methodologist reviewer (JDi, NC or LFR) independently extracted data concerning
details of the study design, participants, index test(s) or test combinations and criteria for index test positivity, reference
standards, and data required to populate a 2x2 diagnostic contingency table for each index test using a piloted data
extraction form. Data were extracted at all available index test thresholds. Disagreements were resolved by consensus or by
a third party (JDe, CD, HW, and RM).
Authors of included studies were contacted where information relating to the diagnostic threshold was missing. Authors of
conference abstracts published from 2013 to 2015 were contacted to ask whether full data were available. If no full paper
was identified, we marked conference abstracts as 'pending' and will revisit them in a future review update.
Dealing with multiple publications and companion papers
Where multiple reports of a primary study were identified, we maximised yield of information by collating all available data.
Where there were inconsistencies in reporting or overlapping study populations, we contacted study authors for clarification
in the first instance. If this contact with authors was unsuccessful, we used the most complete and up-to-date data source
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where possible.
Assessment of methodological quality
We assessed risk of bias and applicability of included studies using the QUADAS-2 checklist (Whiting 2011), tailored to the
topic of skin cancer (see Appendix 6). The modified QUADAS-2 tool was piloted on a small number of full text articles
included across the full series of diagnostic test accuracy reviews. One clinical and one methodologist reviewer (JDi, NC or
LFR) independently assessed quality for the remaining studies; any disagreement was resolved by consensus or by a third
party where necessary (JDe, CD, HW, and RM).
Statistical analysis and data synthesis
Separate analyses were planned according to the point that study participants have reached in the clinical pathway, the
clarity with which the pathway could be determined, and the evaluation of in-person versus image-based diagnosis.
Our unit of analysis was the lesion rather than the person. This is because (i) in skin cancer initial treatment is directed to the
lesion rather than systemically (thus it is important to be able to correctly identify cancerous lesions for each person), and (ii)
it is the most common way in which the primary studies reported data. Although there is a theoretical possibility of
correlations of test errors when the same people contribute data for multiple lesions, most studies include very few people
with multiple lesions and any potential impact on findings is likely to be very small, particularly in comparison with other
concerns regarding risk of bias and applicability. For each analysis, only one dataset was included per study to avoid multiple
counting of lesions. Few studies comparing algorithms were retrieved, however where multiple algorithms were assessed in
an individual study, datasets were selected on the following preferential basis:
i. ‘no algorithm’ reported; data presented for clinician’s overall diagnosis or management decision
ii. pattern analysis or pattern recognition
iii. ABCD algorithm (or derivatives of) or other established algorithm such as 7-point checklist, Menzies algorithm or 3-point
checklist
iv. New algorithm developed by study authors
For the diagnosis of BCC (or cSCC), any melanomas or cSCCs (BCCs) that were positively identified in the ‘disease
negative’ group (i.e. that were mistaken for BCCs) were considered false positive results. The clinical management of a
lesion considered to be a BCC might be quite different to that for a melanoma or cSCC and could potentially lead to a
negative outcome for the participants concerned, for example if a treatment other than excision was initiated.
For each index test, algorithm or checklist under consideration, estimates of sensitivity and specificity were plotted on
coupled forest plots and in receiver operating characteristic (ROC) space. For tests where commonly used thresholds
were reported we estimated summary operating points (summary sensitivities and specificities) with 95% confidence and
prediction regions using the bivariate hierarchical model (Chu 2006; Reitsma 2005). Where inadequate data were
available for the model to converge the model was simplified, first by assuming no correlation between estimates
of sensitivity and specificity and secondly by setting estimates of near zero variance terms to zero (Takwoingi 2017). Where
all studies reported 100% sensitivity (or 100% specificity) the number with disease (or no disease) was summed across
studies and used to compute a binomial exact 95% confidence interval.
Comparisons between visual inspection and dermoscopy results were made with:
a. all visual inspection and all dermoscopy data from all studies, and then
b. only using data from studies that reported both visual inspection data and dermoscopy data for the same
lesions, to enable a robust direct comparison (Takwoingi 2013).
We made comparisons between tests by comparing summary ROC curves using the hierarchical summary receiver-
operator curves (HSROC) model (Rutter 2001) rather than by estimating average operating points as this approach allows
incorporation of data at different thresholds as could arise with different algorithms or checklists. We used an HSROC model
that assumed a constant SROC shape between tests and subgroups, but allowed for differences in threshold and accuracy
by addition of covariates. The significance of the differences between tests was assessed by the likelihood ratio test (LR test)
assessing differences in both accuracy and threshold, and by a Wald test on the parameter estimate testing for differences in
accuracy alone. The P values from both tests are provided in the Tables with the results from the LR test cited in the text, on
the basis that differences in threshold between tests is likely. Simpler models were fitted when convergence was not
achieved due to small numbers of studies, first assuming symmetric SROC curves (setting the shape term to zero), and then
setting random effects variance estimates to zero.
Estimates of accuracy from HSROC models are presented as diagnostic odds ratios (estimated where the SROC curve
crosses the sensitivity=specificity line) with 95% confidence intervals. Differences between tests and subgroups from
HSROC analyses are presented as relative diagnostic odds ratios with 95% confidence intervals. To facilitate interpretation
in terms of rates of false positive and false negative diagnoses, values of sensitivity at the point on the SROC curve with 80%
specificity and of specificity at the point on the SROC curve with 80% sensitivity have been computed. These 80% values
were chosen as they lie within the estimates for the majority of analyses. These results should only be considered as
illustrative examples of possible sensitivities (and specificities) and differences in sensitivities (and specificities) that could be
expected.
Where data were insufficient to estimate HSROC curves (e.g. for the analysis of cSCC), summary operating points
(summary sensitivities and specificities) were estimated with 95% confidence and prediction regions using the bivariate
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hierarchical model (Chu 2006; Reitsma 2005).
For computation of likely numbers of true positive, false positive, false negative and true negative findings in the summary of
findings tables these indicative values were applied to lower quartile, median and upper quartiles of the prevalence observed
in the study groups.
Bivariate models were fitted using the xtmelogit command in STATA 15 and HSROC models fitted using the NLMIXED
procedure in the SAS statistical software package (SAS 2012) and the metadas macro (Takwoingi 2010).
Investigations of heterogeneity
Investigations of heterogeneity, comparisons between algorithms and according to observer experience were made by
comparing summary ROC curves using the hierarchical summary receiver-operator curves (HSROC) model (Rutter 2001),
with additional covariates for differences in threshold and accuracy as used for comparing tests.
Sensitivity analyses
No sensitivity analyses were done.
Assessment of reporting bias
Because of uncertainty about the determinants of publication bias for diagnostic accuracy studies and the inadequacy
of tests for detecting funnel plot asymmetry (Deeks 2005), we did not perform tests to detect publication bias.
Results 
Results of the search
A total of 34,347 unique references were identified and screened for inclusion. Of these, 1051 full text papers were reviewed
for eligibility for any one of the suite of reviews of tests to assist in the diagnosis of melanoma or keratinocyte skin cancer. Of
the 1051 full text papers assessed, 852 were excluded from all reviews in our series (see Figure 5 PRISMA flow diagram of
search and eligibility results).
Of the 466 studies tagged as potentially eligible for any of our reviews of visual inspection or dermoscopy, 24 publications
were included in this review. Exclusions were mainly due to the inability to construct a 2x2 contingency table based on the
data presented (n=74); the use of ineligible index tests (n=35) (for example: reporting of data for ‘clinical diagnosis’ or for
serial use of the index test in a follow-up context); assessment of individual lesion characteristics (n=32); or derivation type
studies developing new algorithms or checklists without a separate training and test set of lesions (n=31). Other reasons for
exclusion included not meeting our requirements for an eligible reference standard (n=32), ineligible study populations (n=37)
(for example, recruiting only malignant or only benign lesions), inadequate sample size (n=30), ineligible definition of the
target condition (n=86; including those eligible only for reviews of the detection of melanoma) or with test interpretation by
medical students or laypersons (n=8). A list of the 442 publications excluded from this review with reasons for exclusion is
provided in Characteristics of excluded studies, with a list of all studies excluded from the full series of reviews available as a
separate pdf.
The authors of 17 publications concerned with the evaluation of visual inspection or dermoscopy were contacted for
further data to allow study inclusion; responses were received from four authors with regard to seven publications.
Two authors provided additional data but this was insufficient to allow inclusion of the studies (Cabrijan 2008; Warshaw
2009; Warshaw 2009a; Warshaw 2010), one replied indicating that dermoscopy was not necessarily used in all study
participants (Youl 2007; Youl 2007a) and one replied but was unable to access the data needed (Fabbrocini 2008).
The authors of a further seven included studies were contacted for further details of study methods. Responses were
received in regard to four studies; three provided further information regarding the diagnostic thresholds used (Amirnia 2016; 
Durdu 2011; Stanganelli 2000) and one provided full anonymised study data (Rosendahl 2011) .
The 24 included study publications report on a total of 24 cohorts of lesions and provide 27 visual inspection datasets (8805
lesions; 2579 malignancies) and 33 dermoscopy datasets (6855 lesions; 1444 malignancies). A summary of the tests and
target conditions evaluated in each study is reported in Appendix 7. Six studies contributed data for in-person visual
inspection alone (Chang 2013; Cooper 2002; Ek 2005; Hacioglu 2013; Schwartzberg 2005; Steiner 1987); three for
dermoscopy added to visual inspection (Amirnia 2016; Durdu 2011; Gokdemir 2011); and five for both in-person
visual inspection alone and combined with dermoscopy (Argenziano 2006; Carli 2002a; Markowitz 2015; Stanganelli 2000; 
Ulrich 2015). Two studies contributed data for image-based visual inspection of clinical photographs alone (Lorentzen 1999; 
Nori 2004); eight for image-based dermoscopy (Altamura 2010; Carli 2002a; Hacioglu 2013 ; Lorentzen 2008; Menzies 2000;
Navarrete Dechent 2016; Witkowski 2016; Zalaudek 2006); and two for both image-based visual inspection and image-
based dermoscopy (Carli 2002b; Rosendahl 2011). Five studies compared the accuracy of visual inspection and/or
dermoscopy to other tests including: exfoliative cytology (Durdu 2011); CAD (Hacioglu 2013); OCT (Markowitz 2015; Ulrich
2015); and RCM (Witkowski 2016). Thirteen studies also contributed data to our reviews of visual inspection (n=9)
and/or dermoscopy (n=9) for the detection of melanoma (Dinnes 2018a; Dinnes 2018b).
Methodological quality of included studies
The overall methodological quality of all included studies is summarised according to in-person or image-based approaches
to dermoscopy or to visual inspection. Fourteen studies reporting data for in-person visual inspection (n = 11) and/or in-
person dermoscopy (added to visual inspection) (n = 8) are presented in Figure 6 with results per study presented in Figure
7. Twelve studies reporting data for image-based visual inspection (n = 4) and/or image-based dermoscopy (n = 10) are
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presented in Figure 8 with results per study presented in Figure 9. Two studies appear in both sets of figures: Carli 2002a
evaluated the accuracy of image-based dermoscopy as well as in-person visual inspection and dermoscopy, while Hacioglu
2013 reported data for in-person visual inspection and image-based dermoscopy.
In-person evaluations
Risk of bias was judged to be ‘Low’ for the majority of studies in only two of five quality domains assessed
(dermoscopy index test, reference standard); risk of bias was judged to be ‘High’ or ‘Unclear’ for the majority of studies
for participant selection, visual inspection index test, and flow and timing (Figure 6). Applicability of study findings were
scored as of ‘High’ or ‘Unclear’ concern in all four domains (participant selection, dermoscopy and visual inspection index
tests, reference standards) assessed for all studies apart from one .
For participant selection: three of the 14 studies (21%) were judged at low risk of bias and three (21%) were
considered high risk (Figure 6) due to exclusion of lesions by size (Hacioglu 2013) or because of missing (Ulrich 2015) or
equivocal pathology (Ek 2005). Five studies (36%) did not report the method of participant selection and 8 (57%)
did not clearly describe exclusions from the study. All studies were considered at high concern for applicability of
participants, primarily due to inclusion of lesions selected for biopsy or excision based on the clinical or
dermoscopic diagnosis. Only one was judged to have included a representative population (Stanganelli 2000). Nine
cohorts (64%) also included multiple lesions per participant (Chang 2013; Cooper 2002; Durdu 2011; Ek 2005; Gokdemir
2011; Markowitz 2015; Schwartzberg 2005; Stanganelli 2000; Ulrich 2015) and three did not clearly report
number of included participants (Argenziano 2006; Carli 2002a; Steiner 1987).
For the index test domain: there are 8 evaluations of in-person dermoscopy and 11 evaluations of in-person visual
inspection (Figure 6). For dermoscopy, 6 evaluations (75%) were considered at low risk of bias and two did not
provide sufficient information to allow the risk of bias to be fully judged. All studies were judged to have made the
diagnosis blinded to the reference standard result given that this is always undertaken prior to histology; six
(75%) also clearly reported pre-specification of the diagnostic threshold (all using named algorithms or pattern).
All 11 visual inspection evaluations were also considered to have made the diagnosis blinded to the reference
standard result. Only three clearly reported pre-specification of the threshold used; two reporting use of formal
algorithms (Argenziano 2006; Stanganelli 2000) and one describing the process by which the diagnosis was reached (
Ulrich 2015).
High concern for the applicability of the index tests was recorded for three in-person evaluations of dermoscopy
(437%) and for 7 evaluations of visual inspection (64%) (Figure 6). For the dermoscopy evaluations this was due
to the presentation of average (Argenziano 2006) or consensus diagnoses (Carli 2002a) as opposed to the
diagnosis of a single observer, and a lack of description of the diagnostic threshold used (Gokdemir 2011). Only two
studies provided sufficient information on which to judge the level of observer expertise in dermoscopy (Carli 2002a; 
Gokdemir 2011). For visual inspection, high concerns were recorded due to the presentation of average (Argenziano 2006
) or consensus (Carli 2002a; Steiner 1987) diagnoses, or lack of detail regarding the threshold for diagnosis (Carli 2002a; 
Chang 2013; Cooper 2002; Ek 2005; Hacioglu 2013; Steiner 1987). The majority of studies (7/11) did not provide sufficient
information on which to judge the level of observer expertise in lesion diagnosis.
For the reference standard: All studies except Stanganelli 2000 were judged at low risk of bias due to the use of an
acceptable reference standard (73%) (Figure 6). In Stanganelli 2000 only 8% included lesions underwent excision,
the remaining 3110 ‘benign’ diagnosed were assumed to be benign based on cancer registry follow-up. Blinding of
the reference standard to the index test was recorded but did not contribute to the overall risk of bias for this domain.
Blinding of the reference standard was reported in only one study (Amirnia 2016). The applicability of the
reference standard was of low concern in one evaluation reporting pathology review by an expert histopathologist
(Argenziano 2006) and was rated as unclear in the remaining 13 (93%). 28 (78%).
For participant flow and timing: five studies were judged at low risk of bias (36%), three were rated unclear (21%) and
six at high risk of bias (43%) (Figure 6). Of those at high risk, one did not use the same reference standard for all
participants (Stanganelli 2000), and five did not include all participants in the analysis. Seven studies were unclear on the
interval between the application of the index test and excision for histology.
Image-based evaluations
Across the 12 studies providing image-based data, risk of bias was judged to be 'High' or 'Unclear' for at least half of
studies in all domains apart from the reference standard domain (Figure 8). Applicability of study findings were also scored
as of ‘High’ concern in almost all studies apart from for the reference standard domain.
For participant selection: six of the 12 evaluations (50%) were judged at high risk of bias, four did not provide sufficient
information to judge this domain, and two were low risk of bias (Figure 8). Three studies (25%) used a case-control
type design with separate sampling of malignant and benign lesions (Altamura 2010; Menzies 2000; Nori 2004), and
two (17%) excluded lesions on the basis of size (Hacioglu 2013) or type of lesion (Navarrete Dechent 2016
excluding seborrhoeic keratosis). Five evaluations (42%) did not report the method of participant selection and six
(50%) did not clearly describe exclusions from the study. All evaluation cohorts were considered at high concern
for applicability of participants, primarily due to the restricted inclusion of lesions selected for excision or biopsy.
Two studies also reported including multiple lesions per participant (Navarrete Dechent 2016; Rosendahl 2011).
For the index test domain: there are 10 evaluations of image-based dermoscopy and four evaluations of visual
inspection of clinical images (Figure 8). Insufficient information was provided on which to judge the risk of bias for
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visual inspection, due to unclear pre-specification of the threshold for diagnosis of skin cancer. For dermoscopy,
five evaluations (50%) were considered at low risk of bias, four were judged unclear (36%) and one at high risk.
The high risk study developed a new algorithm for dermoscopy using previously characteristics suggested to be
associated with BCC but did not use a separate training set to develop the algorithm (Navarrete Dechent 2016).
Four studies did not clearly report pre-specification of the diagnostic threshold used (Altamura 2010; Carli 2002b; Hacioglu
2013; Witkowski 2016).
High concern for the applicability of the index tests was recorded for all four visual inspection and nine of 10
dermoscopy evaluations due to the use of image-based interpretations. None of the visual inspection evaluations
provided further information on the participants concerned and two presented average (Lorentzen 1999) or consensus (Carli
2002b) diagnoses. All four did not provide sufficient detail regarding the diagnostic threshold used. For
dermoscopy, nine studies reported blinded interpretation of dermoscopic images and six reported average (Lorentzen 2008; 
Zalaudek 2006) or consensus (Carli 2002a; Carli 2002b; Navarrete Dechent 2016) diagnoses or were not clear on
the data provided (Menzies 2000). One study reported presentation of the clinical photograph of the lesion
alongside the dermoscopic image (Rosendahl 2011) and also presented data for a single observer. Four studies did not
provide sufficient information on the diagnostic threshold (Carli 2002b; Hacioglu 2013; Lorentzen 2008; Witkowski 2016
) and four did not provide details of the observer expertise (Hacioglu 2013; Menzies 2000; Witkowski 2016; Zalaudek 2006).
For the reference standard: 11 (92%) of the 12 included image-based studies were judged at low risk of bias (Figure 8). Nori
2004 was considered at high risk as it did not meet our criteria or an adequate reference standard (histology or clinical
follow-up in at least 80% of benign lesions). Blinding of the reference standard to the original clinical diagnosis was not
reported in any study. The applicability of the reference standard was rated as unclear concern in 11 studies due to lack of
detail regarding the expertise of the histopathologist or by a dermatopathologist. Nori 2004 was of high concern due to the
use of expert opinion for classifying the final diagnosis of some lesions.
For participant flow and timing: six studies were at high risk of bias (50%), four at low risk (33%) and two (17%) did not
provide enough information on which to judge this domain (Figure 8). Of those at high risk, one evaluations did not use
the same reference standard for all participants (differential verification) (Nori 2004), and all six did not include all
participants in the analysis. Seven studies (58%) were unclear on the interval between the application of the index test
and lesion excision with only five (42%) considered to report consecutive diagnosis and excision or biopsy (Carli 2002b; 
Hacioglu 2013; Lorentzen 1999; Menzies 2000; Witkowski 2016).
Findings
1. Target condition: BCC
A total of 21 studies reported accuracy data for the detection of BCC. Twelve studies provided data for visual inspection
alone; eight evaluations were conducted in-person and four were image-based. Fifteen studies reported accuracy data
for the detection of BCC by using dermoscopy; seven evaluations were in-person and nine were image-based. One
study reported dermoscopy data for both in-person and image based dermoscopy (Carli 2002a).
Summary details of the in-person and image-based studies are provided in Appendix 8. Results for the primary analyses are
presented in Table 1 with heterogeneity investigations presented in Table 2 and Table 3. Forest plots of study data for each
analysis are given in Figure 10 and Figure 11; summary estimates for in-person comparisons are depicted in Figure 12 and
Figure 13 and for image-based comparisons in Figure 14 and Figure 15.
Analyses by clinical pathway and in-person versus image-based design
Attempts to classify studies according to where on the clinical pathway they had been conducted were hindered by
lack of information. Only eight studies were considered to have provided a clear description of the prior testing of
included participants and only three were conducted in a limited prior testing population as opposed to studies in
participants referred for specialist assessment (Appendix 8). We were therefore unable to analyse data by pathway for either
visual inspection or for dermoscopy.
No clear differences in accuracy were noted between studies undertaken in-person and those which evaluated images
(Table 2 and Table 3). The accuracy of visual inspection was non-significantly lower for in-person studies of visual
inspection compared to image-based (RDOR 0.45; 95% CI 0.26, 9.2, LR test P = 0.88) (Table 2; Figure 16), while the
accuracy of in-person dermoscopy was non-significantly higher compared to diagnosis based on dermoscopic images
(RDOR 4.0; 95% CI 0.46, 33.8; LR test P = 0.39) (Table 3; Figure 17). The lack of effect observed is likely due to
other sources of heterogeneity, particularly given the much bigger and highly significant effect observed for this
analysis for the detection of melanoma (Dinnes 2018a). We elected to undertake our primary analyses separately for in-
person and image-based analyses to be consistent with the approach used in the melanoma review.
In-person evaluations
The 11 studies reporting in-person evaluations of visual inspection (n = 8) or visual inspection plus dermoscopy (n
= 7) were all conducted in referred populations undergoing biopsy or excision (Appendix 9), three were considered
to have been conducted in participants with equivocal lesions (Markowitz 2015; Steiner 1987; Ulrich 2015) and one in
participants at high risk for developing skin cancer following renal transplantation (Cooper 2002). Seven
evaluations were prospective case series, one was retrospective (Stanganelli 2000), and three did not clearly report
the direction of the design (Amirnia 2016; Carli 2002a; Gokdemir 2011).
Five of the 11 studies primarily aimed to examine accuracy for the detection of BCC (Amirnia 2016; Markowitz 2015; 
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Schwartzberg 2005; Ulrich 2015) or ‘non-melanoma’ skin cancer (Cooper 2002), the remaining 6 also provided data
for our reviews of visual inspection and/or dermoscopy for the diagnosis of melanoma (Dinnes 2018a; Dinnes 2018b). Two
evaluations included any lesion considered suspicious for skin cancer (Ek 2005; Cooper 2002); two included lesions
suspicious for BCC (Amirnia 2016; Schwartzberg 2005), one restricting to lesions on the face (Amirnia 2016); five
included only pigmented lesions (Stanganelli 2000; Steiner 1987; Carli 2002a; Durdu 2011; Gokdemir 2011; Steiner 1987
) and two to non-pigmented ‘pink’ lesions (Markowitz 2015; Ulrich 2015) one restricting to head and neck lesions
only (Markowitz 2015). The prevalence of BCC ranged from 1% (Stanganelli 2000) to 61% (Markowitz 2015); median 17%
(IQR 10, 53%). The lowest prevalence was generally observed in the studies in pigmented lesions (1% to 10% in four
studies) and the highest in non-pigmented or lesions suspicious for BCC (58 to 61% in three studies). Six studies reported
including invasive melanoma or melanoma in situ (Stanganelli 2000; Carli 2002a; Durdu 2011; Gokdemir 2011; Steiner 1987;
Ek 2005) and two included cSCC (Cooper 2002; Ek 2005) in the disease negative group.
Diagnosis was recorded by dermatologists or clinicians presumed to be dermatologists (based on author’s
institutions) in the majority of studies (9/11; 82%), a mixed group of dermatology residents (trainees) and consultants
(Cooper 2002) or plastic surgery residents, consultants and a clinical assistant (Ek 2005). Where reported (n = 7), the
number of observers ranged from 1 to 17 (median 2).
Test accuracy was reported for a single observer in almost half of evaluations (n = 6), for a consensus of two or three
observers in two (Carli 2002a; Steiner 1987), and this information could not be derived for the remaining 3 evaluations (Ek
2005; Gokdemir 2011; Markowitz 2015).
Visual inspection (in-person)
Across the eight evaluations of visual inspection, no formal algorithm to assist diagnosis was reported in 87% (n =
7) and one reported using the ABCD approach (Stanganelli 2000). Sensitivity ranged from 20% to 90% and specificity
from 29% to 100% (Figure 10). Examinations in six studies were undertaken by dermatologists, (or were assumed to
be dermatologists based on study institution) and in two studies by consultant or registrar dermatologists (Cooper 2002) or
plastic surgeons (Ek 2005). The lowest sensitivities were reported in studies restricted to pigmented lesions, particularly Carli
2002a and Stanganelli 2000. Results were pooled across algorithms and thresholds as a summary ROC curve (7017 lesions
and 1586 BCCs; Figure 12). Estimates of accuracy obtained from the curve suggest that the specificity of visual
inspection would be 77% at a fixed threshold of 80% sensitivity, and sensitivity would be 79% at a fixed threshold of
80% specificity (Table 1). These 80% fixed values were chosen as they lie within the estimates for the majority of
analyses and should only be considered as illustrative examples of the values that might be achieved based on the
observed data (Statistical analysis and data synthesis). Of the three datasets which included melanomas in the disease
negative group (Carli 2002a; Stanganelli 2000; Steiner 1987), 5 of the 15 false positive results were melanoma mistaken
for BCCs (Carli 2002a; Steiner 1987).
Dermoscopy added to visual inspection
For the seven evaluations of dermoscopy added to visual inspection, two did not report using any algorithm to assist
diagnosis (Durdu 2011; Gokdemir 2011), two used pattern analysis (Carli 2002a; Stanganelli 2000), and three
employed formal algorithms to assist diagnosis including the 3-point checklist for BCC (Amirnia 2016) and
Marghoob and colleagues (Marghoob 2010) two-step approach for classifying skin lesions (Markowitz 2015; Ulrich 2015
). Sensitivity ranged from 79% to 100% and specificity from 54% to 100% (Figure 10). The low specificities of 54% (Ulrich
2015) and 56% (Markowitz 2015) appeared as outliers (with non-overlapping confidence intervals), all other studies having
specificities of 96% or above. Both studies included particularly high percentages of BCC (60-61%) and included non-
pigmented lesions with a high clinical suspicion of being BCC.
Results were pooled across algorithms and thresholds as a summary ROC curve (4683 lesions and 363 BCCs; Figure 12
). Estimates of accuracy obtained from the curve suggest that the specificity of dermoscopy would be 99% at a fixed
threshold of 80% sensitivity, and sensitivity would be 93% at a fixed threshold of 80% specificity (Table 1). Of the four
datasets which included melanomas in the disease negative group (Carli 2002a; Durdu 2011; Gokdemir 2011; Stanganelli
2000), three of the 19 false positive results were melanoma mistaken for BCCs (Durdu 2011; Gokdemir 2011).
Comparison of in-person dermoscopy added to visual inspection versus visual inspection alone
The accuracy of visual inspection was compared with the accuracy of dermoscopy estimated from (a) all 8 in-person
visual inspection and all 7 dermoscopy studies (Figure 12) and (b) estimated from direct comparisons in the subset of 4
studies that evaluated both visual inspection and dermoscopy on an in-person basis (3974 lesions and 258 BCCs; Figure
13). In both comparisons the accuracy of dermoscopy in addition to visual inspection exceeded that of visual inspection
alone (Table 1). In (a) the diagnostic odds ratio (DOR) for dermoscopy was 8.2 (95% CI: 3.5 to 19.3; LR test P < 0.001) times
that of visual inspection alone, in (b) it was 7.5 (95% CI: 2.7 to 21.3; LR test P = 0.001) times that of visual inspection
alone. These effects correspond to predicted differences in specificity of (a) 22% (99% vs 77%) and (b) 61% (97% vs
36%) at a fixed sensitivity of 80% (Table 1) and predicted differences in sensitivity of (a) 14% (93% vs 79%) and (b)
16% (87% vs 71%) at a fixed specificity of 80% (Table 1).
Image-based evaluations
The 11 studies reporting image-based diagnosis using clinical photographs (n = 4) or dermoscopic images (n = 9)
were primarily conducted in referred populations undergoing biopsy or excision (Appendix 9). Two studies were
conducted in a limited prior testing setting, recruiting participants from primary care (Rosendahl 2011) or from a
private dermatology practice (Navarrete Dechent 2016). Of the remaining 9, one was conducted in participants with
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equivocal lesions (Witkowski 2016). Two evaluations used a case-control type design, separately recruiting
diseased and non-diseased participants (Altamura 2010; Menzies 2000), one was a prospective case series (Lorentzen
1999), five retrospectively selected series of images for prospective interpretation within the context of the study (Navarrete
Dechent 2016; Nori 2004; Rosendahl 2011; Witkowski 2016; Zalaudek 2006), and three did not clearly report the
direction of the design (Carli 2002a; Carli 2002b; Lorentzen 2008).
Five of the 11 studies primarily aimed to examine accuracy for the detection of BCC (Altamura 2010; Menzies 2000; 
Navarrete Dechent 2016; Nori 2004; Witkowski 2016), the remaining 6 also provided data for our reviews of visual
inspection and/or dermoscopy for the diagnosis of melanoma (Dinnes 2018a; Dinnes 2018b). Four evaluations
included any lesion, pigmented or non-pigmented (Altamura 2010; Lorentzen 1999; Lorentzen 2008; Zalaudek 2006);
four included only pigmented lesions (Carli 2002a; Carli 2002b; Menzies 2000; Rosendahl 2011); two included
non-pigmented lesions only (Navarrete Dechent 2016; Witkowski 2016) and one included biopsy confirmed BCCs and
lesions with a range of common diagnoses (Nori 2004). The prevalence of BCC ranged from 2% (Carli 2002a) to
63% (Navarrete Dechent 2016); median 16% (IQR 11, 47%). The highest prevalence was generally observed in the studies
in non-pigmented lesions or lesions suspicious for BCC (44 to 63% in four studies, one of which used case-control type
design; Altamura 2010). All studies apart from Nori 2004 reported including invasive melanoma or melanoma in situ
and five also included cSCC in the disease negative group (Altamura 2010; Nori 2004; Rosendahl 2011; Witkowski 2016; 
Navarrete Dechent 2016).
Diagnosis was recorded by dermatologists or clinicians presumed to be dermatologists (based on author’s
institutions) in the majority of studies (9/11; 73%), or by a mixed group of clinicians in two (Lorentzen 1999; Zalaudek 2006).
Where reported (n = 9), the number of observers ranged from 2 (reported for five studies) to 150 (median 2).
Test accuracy was reported for a single observer in four studies, for a consensus of two observers in three (Carli 2002a; 
Carli 2002b; Navarrete Dechent 2016), the average across observers in three (Lorentzen 1999; Lorentzen 2008; Zalaudek
2006) and this information could not be derived for one (Menzies 2000).
Visual inspection of clinical photographs
Across the four evaluations of image-based visual inspection, no formal algorithm was reported to have been used to
assist diagnosis. Sensitivity ranged from 48% to 89% and specificity from 62% to 98% (Figure 11). Results were pooled as a
summary ROC curve (853 lesions and 156 BCCs; Figure 14). Estimates of accuracy obtained from the curve suggest
that the specificity of image-based visual inspection would be 87% at a fixed threshold of 80% sensitivity, and
sensitivity would be 85% at a fixed threshold of 80% specificity (Table 1). Of the three datasets which included
melanoma in the disease negative group (Carli 2002b; Lorentzen 1999; Rosendahl 2011), 3 of 39 false positive
results were melanoma mistaken for BCCs (Rosendahl 2011).
Dermoscopic image-based diagnosis
For the nine evaluations of image-based dermoscopy, two did not report using any algorithm to assist diagnosis (Carli 2002b;
Witkowski 2016), two used pattern analysis (Carli 2002a; Lorentzen 2008), and five employed formal algorithms to
assist diagnosis including the 3-point checklist (Zalaudek 2006), the Menzies algorithm for BCC (Menzies 2000) or
a modification thereof (Altamura 2010) or a new algorithm ‘shiny white blotches and strands (Navarrete Dechent 2016
). Only one study provided the clinical photograph alongside the dermoscopic image (Rosendahl 2011), the remainder
reported blinded dermoscopy interpretations. Sensitivity ranged from 40% to 97% and specificity from 50% to 100% (Figure
11). Particularly low sensitivities were observed in Carli 2002a and Navarrete Dechent 2016 (which respectively had the
lowest (2%) and highest (63%) prevalence of BCC), the latter also reporting the lowest specificity (50%). All other studies
reported sensitivities of 85% or above and specificities of 72% or more.
Results were pooled across algorithms and thresholds as a summary ROC curve (2271 lesions and 737 BCCs; Figure 14
). Estimates of accuracy obtained from the curve suggest that the specificity of dermoscopy would be 96% at a fixed
threshold of 80% sensitivity, and sensitivity would be 93% at a fixed threshold of 80% specificity (Table 1). All nine
evaluations included melanomas in the disease negative group; 23 of the 178 false positive results were
melanomas mistaken for BCCs in five studies (Navarrete Dechent 2016; Witkowski 2016; Zalaudek 2006; Rosendahl 2011; 
Menzies 2000) and 45 were cSCCs mistaken for BCCs (Navarrete Dechent 2016; Witkowski 2016). The Navarrete Dechent
2016 study alone was responsible for 53 false positives (44 cSCC and 9 melanomas).
Comparison of diagnosis based on dermoscopic images versus visual inspection of images
The accuracy of image-based visual inspection was compared with the accuracy of dermoscopy estimated from (a) all
4 image-based visual inspection and all 9 dermoscopy studies (Figure 14) and (b) estimated from direct comparisons in the
subset of two studies that evaluated both clinical photographs and dermoscopic images (516 lesions and 79 BCCs; Figure
15). In both comparisons the accuracy of dermoscopy in addition to visual inspection exceeded that of visual inspection
alone (Table 1). In (a) the diagnostic odds ratio (DOR) for dermoscopy was 3.9 (95% CI: 1.2 to 5.0; LR test P = 0.006)
times that of visual inspection alone, in (b) the RDOR was not estimable however the DOR of 275.5 (95% CI 112, 678)
for dermoscopy exceeded of visual inspection alone (DOR 81.1, 95% CI 39.1, 168). These effects correspond to
predicted differences in specificity of (a) 9% (96% vs 87%) and (b) 4% (99% vs 95%) at a fixed sensitivity of 80% (Table 1
) and predicted differences in sensitivity of (a) 8% (93% vs 85%) and (b) 4% (99% vs 95%) at a fixed specificity of 80%
(Table 1).
Secondary analyses for the detection of BCC
Covariate investigations
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Table 2 and Table 3 report the results of the heterogeneity investigations for visual inspection and for dermoscopy
respectively. As discussed above, no clear differences in accuracy were noted between studies undertaken in-person and
those which evaluated images for either test. Although our primary analyses are presented separately for in-person and
image-based approaches, due to a paucity of data, all subsequent covariate investigations are based on the complete
datasets for each test.
Visual inspection: Use of a formal algorithm versus no formal algorithm could not be investigated for visual inspection
due to lack of data. Observed accuracy was significantly higher however, where disease prevalence of BCC was 25%
or less (RDOR 9.7; 95% CI 2.3, 40.8; LR test P = 0.002), compared to those where disease prevalence was greater
than 25% (Table 2). This result appears to be driven by lower specificities with non overlapping confidence
intervals in the studies in the higher prevalence group, the majority of which were conducted in populations
with lesions suspicious for BCC (Schwartzberg 2005; Ulrich 2015; Markowitz 2015; Nori 2004). Sensitivities
reported in these studies were largely within the range of those reported by studies in the lower prevalence group (
Appendix 10).
Dermoscopy: Observed accuracy was somewhat higher in studies using no formal algorithm to assist diagnosis as opposed
those reporting use of an algorithm (RDOR 7.8, 95% CI 0.90, 68.2; LR test P = 0.004) Table 3. Accuracy was also non-
significantly higher, where disease prevalence of BCC was 25% or less (RDOR 4.5; 95% CI 0.49, 41.8; LR test P =
0.04), compared to those with disease prevalence was greater than 25% (Table 3). There is considerable overlap in the
studies included in the ‘named algorithm’ and higher prevalence groups (with 6 of the 7 same studies appearing in each
group – Amirnia 2016; Markowitz 2015; Ulrich 2015; Altamura 2010; Menzies 2000; Navarrete Dechent 2016). It
seems likely that both factors play a role in the observed differences in accuracy (Appendix 10).
Analyses by algorithms used to assist diagnosis
Details of the algorithms used to assist diagnosis are provided in Appendix 9. Results by algorithm used (or not used) are
reported in Table 4 for each of the target conditions under consideration in this review.
For the diagnosis of BCC, Table 4 highlights the lack of available data for formal algorithms to diagnose BCC,
particularly for visual inspection. Although a number of dermoscopic algorithms have been evaluated for the
diagnosis of BCC, only the Menzies algorithm appears to show promise in terms of increasing sensitivity without
sacrificing the specificity which can be achieved by observer diagnosis alone (with no algorithm). The data however
come from the same study which developed the algorithm using dermoscopic images and it remains to be seen
whether results can be replicated on an in-person basis (Menzies 2000).
Analyses by observer experience
Observer experience was generally poorly described in the study reports (Appendix 8), however we attempted broad
classifications by reported expertise in visual inspection or dermoscopy regardless of in-person or image-based approach to
diagnosis. The resulting study subgroups were small, and results highly heterogeneous therefore no further analyses by
observer expertise could be undertaken. None of the included studies provided direct comparisons of observer accuracy
according to expertise or qualifications.
2. Target condition: cSCC
Four studies reported accuracy data for the detection of cSCC. Two studies provided data for in-person visual
inspection (Cooper 2002; Ek 2005) and two for image-based dermoscopy (Navarrete Dechent 2016; Witkowski 2016
) (Appendix 8). Results for the primary analyses are presented in Table 5. Forest plots of study data are given in Figure 18.
Visual inspection (in-person)
Both studies of visual inspection were conducted in secondary clinic specialist clinics, one of which was provided for
renal transplant recipients (Cooper 2002). Both included participants with a range of different lesion types that might
be observed in clinical practice. The prevalence of cSCC was 21% (Cooper 2002) and 20% (Ek 2005). Both studies reported
data for observers’ correct diagnosis of cSCC using no formal algorithm.
Pooled sensitivity and specificity (2684 lesions; 538 cSCCs) were 57% (95% CI 53, 61%) and 79% (95% CI 77, 81%)
respectively. In Cooper 2002 none of the 12 BCCs were mistaken for cSCCs however in Ek 2005, 119 of 1214 included
BCCs were diagnosed as cSCCs (accounting for 28% of the false positives in this study).
Dermoscopic image-based diagnosis
The two studies evaluating dermoscopic images were both conducted in participants with non-pigmented lesions, Navarrete
Dechent 2016 using their own new algorithm for detection of BCC based on the presence of shiny white streaks and blotches
(but also reporting accuracy data for detection of cSCC using the algorithm) and Witkowski 2016 using no algorithm.
Navarrete Dechent 2016 recruited primarily participants with malignant lesions (90% of lesions) whereas Witkowski 2016
included participants with a wider range of different lesion types that might be observed in clinical practice. The
prevalence of cSCC was 23% (Navarrete Dechent 2016) and 5% (Witkowski 2016).
Pooled sensitivity and specificity (717 lesions; 119 cSCCs) were 55% (95% CI 29, 79%) and 84% (95% CI 32, 98%)
respectively. Both sensitivity and specificity were considerably higher in Witkowski 2016 compared to Navarrete Dechent
2016 and the resulting confidence intervals were therefore extremely wide.
Comparison of dermoscopy versus visual inspection
No formal comparison of visual inspection and dermoscopy is possible for the detection of cSCC as visual inspection data is
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from in-person studies and dermoscopy from image-based studies.
3. Target condition: Any skin cancer
In this section we present the results for studies of visual inspection for the identification of any skin cancer, according to the
approach taken for diagnosis: in-person or image-based evaluations. Summary characteristics of studies are presented in
Appendix 8, forest plots of study data in Figure 19 and Figure 20 and results of meta-analyses in Table 6 and Figure 21 and
Figure 22.
In-person evaluations
Five studies evaluated the accuracy of in-person visual inspection for the detection of any skin cancer (Argenziano 2006; 
Chang 2013; Cooper 2002; Ek 2005; Hacioglu 2013) and two evaluated in-person dermoscopy (Argenziano 2006; Durdu
2011). Three of these also reported accuracy data separately for BCC alone (Cooper 2002; Durdu 2011; Ek 2005) or
for cSCC (Cooper 2002; Ek 2005).
All studies were based in secondary care or specialist referral clinics apart from Argenziano 2006 which recruited
participants from primary care (although only lesions selected for excision by an expert could be included). The
prevalence of skin cancer ranged from 20% (Chang 2013) to 68% (Ek 2005). Studies included any lesion type apart from
Durdu 2011 which restricted inclusion to pigmented lesions only. Diagnoses were recorded by GPs (Argenziano 2006
), dermatologists or assumed to be dermatologists based on study institution (Chang 2013; Durdu 2011; Hacioglu 2013
) or by clinician with mixed experience (Cooper 2002; Ek 2005). All studies used a histological reference standard.
Visual inspection
Studies either used no algorithm to aid diagnosis, or reported using the ABCD approach to diagnosis (Argenziano 2006
). Sensitivities ranged from 57% to 98%; specificities ranged from 13% to 86% (Figure 19). In meta-analysis the DOR
was 28.7 (95% CI 5.0, 166) (3618 lesions and 2021 skin cancer cases). Estimates of accuracy obtained from the curve
suggest that the specificity of visual inspection would be 88% at a fixed threshold of 80% sensitivity, and sensitivity
would be 84% at a fixed threshold of 80% specificity (Table 6).
Dermoscopy added to visual inspection
The two studies of in-person dermoscopy reported data using the 3-point checklist (Argenziano 2006) and the ABCD
approach (Durdu 2011) (Figure 19). In Argenziano 2006, GPs diagnosis had a sensitivity of 85% (95% CI 69, 94%) and
specificity of 26% (95% CI 13, 43%) for the subgroup of lesions selected for excision by an expert clinician. Of the six
malignancies missed by GPs, four were BCCs, one cSCC and one melanoma. Durdu 2011 reported a sensitivity of 98%
(95% CI 88, 100%) and specificity 98% (95% CI 94, 100%) for their sample of pigmented lesions which could not be
diagnosed by a dermatologist with visual inspection alone.
In meta-analysis the DOR was 126 (95% CI 9.1, 1751) (277 lesions and 85 skin cancer cases) (Table 6). Estimates of
accuracy were not obtained from the SROC curve due to extreme differences in results between the two studies (evidenced
by the very wide range in confidence intervals around the DOR).
Comparison of in-person dermoscopy versus visual inspection alone
No formal comparison of visual inspection and dermoscopy added to visual inspection was possible due to the
observed heterogeneity in results for the two dermoscopy studies (Figure 21).
Image-based evaluations
Six studies reported data for image-based diagnosis for the detection of any skin cancer. Two evaluated the accuracy of
image-based visual inspection (Carli 2002b; Rosendahl 2011) and all six evaluated diagnosis using dermoscopic images
(Carli 2002b; Hacioglu 2013; Menzies 2000; Navarrete Dechent 2016; Rosendahl 2011; Witkowski 2016). Five of these
also reported accuracy data separately for BCC alone (Carli 2002b; Menzies 2000; Navarrete Dechent 2016; Rosendahl
2011; Witkowski 2016) or for cSCC (Navarrete Dechent 2016; Witkowski 2016).
Two studies were conducted in a limited prior testing setting, recruiting participants from primary care (Rosendahl 2011
) or from a private dermatology practice (Navarrete Dechent 2016). Of the remaining four, one was considered to
have been conducted in participants with equivocal lesions (Witkowski 2016). Four of the six studies primarily aimed
to examine accuracy for the detection of BCC (Menzies 2000; Navarrete Dechent 2016; Witkowski 2016) or ‘non-
melanoma’ skin cancer (Hacioglu 2013), the remaining two also provided data for the diagnosis of melanoma (Carli 2002b; 
Rosendahl 2011). Three studies included only pigmented lesions (Carli 2002b; Menzies 2000; Rosendahl 2011);
two included non-pigmented lesions only (Navarrete Dechent 2016; Witkowski 2016) and one described lesions as
‘suspicious for malignancy’ (Hacioglu 2013). All studies apart from Hacioglu 2013 reported including invasive melanoma or
melanoma in situ as disease negative and four also included cSCC (all apart from Carli 2002b and Menzies 2000)
in the disease negative group. Diagnosis was recorded by dermatologists or by dermatology trainees (Navarrete Dechent
2016). All studies used a histological reference standard.
Visual inspection of images
The two included studies used no algorithm to aid diagnosis and both included pigmented lesions only (Carli 2002b; 
Rosendahl 2011). Sensitivities were 80% (95% CI 56, 94%) and 76% (95% CI 67, 84%) and specificities 74% (95% CI 56,
87%) and 85% (95% CI 81, 88%) in Carli 2002b and Rosendahl 2011, respectively (Figure 20).
In meta-analysis the DOR was 16.3 (95%CI 4.4, 59.9) (517 lesions and 124 skin cancer cases). Estimates of accuracy
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obtained from the curve suggest that the specificity of visual inspection would be 79% at a fixed threshold of 80%
sensitivity, and sensitivity would be 78% at a fixed threshold of 80% specificity (Table 6).
Dermoscopic image-based diagnosis
Across the six studies, no algorithm was used to assist diagnosis in three (Carli 2002b; Hacioglu 2013; Witkowski 2016;
pattern analysis in one (Rosendahl 2011) and new algorithms for detection of BCC in two (Menzies 2000; Navarrete
Dechent 2016).
Sensitivity ranged from 50% to 95% and specificity from 63% to 92% (Figure 20). Results were pooled across algorithms and
thresholds as a summary ROC curve (1526 lesions and 847 BCCs; Figure 22). Estimates of accuracy obtained from
the curve suggest that the specificity of dermoscopy would be 84% at a fixed threshold of 80% sensitivity, and
sensitivity would be 86% at a fixed threshold of 80% specificity (Table 6).
Comparison of diagnosis using dermoscopic images versus visual inspection of images
Accuracy was compared using data from both visual inspection studies and all dermoscopy studies (Figure 22). The
accuracy of diagnosis using dermoscopic images was non-significantly higher than that based on clinical photographs (
Table 6), with an RDOR of 1.5 (95% CI 0.76, 3.0; LR test P = 0.50). Differences in sensitivity and specificity between tests in
the two studies providing paired data were marginal.
Discussion 
Summary of main results
Visual inspection and the addition of dermoscopy for the detection of keratinocyte skin cancers have been evaluated in a
range of study populations, on both an in-person basis and using clinical photographs or dermoscopic images. Although a
small number of published algorithms to assist diagnosis are available, the majority of data relate to diagnosis without the
use of an algorithm and relate to the detection of BCC rather than cSCC. Studies either did not recruit sufficient numbers of
participants with cSCC to meet our inclusion criteria (i.e. >= 5 confirmed cSCCs) or did not present accuracy data for cSCC.
For the detection of BCC, sensitivities and specificities were highly heterogeneous, especially for visual inspection. There
was some suggestion that this heterogeneity was related to the case-mix of included lesions with studies in non-pigmented
lesions or those with a high index of suspicion of BCC having lower and more variable specificity, in comparison to those
including pigmented lesions or lesions suspicious for any skin cancer. Studies were generally at high or unclear risk of bias
across the majority of domains assessed, particularly for image-based interpretations, and of high or unclear concern
regarding applicability of the evidence, limiting the strength of conclusions that can be drawn.
The Summary of findings table 1 presents key results for the primary target conditions of BCC and cSCC and translates
summary estimates to a hypothetical cohort of 1000 lesions. Due to the observed heterogeneity between studies, the results
presented are points estimated from summary ROC curves rather than average sensitivity and specificity operating points.
These are presented for illustrative purposes and should not be quoted as the actual performance of visual inspection or
dermoscopy. Due to the high risk of bias, concerns about applicability, the high level of unexplained heterogeneity and the
necessity of the SROC curve analytical approach, we cannot confidently estimate the actual false negative and false positive
rates for either test. Nevertheless, on average, the addition of dermoscopy to in-person visual inspection of a lesion
increases sensitivity and specificity for the diagnosis of BCC.
Sensitivity: At a fixed specificity of 80%, the use of dermoscopy increased the sensitivity of in-person visual inspection by
14%, from 79% to 93%. Assuming BCC prevalence of 10%, 17% and 53% in a cohort of 1000 lesions, a test sensitivity of
93% would reduce the number of BCCs missed in comparison to using visual inspection alone by 14, 24 and 74 (resulting in
7, 12 and 37 BCCs missed). A test specificity of 80% (for both visual inspection and visual inspection plus dermoscopy)
would result in 180, 166 and 94 false positive test results (i.e. lesions considered to be BCC which might then undergo
unnecessary biopsy or treatment, in this case of benign lesions mistaken for BCCs, or inappropriate management, in the
case of melanomas or cSCCs mistaken for BCCs).
Specificity: At a fixed sensitivity of 80%, the use of dermoscopy increased the specificity of in-person visual inspection by
22%, from 77% to 99%. Applying these results to a cohort of 1000 lesions at the same three prevalences of disease, both
tests would miss 20, 34 or 106 BCCs with the addition of dermoscopy reducing false positives by 198, 183 and 103 per 1000
(from 207, 191 and 108 lesions mistaken as BCCs using visual inspection alone).
A similar pattern was noted for image-based comparisons of visual inspection and dermoscopy, although the
differences in sensitivity and specificity were smaller (Summary of findings table 1). It is notable that for the in-person
evaluations, up to a third of observed false positive results were melanomas mistaken for BCCs (33% [5/15] of false
positives for visual inspection and 16% [3/19] for dermoscopy). This is of particular concern if non-surgical treatment
without biopsy is under consideration for lesions clinically presumed to be BCCs. In contrast to our review of
dermoscopy versus visual inspection alone for the diagnosis of melanoma (Dinnes 2018b), no statistically significant
differences were observed between in-person and image-based evaluations for the diagnosis of BCC. Insufficient data were
available to consider the effect of where in the clinical pathway the study was positioned, the use of formally developed
algorithms to assist diagnosis of BCC, or the effect of observer experience on accuracy.
Data for the detection of cSCC were limited but suggest pooled sensitivity of 57% (95% CI 53, 61%) and specificity 79%
(95% CI 77, 81%) for visual inspection (in-person) and sensitivity of 55% (95% CI 29, 79%) and specificity 84% (95% CI 32,
98%) for dermoscopy (image-based).
Strengths and weaknesses of the review
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The strengths of this review include an in-depth and comprehensive electronic literature search, systematic review methods
including double extraction of papers by both clinicians and methodologists, and contact with authors to allow study inclusion
or clarify data. A clear analysis structure focusing on estimating incremental gains in accuracy was adopted. A detailed and
replicable analysis of methodologic quality was undertaken.
The main concerns for the review are a result of relatively small numbers of studies, variation in the spectrum of
included lesions and poor reporting of primary studies, hindering the assessment of study quality and limiting the
conclusions that can be drawn from the data. Our review of visual inspection for the diagnosis of melanoma identified
a general trade-off between sensitivity and specificity along the clinical pathway with higher sensitivity and lower
specificity in limited prior testing studies compared to those in referred populations (Dinnes 2018a). The lack of data from
limited prior testing populations in this review and the lack of detailed information on the prior testing of participants included
in referred populations meant that no clear patterns in sensitivity or specificity could be derived. Some evidence of more
variable accuracy, especially in terms of specificity, was observed in studies with a higher prevalence of BCC and/or those
conducted in populations of non-pigmented lesions. Many of these studies however, also employed new algorithms for
detection of BCC rather than relying on the clinician’s diagnosis. The quality of dermatoscope and their resultant images may
vary greatly, and there are further variations such as whether they are used with oil immersion or other light sources. None of
our included studies provided enough detail to evaluate such effects on test performance. All of these factors together make
it difficult to fully determine the cause of the observed heterogeneity.
Given these limitations, our results should be considered as exploratory rather than conclusive. We have however
identified a clear suggestion of benefit from dermoscopy for the diagnosis of BCC which requires further investigation.
This is the first systematic review, to our knowledge, to have examined this critical question of dermoscopy use for the
diagnosis of BCC, particularly given the increasing availability of newer imaging tests such as OCT or RCM which
purport to assist in the diagnosis of BCC (Dinnes 2018c; Ferrante di Ruffano 2018b).
Applicability of findings to the review question
Our findings are particularly relevant to the use of visual inspection and dermoscopy for the diagnosis of BCC in referral
settings. Limited data were available to consider accuracy in primary care or according to observer experience. We cannot
be clear as to the likely error rates of visual inspection or dermoscopy in any particular lesion population due to varying
definitions and lack of clarity regarding the clinical pathway and any prior testing undergone.
Authors' conclusions 
Implications for practice 
Dermoscopy may be a valuable tool to support visual inspection of a suspicious skin lesion for the diagnosis of BCC. The
evidence primarily comes from secondary care (referred) populations and populations with pigmented lesions or mixed lesion
types. There is no clear evidence supporting the use of formal algorithms to assist diagnosis.
Implications for research 
Surveys and qualitative research documenting dermoscopy use in a primary care setting in different countries and health
care systems would help to better understand the purpose for which dermoscopy is being used. It may be that it is mainly
used for triaging suspected melanoma (or high risk keratinocyte skin cancer) for urgent secondary referral; alternatively
dermoscopy may be used to differentiate between types of skin cancer (melanoma, BCC or cSCC) with a view to initial
treatment of some lesions in primary care and referral of others to a secondary care setting. Prospective studies evaluating
the use of dermoscopy in primary care for all forms of suspected skin cancer could better define where the gains might
reside in terms of triage, and help to quantify diagnostic test accuracy. The need to not miss potentially lethal cancers such
as melanomas must be balanced against the avoidance of unnecessary referral and biopsy resulting in a morbidity and cost.
Further prospective evaluation of dermoscopy added to visual inspection in populations with a high clinical suspicion of BCC
in both a primary care and secondary care setting by users with defined expertise is also likely to be warranted. Such
evaluations should be conducted on an in-person basis with prospective recruitment of consecutive series of participants and
with systematic follow-up of non-excised lesions to avoid over-reliance on a histological reference standard that can only
provide information on excised cases. A clear identification of the level of training and experience required to achieve good
results is required. It is unclear whether further research is warranted on the potential additional value of dermoscopy to
visual inspection for lesions that are suspected to be cSCC in a primary and secondary care setting, unless they are
conducted in specific populations such as people with immunosuppression or who have received organ transplants in whom
cSCC is a common problem.
Given the mixed results to date, it is unclear whether further research into the added value of dermoscopy algorithms
to assist diagnosis above pattern recognition of characteristic morphological features is warranted. Any future
research study needs to be clear about the diagnostic pathway followed by study participants prior to study
enrolment, and should conform to the updated Standards for Reporting of Diagnostic Accuracy (STARD) guideline (Bossuyt
2015).
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Differences between protocol and review 
The proposed primary objective to analyse studies according to the prior testing undergone by study participants (comparing
those with limited prior testing with those referred for further evaluation of a suspicious skin lesion) was not possible due to
limited data.
The primary objectives were also amended to conduct separate analyses by in-person/image-based diagnosis rather to
investigate the effect on accuracy as a secondary objective, as originally proposed in the generic protocol. This decision was
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taken very early in the review process and was based on the fact that a diagnosis based on a dermoscopic image or clinical
photograph cannot approximate the context of a face-to-face patient clinician consultation, and was not based on observed
results.
Secondary objectives were expanded to include: test comparisons restricted to studies where both tests were evaluated in
the same studies (direct test comparisons); and investigations of the accuracy of individual algorithms used to assist visual
inspection or dermoscopy and any effect from observer experience on diagnostic accuracy
Sources of heterogeneity that could be investigated were restricted due to lack of data.
To improve clarity of methods, this text from the protocol “We will include studies developing new algorithms or
methods of diagnosis (i.e., derivation studies) if they use a separate independent ’test set’ of participants or images to
evaluate the new approach.We will also include studies using other forms of cross validation, such as ’leave-one-out’
cross-validation (Efron 1983). We will note for future reference (but not extract) any data on the accuracy of lesion
characteristics individually, e.g., the presence or absence of a pigment network or detection of asymmetry.”
has been replaced with “Studies developing new algorithms or methods of diagnosis (i.e., derivation studies) were included if
they:
used a separate independent 'test set' of participants or images to evaluate the new approach, or
investigated lesion characteristics that had previously been suggested as associated with melanoma and the study
reported accuracy based on the presence or absence of particular combinations of characteristics.
Studies were excluded if they:
used a statistical model to produce a data driven equation, or algorithm based on multiple diagnostic features, with no
separate test set.
used cross-validation approaches such as 'leave-one-out' cross-validation (Efron 1983)
evaluated the accuracy of the presence or absence of individual lesion characteristics or morphological features, with no
overall diagnosis of malignancy
reported accuracy data for ‘clinical diagnosis’ with no clear description as to whether the reported data related to visual
inspection alone or included dermoscopy in all study participants·
were based on the experience of a skin cancer-specific clinic, where dermoscopy may or may not have been used on an
individual patient basis.
We proposed to supplement the database searches by searching the annual meetings of appropriate organisations (e.g.,
British Association of Dermatologists Annual Meeting, American Academy of Dermatology Annual Meeting, European
Academy of Dermatology and Venereology Meeting, Society for Melanoma Research Congress, World Congress of
Dermatology, European Association of Dermato Oncology), however due to volume of evidence retrieved from database
searches and time restrictions we were unable to do this.
For quality assessment, the QUADAS-2 tool was further tailored according to the review topic.
In terms of analysis, restriction to analysis of per patient data was not performed due to lack of data. Heterogeneity
investigations and sensitivity analyses were not performed as planned due to lack of data.
Published notes 
Characteristics of studies
Characteristics of included studies 
Altamura 2010
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case control
Data collection: Retrospective
Period of data collection January 1991-May 2007
Country Italy, Australia and Austria
Test set derived. BCC characteristics assessed
on a random sample of BCC lesions; observer
accuracy for diagnosis of BCC assessed on a
separately derived random sample of four lesion
types.
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Skin lesions randomly selected
from digital image databases of the all lesions
excised; separately sampled BCCs melanomas, 50
melanocytic nevi, and nonmelanocytic skin lesions.
Setting: Secondary; Departments of Dermatology of
the University of L'Aquila. Specialist unit; tertiary
referral centre of the Sydney Melanoma Diagnostic
Center (Sydney, Australia);
Prior testing: Unclear; all selected for excision
Setting for prior testing: Unspecified
Exclusion criteria: Poor quality images excluded
(considered under Flow and Timing)
Sample size (patients): Not reported
Sample size (lesions): No. included: 300
Participant characteristics: Not reported for test set
of images
Lesion characteristics: Not reported in full for test set
of images. BCC included 38 pigmented, 38 heavily
pigmented, 37 nonpigmented, and 37 lightly
pigmented); median Breslow thickness for
melanomas 0.4 mm; range 0-2.7 mm. Non-BCC
lesions reportedly had "a similar degree and
distribution of pigmentation"
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Dermoscopy Modified version of Menzies algorithm for BCC (Menzies 2000)
Method of diagnosis: Dermoscopic images
Prior test data: No further information used; images were scored "without knowledge of any clinical
data of the patients and lesions"
Diagnostic threshold: Observer diagnosis of BCC. On diagnosis of a BCC, observer were asked to
report the presence absence of 'classic' and 'nonclassic' BCC dermatoscopic patterns as identified in
the first phase of the study (assessment of 609 confirmed BCCs for global and local dermatoscopic
features as described in Menzies 2000 and Menzies 1996; 'classic' BCC patterns were defined as
those associated with pigmented BCC (i.e. ulceration, multiple blue/gray globules, leaflike areas, large
blue/gray ovoid nests, spoke-wheel areas, and arborizing telangiectasia), 'nonclassic' patterns were
dermoscopic features "representing a possible variation on the theme of the (classic) patterns ... (i.e.
short fine superficial telangiectasia, multiple small erosions, concentric structures, multiple in-focus
blue/gray dots)).
Diagnosis based on: Single observer (n = 3)
Observer qualifications: likely dermatologists; described as "3 observers experienced in dermatoscopic
evaluation". It is unclear whether the same observer participated in the first phase of the study.
Experience in practice: assumed High "experienced in dermatoscopic evaluation"
Experience with index test: assumed High
Visual Inspection (in-person)
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (in-person)
A. Risk of Bias
B. Concerns regarding applicability
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Visual inspection (image based)
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (image based)
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Details: None provided; states "blinded to the
histopathologic diagnosis"
Target condition (Final diagnoses)
BCC: 150; Melanoma (invasive): 40; Melanoma (in situ):
10; cSCC: 2
Melanocytic naevi 50 (including 28 atypical, 9 Spitz/
Reed, 5 blue, 5 dermal, 3 compound); Nonmelanocytic
nevi 50 (20 seborrhoeic keratosis, 12 AKs, 10
Dermatofibromas, 4 haemangiomas, 1 eccrine poroma,
1 viral wart)
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge
of the results of the index tests? Unclear
Were the reference standard results interpreted without knowledge
of the referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation
have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Participant exclusions: Poor quality index
test image 'large lesions present on the
database but not completely comprised
within the field of view were not included in
the study.'
Index test to reference standard interval:
Not described
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
Unclear
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Amirnia 2016
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Unclear
Period of data collection February 2012
to February 2014
Country Iran
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Randomly selected patients
suspected of BCC or melanocytic nevi of the face
referred to dermatology clinic for excision or
examination; all included lesions were excised
Setting: Secondary (general dermatology)
Prior testing: Selected for excision (no further detail)
Setting for prior testing: NR
Exclusion criteria: None reported
Sample size (patients): No. eligible: 67; No.
included: 61
Sample size (lesions): No. eligible: NR; No.
included: 61
Participant characteristics: Mean age: 49.5y (+/-
18.9; 24-81y). Male: 25 (41%)
Lesion characteristics: Face (100%). Mean lesion
duration 6 years and 10 months (1 month to 20
years).
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Dermoscopy; 3-point checklist
Method of Diagnosis: In person diagnosis
Prior test Clinical examination
Diagnostic threshold: Presence of two or more criteria. Asymmetry in colour or structure in one or two
orthogonal axis asymmetric; pigment network with irregular holes and thick lines atypical network; any
kind of blue or white colour.
Diagnosis based on: Single observer (n=NR)
Observer qualifications: Not reported; assume dermatologist
Experience in practice: Not reported
Experience with index test: Not reported
Visual Inspection (in-person)
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (in-person)
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Visual inspection (image based)
A. Risk of Bias
B. Concerns regarding applicability
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Dermoscopy (image based)
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone (biopsy)
Target condition (Final diagnoses)
BCC:27
Melanocytic nevi: 28; Sebhorrheic
keratosis:1; 1 reaction to foreign substance,
1 folliculitis associated with calcification, 1
abscess; 2 reported as "in situ carcinoma"
but not further described.
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Were the reference standard results interpreted without knowledge of the
referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval:
Not described
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Notes
Notes -
 
Argenziano 2006
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Randomised controlled trial
allocating primary care physicians to use
either visual inspection alone or visual
inspection plus dermoscopy (only excised
lesions can be included for each arm)
Data collection: Prospective
Period of data collection May 2003 to Sept
2004
Country Italy and Spain
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients asking for screening or
exhibiting one or more skin tumours as seen during
routine physical examination (patient-finding
screening) were considered for inclusion; those
undergoing excision were included in this review (i.e.
those deemed sufficiently suspicious by the Expert
evaluation). PCPs were invited to participate in the
trial; only those who attended the training sessions
and who then screened patients and referred them
to the Pigmented Lesion Clinics were randomised.
Setting: Primary
Prior testing: No prior testing
Setting for prior testing: N/A
Exclusion criteria: NR
Sample size (patients): No. eligible: 3271 patients
screened; 1325 patients allocated to Naked Eye
observation and 1197 patients allocated to
dermoscopy observation; No. included: 162 received
histology after Expert evaluation at the PLC
Sample size (lesions): 85 in VI arm and 77 in
Dermoscopy arm underwent excision
Participant characteristics: Based on full sample:
mean age 40, range 2-90 (visual inspection group)/
41, range 3-94 (dermoscopy group). Male 498 (38%)
: VI group / 451 (38%) dermoscopy
Lesion characteristics NR
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
Visual inspection (VI) ABCD (control arm of RCT comparing naked eye examination to naked eye plus
dermoscopy)
Method of diagnosis: In person diagnosis
Prior test data: N/A in person diagnosis
Diagnostic threshold: Qualitative NR; Described in Intro as: simple morphologic features summarized
by the asymmetry, border irregularity, colour variegation, and diameter 5 mm (ABCD)
Diagnosis based on: Average (n=37)
Observer qualifications: Primary care physicians
Experience in practice: Not described
Experience with index test: Not described
Other detail: Pre-randomisation all participating PCPs underwent training in ABCD rule for clinical
diagnosis and 3-point checklist for dermoscopy.
Dermoscopy 3-point rule (intervention arm of RCT)
Method of diagnosis: In person diagnosis
Prior test data: N/A in person diagnosis
Diagnostic threshold: >=2 chars present (algorithm is based on the recognition of only three individual
features: dermoscopic asymmetry (in colour and/or structure, not in shape), atypical network
(pigmented network with thick lines and irregular distribution), and blue-white structures (presence of
any blue and/or white colour within the lesion). Each PCP in both groups examined the individual
lesions and scored the patient outcome, as banal or suggestive of skin cancer
Diagnosis based on: Average (n=36)
Observer qualifications: Primary care physicians
Experience in practice: Not described
Experience with dermoscopy: Not described
Dermoscopy training: All PCPs received training (2 hour session) on the clinical ABCD rule for
diagnosis of melanoma, basic recognition of nonmelanoma skin cancers including BCC and SCC plus
a 2 hour session describing the dermoscopy 3-point checklist.
Visual Inspection (in-person)
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy (in-person)
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection (image based)
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A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (image based)
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
All lesions considered suggestive of skin cancer at the
PLC were excised and subsequently diagnosed
histopathologically. Equivocal lesions by histopathologic
examination were reviewed by a second independent
pathologist and a final diagnosis made.
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not reported): 12; BCC:
66; cSCC: 14
Sebhorrheic keratosis: 13; Melanocytic nevi 51; Other: 6
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without
knowledge of the results of the index tests? Unclear
Were the reference standard results interpreted without
knowledge of the referral diagnosis?
Could the reference standard, its conduct, or its interpretation
have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: Data can only be
extracted for those with histology (i.e. patients
considered to have lesions suggestive of skin
cancer); remainder had expert diagnosis (not
included in the final 2x2 data extracted)
Time interval to reference test: Not reported
Time interval between index test(s): N/A
(RCT)
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
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Carli 2002a
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Unclear. Visual inspection and in-
vivo dermoscopy diagnoses recorded at time of
patient consultation; Ex vivo (image-based)
dermoscopy interpretation undertaken
retrospectively
Period of data collection June 1997 - December
1998
Country Italy
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Clinically equivocal or suspicious
pigmented skin lesions subjected to excisional
biopsy at the Institute of Dermatology
Setting: Secondary (not further specified)
Prior testing: Clinical and/or dermatoscopic
suspicion
Setting for prior testing: Secondary
Exclusion criteria: None reported
Sample size (patients): NR
Sample size (lesions): 256
Participant characteristics: None reported
Lesion characteristics Of the cutaneous melanomas,
14 (25.9%) were in situ melanoma (Clark level I), 18
(33.3%) were invasive with less than 0.75 mm
thickness, 19 (35.3%) were of intermediate
thickness (0.76–1.50 mm) and three (5.5%) were
thicker than 1.5 mm. The median thickness of
invasive melanomas was 0.94 mm ± 0.5 (SD) (range
0.2–6).
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: In person diagnosis
Prior test data: Unclear
Other test data: clinical examination and in vivo dermoscopy were performed before excision by two
trained dermatologists and diagnosis reached
Diagnostic threshold: Not reported
Diagnosis based on: Consensus (2 observers); final clinical diagnosis was based on agreement
between the two observers. In case of disagreement, the opinion of a third observer (B.G.) was
considered to be the judge for the diagnosis
Observer qualifications: Dermatologist
Experience in practice: High experience or ‘Expert’; described as “dermatologists with extensive
experience in both clinical and dermoscopic diagnosis of pigmented skin lesions”
#
Dermoscopy Pattern analysis
Method of diagnosis: In person diagnosis and image-based diagnosis. Clinical examination and in vivo
dermoscopy were performed before excision by two trained dermatologists and diagnosis reached.
Dermoscopic images were re-analysed by the same two observers at the end of the inclusion period
(December 1998), blind to the previous clinical and histological diagnoses.
Prior test data: N/A for in person; For image-based: slides of dermoscopic images were evaluated
using a viewer that made it impossible to analyse the clinical features of the lesion; both observers had
access to clinical information, including the age of the patient, the site of the lesion, the history of
change over time as reported by the patient at the time of in vivo examination.
Diagnostic threshold: dermoscopic diagnosis was based on the ELM pattern analysis criteria, using the
same diagnostic categories used for clinical diagnosis; characteristics investigated included pigment
network, pigmentation, hypopigmentation, brown globules, black dots, pseudopods, radial streaming,
grey-blue veil, atypical vascular pattern
Test observers as described for Visual Inspection (above)
Visual Inspection (in-person)
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy (in-person)
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection (image based)
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A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (image based)
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone
Target condition (Final diagnoses) 
Melanoma (invasive): 40; Melanoma (in situ):
14
BCC: 5
Sebhorrheic keratosis: 4; Benign naevus: 90
common melanocytic naevi; 78 melanocytic
naevi; 9 blue naevi; 16 Spitz reed naevi
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the
referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: not reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Notes
Notes -
 
Carli 2002b
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Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Not reported
Period of data collection NR
Country Italy
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Clinically suspicious or equivocal
pigmented skin lesions undergoing excision for
diagnostic purposes; only lesions with a diameter of
14 mm or less were included
Setting: Secondary (general dermatology)
Prior testing: Clinical suspicion of malignancy
without dermatoscopic suspicion
Setting for prior testing: Secondary (general
dermatology)
Exclusion criteria: None reported
Sample size (patients): No. included: NR
Sample size (lesions): No. included: 57
Participant characteristics: None reported
Lesion characteristics: thickness ≤1mm: 11 cases (5
in situ 6 invasive); All <=14mm diameter
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: Clinical photographs; Fixed focus distance of 10cm; images observed using a
viewer in two separate diagnostic sessions
Prior test data: No further information used; Contact (dermoscopic) images viewed first and then
distant images (clinical), without knowing the classification of the contact image of the individual
lesions.
Diagnostic threshold: Not reported
Diagnosis based on: Consensus (2 observers); n=2
Observer qualifications: Dermatologist
Experience in practice: High experience or ‘Expert’; States 'with experience in the field of PSL'
Experience with dermoscopy: High experience /‘Expert’ users; 'experienced in the field of PSLs'
Other detail: Any other detail Used an AF micro Nikkor 60 lens objective mounted on a Nikon f50
camera, with a fixed focus distance of 10cm
#
Dermoscopy No algorithm
Method of diagnosis: Dermoscopic images
Prior test data: No further information used; Contact (dermoscopic) images viewed first and then
distant images (clinical), without knowing the classification of the contact image of the individual
lesions.
Diagnostic threshold: Not reported
Test observers as described for Visual Inspection (above)
Any other detail Dermaphot device placed directly on the lesion without previous application of oil; only
lesions with a diameter of 14 mm or less were included in the study. The image has an automatic,
original magnification of x 10.
Visual Inspection (in-person)
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (in-person)
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection (image based)
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy (image based)
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
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B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone (not further described) 
Target condition (Final diagnoses)
Melanoma (invasive):6; Melanoma (in situ):5;
BCC:10
'Benign' diagnoses:36
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Were the reference standard results interpreted without knowledge of the
referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: No exclusions reported
Time interval to reference test: Photographic
procedures performed consecutively prior to
surgery
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the
interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Notes
Notes -
 
Chang 2013
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective
Period of data collection: Jan 2006 to Jul 2009
Country: Taiwan
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Potentially malignant biopsied or
excised skin lesions (non-tumour specimens
excluded)
Setting: Secondary (general dermatology)
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Secondary (general
dermatology)
Exclusion criteria: prior surgery; image mis-
registered or poor quality images (unfocused or
containing a motion artefact) (considered under Flow
and Timing)
Sample size (patients): No. eligible: 3964; No.
included: 676
Sample size (lesions): No. eligible: 4192; No.
included: 769
Participant characteristics: Mean age: 47.6 (SD
21.0); Male: 296; 43.8%
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: In person diagnosis
Prior test data: N/A in person diagnosis
Diagnostic threshold: Not reported; clinicians’ impressions prior to biopsy were classified as ‘‘benign’’,
‘‘malignant’’, or ‘‘indeterminate’’. When the clinicians were not confident enough to make a definite
benign or malignant diagnosis, the clinical impression was considered as ‘‘indeterminate’’ data
extracted for malignant vs rest and malignant/indeterminate vs rest
Diagnosis based on: Single observer; board-certified staff dermatologists from institute; n= 25
Observer qualifications: Dermatologist
Experience in practice: Board certified
Experience with index test: High 
Visual Inspection (in-person)
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
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B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy (in-person)
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection (image based)
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (image based)
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histology (not further
described) 
Target condition (Final diagnoses) 
Melanoma (invasive): 4; Melanoma (in
situ): 4; BCC: 110; cSCC: 20
'Benign' diagnoses: 595
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results
of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the referral
diagnosis?
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: mis-registered or poor
quality images (unfocused or containing a
motion artefact) as a study inclusion criterion
Time interval to reference test: Not described
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
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Notes -
 
Cooper 2002
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection May to September
2000
Country UK
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients attending the open access
dermatology renal transplant clinic with lesions
suspicious for malignancy or premalignancy and
booked for biopsy
Setting: Specialist unit; dermatology renal transplant
clinic
Prior testing: Clinical suspicion
Setting for prior testing: Specialist unit
Exclusion criteria: None reported
Sample size (patients): No. eligible: 70; No.
included: NR
Sample size (lesions): No. eligible: 125; No.
included: 102
Participant characteristics: Mean age: 60y; Male:
75%
Lesion characteristics Head/Neck: 43; 34.4%;
Limbs: 21 16.8%; 3 genitals; 2.4%
Are the included patients and chosen study setting appropriate? Unclear
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: In person diagnosis
Prior test data: N/A in person diagnosis
Diagnostic threshold: Observer provisional diagnosis
Diagnosis based on: Single observer (n=2)
Observer qualifications: A consultant dermatologist and a registrar
Experience in practice: Not described
Experience with index test: Not described
Visual Inspection (in-person)
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy (in-person)
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection (image based)
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (image based)
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone (biopsy,
no further details)
Target condition (Final diagnoses) 
BCC: 12; cSCC: 23 (incl 2 keratoacanthoma)
Bowen's disease 19; viral warts 7; solar keratoses 16;
other 25
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without
knowledge of the results of the index tests? Unclear
Were the reference standard results interpreted without
knowledge of the referral diagnosis?
Could the reference standard, its conduct, or its interpretation
have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Participant exclusions: 23 lesions did not
undergo biopsy; 11 resolved prior to biopsy,
6 patients died (10 lesions) and two patients
failed to attend (two lesions). No diagnosis
was made in a further three samples.
Index test to reference standard interval:
Not described
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Durdu 2011
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection Jan 2006 to
January 2009
Country Turkey
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Pigmented skin lesions that could
not be diagnosed with only dermatologic physical
examination
Setting: Secondary (general dermatology)
Prior testing: Clinical examination and dermoscopy
Setting for prior testing: Secondary (general
dermatology)
Exclusion criteria: None reported
Sample size (patients): No. included: 176
Sample size (lesions): No. included: 200
Participant characteristics: Mean age: 48y (4 to 85y).
Male: 64; 36.4%
Lesion characteristics: 9% nodulo-ulcerative, 56%
papular, 17% macular, 10% nodular, 8% plaque.
Are the included patients and chosen study setting appropriate? Yes
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
Dermoscopy: No algorithm
Method of diagnosis: In person diagnosis
Prior test data: Clinical examination
Diagnostic threshold: Two step process: step 1 melanocytic and non melanocytic were
differentiated (Braun 2005; Zalaudek 2008); step 2 ABCD applied to melanocytic lesions for diagnosis
of melanoma only (threshold > 5.45). Previously reviewed dermoscopic characteristics used to
diagnose non melanocytic lesions
Diagnosis based on: Single observer; n = 2; one for dermoscopy diagnosis and one for Tzanck smear
Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with dermoscopy: Not described
Visual Inspection (in-person)
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (in-person)
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Visual inspection (image based)
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (image based)
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone (Excisional
biopsies (n=166) or punch biopsy (n=34)
Details: "Biopsy specimens were stained with hematoxylin and
eosin. Immunohistochemical (anti-S-100 and human
melanoma black [HMB]-45) and histochemical (Fontana-
Masson) stains were also applied, if necessary"; interpretation
by a 'pathologist'
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not reported): 10; BCC: 34;
1 pigmented mammary Paget disease; 1 pigmented metastatic
mammary carcinoma
Sebhorrheic keratosis: 24; Benign melanocytic naevus: 100;
Dermatofibroma 12; Warts 16; 1 Dirt; 1 hereditary hemorrhagic
telangiectasia
Is the reference standards likely to correctly classify the
target condition? Yes
Were the reference standard results interpreted without
knowledge of the results of the index tests? Unclear
Were the reference standard results interpreted without
knowledge of the referral diagnosis? Unclear
Could the reference standard, its conduct, or its
interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Time interval to reference test: appears consecutive.
Following dermoscopic examination and cytology "either a
punch or an excisional biopsy specimen was taken from
the lesions and was examined histopathologically"
Was there an appropriate interval between index test and
reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of
borderline/benign appearing lesions, was there a minimum
follow-up following application of index test(s) of at least: 3
months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was
the interval between application of the different algorithms 1
month or less?
Could the patient flow have introduced bias? Low risk
Notes
Notes -
 
Ek 2005
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection January 2001 to
December 2002
Country Australia
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Lesions excised at tertiary referral
centre for the management of cancers; only those
lesions in which malignancy could not be excluded were
included
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Specialist unit (skin
cancer/pigmented lesions clinic)
Exclusion criteria: Punch, shave or incisional biopsies
and palliative excisions. Equivocal pathology report
(n=56).
Sample size (patients): No. eligible: 1302; No. included:
1223
Sample size (lesions): No. eligible: 2678; No. included:
2582
Participant characteristics: Mean age: 73.6y (16–102y).
Male: 784 (64.1%); History of melanoma/skin cancer (%)
224; 8.7% recurrent lesions
Lesion characteristics: Head/Neck: 61%; Trunk: 14.4%;
Limbs: 24.6%
Are the included patients and chosen study setting appropriate? Unclear
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: In person diagnosis
Prior test data: N/A in person diagnosis
Diagnostic threshold: Not reported pre-operative diagnosis
Diagnosis based on: Unclear; Likely single (n= 5).
Observer qualifications: Three consultants, a plastic surgery trainee and a clinical assistant.
Experience in practice: Mixed (low and high experience combined); Plastic surgery trainee usually 1st
year, on 6 month rotation; clinical assistant described as having “many years of experience”.
Other detail: Some results are presented for consultant, senior registrar and registrar but underlying
patient numbers are not provided per observer to allow separate 2x2 estimation. The discussion does
describe the “six MM misdiagnosed as benign … as .. assessed by non-consultants”.
Visual Inspection (in-person)
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy (in-person)
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection (image based)
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (image based)
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not
reported): 23
BCC: 1214; cSCC: 517
'Benign' diagnoses: 188 (7.3%) SCC in situ
(Bowen’s disease),330 (12.8%) solar keratoses,
63 (2.4%) seborrhoeic keratoses247 (9.6%)
were other benign lesions
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the
referral diagnosis?
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Excluded participants: Lesions with incomplete
or incorrectly entered pro formas were
excluded (n=40).
Index to reference interval: Consecutive; used
pre-operative clinical diagnosis of lesions
undergoing biopsy
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Gokdemir 2011
Patient Selection
A. Risk of Bias
Patient Sampling
Study design:Case series
Data collection: Not reported
Period of data collection: 2005-2009
Country: Turkey
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients with melanocytic and non-
melanocytic skin lesions excised due to
dermoscopic suspicion of malignancy or dysplasia .
Setting: Secondary (general dermatology)
Prior testing: Not reported
Setting for prior testing: Unspecified
Exclusion criteria: None reported
Sample size (patients): No. eligible: 1264; No.
included: 362
Sample size (lesions): No. included: 449
Participant characteristics: Mean age 40.3 yrs (+/-
1.08), range 1 to 89 yrs; Male: 160; 44.2%
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
Dermoscopy No algorithm
Method of diagnosis: Unclear; appears to be in person diagnosis
Prior test data: Clinical examination
Diagnostic threshold: Not reported; diagnosis of melanoma
Diagnosis based on: Unclear (n=NR)
Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with dermoscopy: High experience - at least 2 years experience with Molemax II.
Visual Inspection (in-person)
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (in-person)
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Unclear
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection (image based)
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (image based)
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone; not further described 
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not
reported): 13; BCC: 45
Benign: Not described
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the
referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval:
Not reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Notes
Notes -
 
Hacioglu 2013
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Unclear; diagnoses recorded
at initial consultation but unclear whether the
study was prospective in design. Also report
prospective interpretation of previously
acquired images (SIAscopy and dermoscopy)
Period of data collection Jan 2009 - Jan 2010
Country Turkey
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients with skin lesions < 12 mm
in diameter suspicious for malignancy; only excised
lesions included
Setting: Secondary (general dermatology)
Prior testing: Selected for excision
Setting for prior testing: Unspecified
Exclusion criteria: lesion size >12mm; lesions with a
crusted or rough surface
Sample size (patients): No. included: 76
Sample size (lesions): No. included: 80
Participant characteristics: Mean age: 57.6y (SD
15.48: range 23-84y). Male: 45 men (52%)
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
Visual inspection (VI): No algorithm
Method of diagnosis: In person; "clinical diagnosis based on the patient's history and dermatological
findings." [NB unclear whether dermoscopy was used to inform initial diagnosis; dermoscopy use not
described but dermoscopic images later evaluated]
Prior test data: N/A in person diagnosis
Diagnostic threshold: Observer diagnosis
Diagnosis based on: Single observer (n=3)
Observer qualifications: NR; likely dermatologist
Experience in practice: Not described; three investigators - one made preliminary clinic diagnosis and
evaluated Siascope images 8 months later; second investigator evaluated all Siascope images; a third
investigator evaluated dermoscopic images.
Experience with index test: Not described;
#
Dermoscopy: No algorithm
Method of diagnosis: Dermoscopic images
Prior test data: No further information used; "a third investigator (EBB), also blinded to the previous
diagnoses, evaluated all the lesions using dermatoscopic images only."
Diagnostic threshold: Observer diagnosis
Observers: as described above.
Visual Inspection (in-person)
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy (in-person)
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection (image based)
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (image based)
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
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Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Details: skin biopsies (3 or 4 mm in size)
Target condition (Final diagnoses) 
BCC: 24; Melanoma (in situ and invasive, or not
reported): cSCC 3; Basosquamous cancer 2
Sebhorrhoeic keratosis: 19; actinic keratosis 8;
intradermal nevus 4; dermatofibroma 3;
keratoacanthoma 2; Other 12 - including: epidermal
proliferation, pseudoepithelial hyperplasia, solar
degeneration, lichen simplex chronicus, compound
naevus, dysplastic naevus, prurigo nodularis, chronic
inflammatory granulation, dysplastic junctional naevus
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge
of the results of the index tests? Unclear
Were the reference standard results interpreted without knowledge
of the referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval:
Appears consecutive; "Images ... were
obtained ... and skin biopsies ... were taken".
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Notes
Notes -
 
Lorentzen 1999
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection Between 1994 and
1997
Country Denmark
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients with lesions suspicious for
CMM referred to outpatients clinic; only excised
included
Setting: Not reported
Prior testing: Clinical suspicion of malignancy
without dermatoscopic suspicion
Setting for prior testing: Not reported
Exclusion criteria: Poor quality index test image
(considered under flow/timing)
Sample size (patients): No. eligible: 242; No.
included: 232
Sample size (lesions): No. eligible: 242; No.
included: 232*
Participant characteristics: None reported
Lesion characteristics: None reported
*NB Not all cases were assessed by all observers;
2x2 are based on presented sensitivity and
specificity estimates for full dataset of lesions; "the
dermatoscopy experts assessed almost all cases
(98 ± 100%), whereas the non-expert group
completed fewer assessments, from 76 to 98%.
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: Clinical photographs
Prior test data: No further information used; no option to change clinical diagnosis after viewing
dermoscopic image
Other test data: Dermoscopic images presented to observer subsequent to diagnosis using clinical
images alone; clinical images presented before dermoscopic images
Diagnostic threshold: Not reported; clinical diagnosis
Diagnosis based on: Average; n= 9
Observer qualifications: Dermatologist
Experience in practice: High; Moderate; Mixed (average reported); 4 'experienced dermatologists' (4-5
years daily experience) & 5 'non-expert dermatology residents' (1-2 years interest and formal training
in dermatoscopy]
Experience with index test: High; Moderate; Mixed
Visual Inspection (in-person)
A. Risk of Bias
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B. Concerns regarding applicability
Dermoscopy (in-person)
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection (image based)
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy (image based)
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Details: a co-author from Dept of Pathology "re-
evaluated all cases to confirm the pathology
diagnosis, which was used as the gold standard
in this study."
Target condition (Final diagnoses)
Melanoma (invasive): 49 'malignant melanoma'
BCC: 16
Sebhorrheic keratosis: 12; Benign naevus: 137
(pigmented nevi=116; blue nevi=16; atypical
nevi=5); Other: 18 (Spitz nevi, Bowen's disease,
sarcoid, nevus spilus, hemangioma, and others)
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the
referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Excluded participants: 10 cases were "considered unfit
for evaluation" due to poor quality image
Reference interval: "biopsy specimens...were obtained
after the clinical and dermatoscopic photographs had
been performed"
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of
borderline/benign appearing lesions, was there a minimum follow-
up following application of index test(s) of at least: 3 months for
melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was
the interval between application of the different algorithms 1 month
or less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Lorentzen 2008
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Not reported
Period of data collection not reported
Country Denmark
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients referred to the specialist
naevus clinic for lesion excision
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: Not reported
Setting for prior testing: Not reported
Exclusion criteria: Not specified
Sample size (patients): No. eligible: 120; No. included:
119
Sample size (lesions): No. included: 119
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Dermoscopy: Mixed/no algorithm; describes using "the risk stratification and pattern analysis
procedure as described by Kenet 2001 and Lorentzen 2000".
Method of diagnosis: Dermoscopic images; compared accuracy using standard dermoscopy images
(Dermaphot) and images obtained using a globe magnifier. Slides were randomised and evaluated on
2 different occasions with 3 week intervals
Prior test data: No further information used
Diagnostic threshold: Observer correct diagnosis of each lesion type
Diagnosis based on: Unclear (assumed Average) (n=NR)
Observer qualifications: Dermatologist
Experience in practice: High; "dermatologists who have performed dermatoscopy for 5–10 years,
published scientific papers on dermatoscopy and carried out pre- and post specialist training in
dermatoscopy"
Experience with dermoscopy: High
Visual Inspection (in-person)
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (in-person)
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection (image based)
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (image based)
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard: Histological diagnosis alone
Details: used haematoxylin-eosin staining a well as
histochemistry was performed using S-100 and
HMB-45 on suspect melanoma lesions.
Target condition (Final diagnoses) 
Melanoma (invasive): 24
BCC: 13
Mild//moderate dysplasia: 2; Sebhorrheic keratosis:
9; Haemangioma: 2; Naevus pigmentosus- 69
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of
the referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: One dermatofibroma
excluded
Time interval to reference test: Not described
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of
borderline/benign appearing lesions, was there a minimum follow-up
following application of index test(s) of at least: 3 months for
melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the
interval between application of the different algorithms 1 month or
less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Markowitz 2015
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: Not reported
Country: USA
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Consecutive patients with at least
one clinically challenging pink lesion on the head or
neck that was suspicious for BCC and was therefore
to be biopsied to rule BCC in or out; all eligible for
Mohs surgery. Clinically challenging defined as
lesions that did not have the usual characteristics of
BCC, such as ulceration, bleeding, crusting, isolated
pink scaly patches, or pearly papules.
Setting: Secondary (general dermatology)
Prior testing: Clinical suspicion of malignancy
without dermatoscopic suspicion
Setting for prior testing: Secondary (general
dermatology)
Exclusion criteria: Previous history of skin cancer/
prior treatment at site; > three lesions per
participant;
Sample size (patients): No. included: 100
Sample size (lesions): No. included: 115
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: In person diagnosis
Prior test data: N/A in person diagnosis
Diagnostic threshold: Observer diagnosis of possible BCC; "lesions were diagnosed based on the
patient’s clinical history of a nonhealing area of concern or the clinician’s inability to rule out BCC"
Diagnosis based on: Unclear; appears that diagnoses made in clinic after acquisition of each type of
image
Number of examiners not specified
Observer qualifications: Not described; likely dermatologist
Experience in practice: Not described
Experience with index test: Not described
#
Dermoscopy: Two step algorithm
Method of diagnosis: In person diagnosis; images also taken but diagnosis made in person
Prior test data: Clinical examination; diagnoses made after each step in the clinical process
Diagnostic threshold: Observer diagnosis of possible BCC; 2 step algorithm described as similar to
Marghoob 2010 and Malvehy 2002. Lesions inspected for dermoscopic features consistent with BCC
... "including arborized vessels, pink white shiny background, blue/grey ovoid nests, ash leaf pattern,
dot-globular-like pattern, spoke wheel, and crystalline-like structures"
Test observers as described for Visual Inspection (above)
Visual Inspection (in-person)
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Dermoscopy (in-person)
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Visual inspection (image based)
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (image based)
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Details: A biopsy was taken and the final
diagnosis and lesion depth based on
histopathology
Target condition (Final diagnoses) 
BCC: 70; 'Benign' diagnoses: 45
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the
referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval:
Consecutive; After "the patient was returned
for standard-of-care treatment. A biopsy was
taken"
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Notes
Notes -
 
Menzies 2000
Patient Selection
A. Risk of Bias
Patient Sampling
Study design Case control
Data collection Retrospective image selection /
Prospective interpretation
Period of data collection: NR
Country: Australia and USA
Test set derived: Sample randomly divided into
training and test sets
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria Pigmented skin lesions with
dermoscopic images and histological diagnoses;
BCCs, invasive melanomas and clinically atypical
'nonmelanoma' lesions separately sampled
Study setting Specialist unit; Sydney Melanoma Unit
and Florida Skin and Cancer Unit databases
Prior testing Selected for excision (no further detail)
Exclusion criteria: None reported
Sample size (patients): Not reported
Sample size (lesions) No. included: 213
Participants Characteristics: None reported
Lesion characteristics: median Breslow thickness for
invasive melanoma (71/213) was 0.67mm for the test
set
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Dermoscopy: Own new algorithm (Menzies) for diagnosis of pigmented BCC
Method of diagnosis: Dermoscopic images; images studies on a viewer
Prior test: No further information used
Diagnostic threshold: Pigment network absent with at least one positive feature present: ulceration,
large blue-gray ovoid nests, multiple blue-gray globules, maple leaflike areas, spoke wheel areas,
aborizing (treelike) telangiectasia (all defined in detail)
Diagnosis based on: Unclear; training set images assessed by two observers; unclear if consensus or
average and whether same observers also assessed the test set images; n=2
Observer qualification:Not reported; likely dermatologists
Observer experience in practice: Not reported
Observer experience with index test: Not reported
Derivation aspect: Training set was assessed for the presence/absence of 45 dermoscopic features
and a simple model constructed using negative features with low sensitivity and high specificity for
invasive melanoma and benign nonmelanoma lesions. The optimal model was then evaluated on the
test set of images.
Visual Inspection (in-person)
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (in-person)
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection (image based)
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (image based)
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone (not
further described)
Target condition (Final diagnoses) 
Test set:
BCC:71; Melanoma (invasive):71;
Sebhorrheic keratosis:5; Ephelis 1 Solar lentigo 3
Common nevus 19 Dysplastic nevus 38 Blue nevus 2
Dermatofibroma 1 Hemangioma 1 Other1
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of
the referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval: PSLs
photographed prior to excision
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the
interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Notes
Notes -
 
Navarrete Dechent 2016
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection: 2009-2012
Country: US
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Consecutively excised nonpigmented
lesions with no discernible pigment on clinical or
dermoscopic images.
Setting: Specialist unit; Memorial Sloane Kettering
Cancer Centre
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Specialist unit
Exclusion criteria: Collision tumours, dermatofibromas
and seborrhoeic keratoses were excluded
Sample size (patients): No. eligible: 2375; No.
included: NR
Sample size (lesions): No. eligible: 2891; No. included:
457
Participant characteristics: Mean age: 64.3 (SD 14.1);
Male: 282; 61.7%
Lesion characteristics: Head/Neck: 134; 29.3%; Trunk:
124; 27.1%; Upper extremity 84; 18.4%; Lower
extremity 113; 24.7%; Genitalia 1; 0.2%Missing 1;
0.2%
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
Dermoscopy: Own new algorithm (Shiny White Streaks)
Method of diagnosis: Dermoscopic images; Each individual lesion’s close-up clinical (cropped images
without patient identifiers) and dermoscopic images were reviewed for inclusion by a single author.
Prior test data: No further information used
Diagnostic threshold: Presence of any shiny white streaks (SWS); SWSs were classified as
(1) blotches (also known as clods; discrete, small or large structureless areas); (2) strands
(long thick or thin lines, randomly distributed or parallel, and not orthogonally oriented); (3)
rosettes (cluster of 4 white dots in a 4-leaf clover–like arrangement); and (4) short white lines
(also known as crystalline structures and chrysalis; fine lines that intersect or are oriented
orthogonally to each other) (Liebman 2012; Liebman 2011). Shiny white structures that could
not be classified into one of these specific morphologies were categorized as nonspecified.
[All lesions were also evaluated for Menzies criteria (Menzies 2000); those without Menzies criteria
were considered featureless and were further evaluated for presence of: SFT; multiple in-focus, blue-
gray dots; multiple small erosions;and concentric structures.
Diagnosis based on: Consensus (2 observers); n=2
Observer qualifications: One observer appears to be a dermatologist and the other was a medical
student (based on authors' institutions); both trained by a third observer (expert dermoscopist) who
also acted as arbitrator in case of any disagreement
Experience in practice: Not described
Experience with index test: Trained; Described as 'trained in dermoscopic analysis by an expert
dermoscopist'
Any other detail: Images were captured with a Nikon 1 camera (Nikon USA, Inc) using Dermlite DL2
pro HR for polarized images and Dermlitefluid for nonpolarized images at 10-fold magnification(3Gen,
LLC).
Visual Inspection (in-person)
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (in-person)
A. Risk of Bias
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B. Concerns regarding applicability
Visual inspection (image based)
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (image based)
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone
Target condition (Final diagnoses) 
BCC: 287; cSCC: 106; Melanoma (in situ
and invasive, or not reported): 21
Lichen planus–like keratosis 39; Nevus 4
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the
referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval:
Appears consecutive; "Standard procedures in
this practice included capturing clinical and
dermoscopic images of all lesions selected for
biopsy"
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Notes
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Notes -
 
Nori 2004
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case control
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection 2 years - date range not
specified
Country US and Spain
Was a consecutive or random sample of patients enrolled? No
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Biopsy confirmed BCC and
convenience sample of non-BCC with 'range of
common diagnoses'; of these images with superior
clinical quality were selected for clinical assessment
Setting: Secondary (general dermatology); Private
care
Prior testing: Most underwent biopsy but no detail of
selection process
Setting for prior testing: Unspecified
Exclusion criteria: None reported
Sample size (patients): No. included: 145
Sample size (lesions): No. included: 152; 105 in VI
analysis
Participant characteristics: Male: 98; 64%
Lesion characteristics: Face/Ears: 35%; Trunk: 13%;
Limbs: Extremities 45%; Back 7%; only 7 of 69 non-
BCC lesions "had BCC on the list of possible
differential diagnoses"
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Visual inspection (VI): No algorithm
Method of diagnosis: Clinical photographs; "set of randomised clinical images was ... analysed in a
blinded fashion by two dermatologists"
Prior test data: No further information used
Diagnostic threshold: High and High/Medium probability of BCC. Lesions assigned to: High probability
(BCC until proven otherwise), medium probability (would biopsy to rule out BCC), and low probability
(no biopsy needed).
Diagnosis based on: Single observer (n=2)
Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with index test: Not described
Visual Inspection (in-person)
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A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (in-person)
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection (image based)
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy (image based)
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
plus other
Histology (not further described)
Expert opinion: 15 lesions were not biopsied
(e.g. lesions like seborrhoeic keratosis)
because the clinical diagnosis was
considered diagnostic
Target condition (Final diagnoses) 
BCC: 83; 58 in VI analysis; cSCC: 4
'Benign' diagnoses: 65
Is the reference standards likely to correctly classify the target condition? No
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the
referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? High risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard No
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? High
Flow and Timing
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A. Risk of Bias
Flow and timing
Participant exclusions: 47 lesions were not
included because of poor clinical image
quality
Index test to reference standard interval:
Not described
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Rosendahl 2011
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection 30-month period; dates
NR
Country Australia
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Consecutive series of pigmented
lesions submitted for histology from the primary care
skin cancer practice of one author.
Setting: Primary care skin cancer practice
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Primary
Exclusion criteria: Poor image quality (considered
under Flow and Timing)
Sample size (patients): No. included: 389
Sample size (lesions): No. eligible: 466 pigmented
lesions out of 1959 lesions excised or biopsied; No.
included: 463
Participant characteristics: Mean age: 57y (SD 17).
Male gender: 67.4%
Lesion characteristics: (53.1%) melanocytic. Lesion
site: 17.7% head or face; Trunk: 52.1%; 27.6%
extremities; 2.2% palms or soles. Melanoma
thickness: ≤1mm: 1/29 melanoma (3.4%)
Are the included patients and chosen study setting appropriate? Yes
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: Clinical photographs overview and close up image presented
Prior test data: No further information used
Other test data: Dermoscopic images presented to observer subsequent to diagnosis using clinical
images alone.
Diagnostic threshold: Clinical diagnosis/subjective impression. Observers gave a diagnosis with level
of confidence (from 0 for definitely benign to 100 for definitely malignant) after viewing the clinical
images. (NB used authors threshold for detection of any skin cancer which includes lesions clinically
considered to be MM, BCC pigmented epithelial carcinoma including SCC, keratoacanthoma, actinic
keratosis and Bowen's disease as test positive; review only considered histologically confirmed MM,
BCC or invasive SCC to be disease positive)
Diagnosis based on: Single observer (n=NR)
Observer qualifications: Expert dermatologist (based on author communication).
Experience in practice: Expert
Experience with dermoscopy: Expert
#
Dermoscopy Pattern analysis; new algorithm - Chaos and clues
Method of diagnosis: Clinical photographs (one overview and one close-up), followed by one
dermoscopic image presented to a blinded observer on a computer screen
Prior test data: Clinical image only; Diagnosis made based on clinical image before presentation of
dermoscopic image
Diagnostic threshold: Observers gave a diagnosis with level of confidence (from 0 for definitely benign
to 100 for definitely malignant).
Chaos and clues short algorithm - each assessed for evidence of ‘‘chaos’’ (asymmetry of colour or
structure); if present then ‘‘clues’’ searched for. Chaos - asymmetry of structure and colour defined
according to the basic principles of pattern analysis as revised by Kittler 2007. Clues included:
eccentric structure-less zone (any colour except skin colour), grey or blue structures, peripheral black
dots or clods, segmental radial lines or pseudopods, polymorphous vessels, white lines,thick reticular
or branched lines, and parallel lines on ridges (acral lesions).
Observers as for visual inspection
Visual Inspection (in-person)
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (in-person)
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection (image based)
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy (image based)
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others? No
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Details: Excise or biopsy
Target condition (Final diagnoses) 
Melanoma (invasive): 9; Melanoma (in situ): 20; BCC:
72; cSCC: 5 (including 2 keratoacanthoma)
'Benign' diagnoses: 18 Bowen's disease and 14 actinic
keratosis, 217 benign melanocytic plus additional 140
benign non melanocytic
*authors considered Bowen's disease, actinic keratosis
and keratoacanthoma as malignant; all considered
benign for review analysis
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without
knowledge of the results of the index tests? Unclear
Were the reference standard results interpreted without
knowledge of the referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation
have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: Lesions were excluded due
to poor image quality (n=3)
Time interval to reference test: Unclear; lesions
'routinely photographed' if scheduled for excision
or biopsy but not further described
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application
of index test(s) of at least: 3 months for melanoma or cSCC or 6 months
for BCC?
If more than one algorithm was evaluated for the same test, was the
interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
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Notes -
 
Schwartzberg 2005
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection October 2002
through December 2003
Country US
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients with suspected BCC undergoing
biopsy; dermatology faculty performing biopsies on
patients in whom BCC was a consideration were asked to
complete a study questionnaire.
Setting: Secondary; refers to 'Dermatology faculty'
Prior testing: Clinical suspicion
Setting for prior testing: Unspecified
Exclusion criteria: None reported
Sample size (patients): No. eligible: 161; No. included:
141. If multiple biopsies were performed on the same
patient, only the first biopsy performed was included in the
study
Sample size (lesions): No. eligible: 161; No. included: 141
Participant characteristics: Mean age: 64y (28-92y); Male:
65%; Immunosuppresion (%) 5.7%
Lesion characteristics: Pigmented: 19%; Non-pigmented:
81%; Ulcerated (%): 25%; erythematous 49%
telangiectasis 60% pearly border 75% crusty 33% scaly
41%. Head/Neck: 61%; Mean lesion area was 31 mm2
(range 1 mm2–1.8 cm2).
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: In person diagnosis
Prior test data: No further information used
Diagnostic threshold: Clinical diagnosis (Certainty of diagnosis of BCC); plus combinations of
characteristics predictive of BCC
Diagnosis based on: Single observer
Number of examiners 17 (11 full-time faculty members and 6 part-time faculty)
Observer qualifications: Likely all dermatologists; [One full-time faculty member and one part-time
faculty member perform Mohs surgery and the others perform dermatologic surgery within the context
of their general dermatology practice]
Experience in practice: Assumed High
Experience with index test: Not described
Other detail: Information about the lesions being biopsied was collected including: length of time the
lesion was present, the location, and the presence of telangiectasias, ulceration, crusting, surrounding
erythema, scale, pigmentation, and/or a pearly border. Multivariate logistic regression analysis using
backward selection used to id best predictors of BCC diagnosis.
Visual Inspection (in-person)
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Dermoscopy (in-person)
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection (image based)
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (image based)
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Details: Dermatology faculty performed biopsies. No
further detail
Target condition (Final diagnoses) 
BCC: 82
Other diagnoses not reported apart from FPs for those
with clinical certainty level 1 (6 were actinic keratoses, 2
were dermal nevi, and 1 each were scar, dermal
elastosis, and trichoepithelioma)
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge
of the results of the index tests? Unclear
Were the reference standard results interpreted without knowledge
of the referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval:
Consecutive; diagnoses recorded prior to
dermatology faculty performing biopsies
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Notes
Notes -
 
Stanganelli 2000
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective
Period of data collection 1994-1996
Country Italy
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients with pigmented skin lesions
referred by dermatologists and general practitioners
either for pre-surgical assessment or consultation
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: patients referred for pre-surgical
assessment or consultation indicating they have had
prior tests
Setting for prior testing: Primary some patients referred
for consultation only; dermoscopy findings are reported
back and management decision remains with referring
clinician; Secondary (general dermatology)
Exclusion criteria: None reported
Sample size (patients): No. eligible: 1556
Sample size (lesions): No. eligible: 3372; No. included:
3372
Participant characteristics: Median age 30 years, range
10 to 94; Male: 522 (34%)
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? Yes
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Visual inspection (VI) ABCD
Method of diagnosis: In person diagnosis
Prior test data: N/A in person diagnosis
Other test data: Dermoscopic and clinical images subsequently presented separately to observer
subsequent to diagnosis using clinical images alone.
Diagnostic threshold: NR
Diagnosis based on: Single observer; n = 1
Observer qualifications: Not reported; described as one of the co-authors and study based in skin
cancer clinic - likely dermatologist
Experience in practice: Not described
Experience with dermoscopy: Not described
Other detail: A crude clinical image (magn X6 and X10) was recorded in the digital database
#
Dermoscopy: Pattern analysis
Method of diagnosis: Unclear; Patients seen in person but dermoscopic diagnosis made based on
digital ELM image (by same clinician as in person clinical dx)
Prior test data: Combined clinical/dermoscopy diagnosis
Diagnostic threshold: Diagnosis described as based on an integrated synopsis of the patterns
most commonly described in the literature (Steiner 1993) and generally associated with known
histologic counterparts. Features were assessed described in detail with multiple references, including:
presence of pigment network, sharp margins, abrupt edge of pigment network, branched streaks,
pseudopods, radial streaming, brown globules, pigment dots, whitish or whitish blue veil, gray-blue
areas, white or depigmented areas, maple leaf areas, milia-cysts, horny plugs and vascular patterns.
Test observers as described for Visual Inspection (above)
Experience with dermoscopy: 
Any other detail The equipment consisted of a Leica Wild M-650 stereomicroscope (Leica AG,
Heerbrugg, Switzerland), a Sony 3ccd DXC-930P colour video camera, an AT-Vista videographics
adapter, and IBM personal computer, a Sony Trinitron Analog PVM-2043MD monitor, and the
DBDERMO MIPS software
Visual Inspection (in-person)
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Dermoscopy (in-person)
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
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Visual inspection (image based)
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (image based)
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
plus follow up; histology report of known
surgical excisions (n = 262) plus a cancer-
registry based follow up of benign cases (n
= 3110)
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not
reported): 55; BCC: 43
'Benign' diagnoses: 3274
Is the reference standards likely to correctly classify the target condition? No
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the
referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? High risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: not reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of index
test(s) of at least: 3 months for melanoma or cSCC or 6 months for BCC?
Yes
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Steiner 1987
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection not specified
Country Austria
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Small (< 10 mm) pigmented skin
lesions considered diagnostically equivocal in that there
was no absolute agreement on the clinical diagnosis
among investigating clinicians at a pigmented lesions
clinic.
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: Clinical suspicion of malignancy without
dermatoscopic suspicion
Setting for prior testing: Specialist unit (skin
cancer/pigmented lesions clinic)
Exclusion criteria: > 10mm diameter
Sample size (patients): Not reported
Sample size (lesions): 318
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
Visual inspection (VI): No algorithm
Method of diagnosis: In person diagnosis
Prior test data: N/A
Other test data: Dermoscopy undertaken by same clinician(s) subsequent to clinical evaluation
Diagnostic threshold: Not reported
Diagnosis based on: Consensus (3 observers) "All lesions were independently seen and diagnosed by
the three investigators, and the diagnosis that appeared most probable to at least two of the three
investigators was recorded as the clinical"; n = 3
Observer qualifications: Dermatologist
Experience in practice: High experience or ‘Expert’; "experienced dermatologists"
Experience with dermoscopy: - Unclear; not explicitly described. Discussion describes ELM as
standard procedure in clinic
#
Study reported data for dermoscopy; however, a breakdown of incorrect diagnoses by final diagnosis
was not provided to allow a 2x2 to be estimated.
Visual Inspection (in-person)
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy (in-person)
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection (image based)
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (image based)
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Target condition (Final diagnoses) 
Melanoma (invasive): 49; Melanoma (in situ): 15;
BCC: 20; Lentigo maligna 9 (also includes lentigo
maligna melanoma)
Sebhorrheic keratosis: 20; Junctional naevi 39;
Blue naevus 29; Dysplastic naevus 75; Lentigo
simplex and nevoid lentigo 19; Angioma/
angiokeratoma 15
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of
the referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: assumed
consecutive; following diagnosis, lesions
subsequently excised
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Notes
Notes -
 
Ulrich 2015
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: April 2013 to
March 2014
Country: Germany
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients with non-pigmented pink
lesions with clinical suspicion of BCC requiring biopsy
for diagnostic confirmation. Pink lesions defined as
clinically unclear erythematous papule or plaque;
either reddish macules, patches or small papules with
or without scale.
Setting: Multicentre study; authors' institutions
included Dermatology departments (n=4) and private
dermatology offices (n=3)
Prior testing: Clinical suspicion of malignancy
Setting for prior testing: Unspecified
Exclusion criteria: Lesions with the typical clinical
appearance of BCC on clinical examination (such as
the presence of a pearly border, central ulceration
and obvious telangiectasias), as well as pigmented
lesions, were excluded from the protocol. Patients
with unstable or uncontrolled clinically significant
medical conditions were excluded. Lesions with
missing histology also excluded (n=21)
Sample size (patients): No. eligible: 164; No.
included: 155
Sample size (lesions): No. eligible: 256; No. included:
235 (different sets of 231 lesions were available for
each test)
Participant characteristics: Median age: 70y (33-90y)
Lesion characteristics Head/Neck: 41%; Upper body
48.8%
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Visual inspection (VI): No algorithm
Method of diagnosis: In person diagnosis; "All assessments were documented before the histological
results were available"
Prior test data: N/A in person diagnosis
Diagnostic threshold: Clinical diagnosis of BCC; describes diagnostic criteria as "pink or red lesions
that could be either macules, patches or small papules with or without scale" however these also form
part of inclusion criteria.
Diagnosis based on: Single observer; in clinic diagnosis (n=NR)
Observer qualifications: Not described; probably dermatologists given authors institutions
Experience in practice: Not described
Experience with index test: Not described
#
Dermoscopy; No algorithm (referenced Marghoob 2012)
Method of diagnosis: In person diagnosis
Prior test data: Clinical examination
Diagnostic threshold: Observer diagnosis of BCC: scattered vascular global pattern with loose
haphazard distribution; shiny white to red structures with or without chrysalis-like structures; small fine
telangiectasias appearing as fine, kinked vessels of small calibre, with length < 1 mm in superficial
BCC and larger arborizing vessels in more invasive BCC (nodular/infiltrative).
Observers: as above
Any other detail After clinical examination dermoscopy was carried out using a Dermlite ProHr (3Gen
Inc., San Juan Capistrano, CA,U.S.A.), attached to a Sony Cybershot DSC-W710 camera (Sony,
Tokyo, Japan) (supplied by MDL). As polarized light was used, no preparation of the area under
examination was necessary
Visual Inspection (in-person)
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Dermoscopy (in-person)
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Visual inspection (image based)
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (image based)
#165 Visual examination and dermoscopy, alone or in combination, for the diagnosis of keratinocyte skin cancers in ad...
80 / 231
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone
Details: a biopsy or excision of the lesion
was taken and sent for histological analysis.
Target condition (Final diagnoses) 
BCC: 141 (as different sets of 231 lesions
were available for each test, the number
diseased per 2x2 varies)
'Benign' diagnoses: 94
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the
referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: Histology was missing for
21 lesions, and one case was found to have a
combination of both BCC and SK or AK,
leaving235 lesions for analysis in the ITT group
Index test to reference standard interval:
Consecutively done after index test "All
diagnostic steps had to be completed before
histological confirmation was made."
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the
interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Witkowski 2016
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection: January 2009–2011
Country: Italy
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Consecutive clinically equivocal
‘pink’ cutaneous lesions with absent pigmentation or
containing less than 10% pigment and absence of
pigment network. All lesions were excised at first
visit or follow-up video dermoscopy control visit and
had available digital dermoscopy images and a
complete standard set of RCM images, with
histopathology reports
Setting: Secondary (general dermatology)
Prior testing: Clinical suspicion of malignancy
without dermatoscopic suspicion
Setting for prior testing: Secondary (general
dermatology)
Exclusion criteria: Benign diagnosis made with high
confidence; lack of histological report as a result of
the lesion not being excised
Sample size (patients): NR
Sample size (lesions): No. eligible: 3869 consecutive
cases were reviewed; No. included: 260
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Dermoscopy No algorithm
Method of diagnosis: Dermoscopic images
Prior test data: No further information used
Diagnostic threshold: Correct diagnosis (of BCC, MM and SCC) and correct management decision
(excise or not)
Diagnosis based on: Single observer (n=2; one reader evaluated only dermoscopic images while the
second reader evaluated RCM images)
Observer qualifications: not clear; only given initials of the reader, likely dermatologist
Experience in practice: Not described
Experience with index test: Not described
Any other detail: Digital dermoscopy images were obtained with DermLite FOTO System (DermLite
Photo 3Gen, San Juan Capistrano, CA, USA).
Visual Inspection (in-person)
A. Risk of Bias
B. Concerns regarding applicability
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Dermoscopy (in-person)
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection (image based)
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (image based)
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Target condition (Final diagnoses) 
BCC: 114; cSCC: 13; Melanoma (in situ and invasive, or
not reported): 12; Other malignant: 1 syringoid eccrine
carcinoma
Sebhorrheic keratosis: 25 grouped solar
lentigo/seborrhoeic keratosis/lichen planus-like keratosis/
actinic keratosis (SL/SK/LPLK/AK); Benign naevus: 47
nevi; 6 Spitz nevi; 18 dermatofibromas (DF), 4 vascular
lesions, and 20 other type benign lesions. Other types of
benign lesions included 1 clear cell acanthoma, 1 discoid
lupus, 10 inflammatory lesions, 1 perivascular hyperplasia,
4 granulomatous hyperacanathosis reactions, 1 papulous
fibrosis, 1 eccrine poroma, and 1 eczematous lesion.
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without
knowledge of the results of the index tests? Unclear
Were the reference standard results interpreted without
knowledge of the referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation
have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Excluded participants: Around 357 cases were
excluded due to the lack of a histopathology
report, as a result of the lesion not being excised,
or a benign diagnosis was made with high
confidence.
Time interval to reference test: lesions excised at
first visit or follow-up video dermoscopy control
visit
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application
of index test(s) of at least: 3 months for melanoma or cSCC or 6 months
for BCC?
If more than one algorithm was evaluated for the same test, was the
interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Notes
Notes -
 
Zalaudek 2006
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection February 2003 to
January 2004
Country Naples, Italy
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Excised, equivocal and nonequivocal,
pigmented and nonpigmented skin lesions with good
image quality and melanin or haemoglobin pigmentation
in all or part of the lesion.
Setting: Specialist unit; specialized Pigmented Lesion
Clinic database
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Specialist unit
Exclusion criteria: None reported
Sample size (patients): NR
Sample size (lesions): Eligible: 2621; Included - 150
(plus 15 lesions used for training purposes)
Participant characteristics: None reported
Lesion characteristics 37/165 (26%) considered
equivocal on clinical and dermoscopic grounds
Thickness/depth: Mean Breslow 0.9mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
Dermoscopy: 3 point checklist
Method of diagnosis: Dermoscopic images, 'optimized for colour, brightness and contrast by using
Adobe photoshop standards'
Prior test data: Age, site, and gender provided
Diagnostic threshold: >= 1 criterion present indicates malignancy (asymmetry - in colour and ⁄or
structure, not in shape; atypical network - pigment network with thick lines and irregular holes; and
blue white structures - presence of any blue and ⁄or white colour within the lesion
Diagnosis based on: Average (n=150 out of 170 participating observers, who finished all 15 training
cases and performed at least one evaluation of the main set of images (test set). Participation was
open to all individuals regardless of professional profile and experience in dermoscopy; study was
advertised through personal communication, e-mail correspondences, adverts during congresses and
courses, as well as via the website (http://www.dermoscopy.org).).
Observer qualifications: For full sample of 170: Dermatologists (n=125); GPs (n=15); Other
professionals in the field of skin lesions (n=12); Medical students (n=7); Other medical specialty (n=11)
Experience in practice: Not described
Experience with dermoscopy: Mixed; 146/170 (86%) reported some experience with dermoscopy; 24
with no dermoscopy experience, 45 (26%) with >5 years experience.
#
Dermoscopy training: A web-based tutorial was provided to describe the concept of the three point
checklist of dermoscopy including complete definitions of criteria and example images. Following web-
based tutorial, observers initially scored a random sample of 15 images, receiving real-time feedback
for that case as judged by an expert observer.
Training format: Online
Visual Inspection (in-person)
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (in-person)
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection (image based)
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A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy (image based)
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone (no
further details)
Target condition (Final diagnoses) 
Melanoma (invasive): 18; Melanoma (in situ): 11
BCC: 18
79 melanocytic naevi; 26 seborrhoeic keratoses; 8
vascular tumours and 3 dermatofibromas
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge
of the results of the index tests? Unclear
Were the reference standard results interpreted without knowledge
of the referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: Poor quality index
test image as exclusion criterion
Index test to reference standard interval:
Not described
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
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Footnotes
NR – not reported; PSL – pigmented skin lesion; PLC – pigmented lesion clinic; MM – malignant melanoma; MiS – melanoma
in situ (or lentigo maligna); BCC – basal cell carcinoma; cSCC – cutaneous squamous cell carcinoma; LS – lentigo simplex;
SK – seborrhoeic keratosis; SN – Spitz nevi; AK – actinic keratosis; BN – benign naevi; BD – Bowen’s disease; DF –
dermatofibroma; FU – follow-up; R – retrospective; P – prospective; CS – case series; CCS – case control study; WPC –
within person comparison (of tests); BPC – between person comparison (of tests); NC – non comparative; RCM – reflectance
confocal microscopy; CAD – computer-assisted diagnosis
Characteristics of excluded studies 
Abbasi 2004
Reason for exclusion EXCLUDE not a primary study
systematic review
 
Ahnlide 2013
Reason for exclusion EXCLUDE on index test
'clinical diagnosis' study
 
Ahnlide 2016
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Akasu 1996
Reason for exclusion EXCLUDE on 2x2 data
no 2x2 data only describing the dermoscopic features present in the lesions
 
Al Jalbout 2013
Reason for exclusion EXCLUDE on sample size
case study
 
Alarcon 2014
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Aldridge 2011
Reason for exclusion EXCLUDE on test observer
medical students and lay persons
 
Aldridge 2011a
Reason for exclusion EXCLUDE on test observer
 
Aldridge 2013
Reason for exclusion EXCLUDE on 2x2 data
not test accuracy study
 
Alendar 2009
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Reason for exclusion EXCLUDE on reference standard
only 7 reported verified histologically
 
Altamura 2006
Reason for exclusion EXCLUDE if individual lesion characteristics
EXCLUDE on 2x2 data
looking for chars associated with acral melanoma; does not give 2x2 for overall dx
 
Annessi 2007
Reason for exclusion EXCLUDE on target condition; does not report data for BCC or cSCC
 
Antonio 2013
Reason for exclusion EXCLUDE on target condition
Atypical nevi does not fall within our definition of D+
 
Antoszewski 2015
Reason for exclusion EXCLUDE on sample size
All excised lesions were benign.
EXCLUDE on 2x2 data
 
Aoyagi 2010
Reason for exclusion EXCLUDE on sample size
 
Arevalo 2008
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Argenziano 1997
Reason for exclusion EXCLUDE on study population
Only melanoma included
 
Argenziano 1998
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Argenziano 1999
Reason for exclusion EXCLUDE on study population
Only includes melanoma
 
Argenziano 2002
Reason for exclusion EXCLUDE not a primary study
 
Argenziano 2003
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Reason for exclusion EXCLUDE on 2x2 data
Table V gives se/sp data for 108 lesions but can't derive the number of melanoma for
this subset of the original 128
EXCLUDE but contact authors; contacted 10-5-16 and 24-6-16
 
Argenziano 2004
Reason for exclusion EXCLUDE if individual lesion characteristics
only lesions with vascular structures included; presence of 10 different characteristics
assessed. 2x2 would be possible
 
Argenziano 2004a
Reason for exclusion EXCLUDE not a primary study
letter
 
Argenziano 2008
Reason for exclusion EXCLUDE on index test
surveillance/monitoring study
 
Argenziano 2010
Reason for exclusion EXCLUDE on index test
test used for follow-up looking at dermoscopic features of melanomas diagnosed 1 yr
after follow up
EXCLUDE on 2x2 data
 
Argenziano 2011
Reason for exclusion EXCLUDE on target condition
EXCLUDE on sample size
only 2 melanomas
 
Argenziano 2011a
Reason for exclusion EXCLUDE on target condition
5 melanoma metastases included as D+
 
Argenziano 2011b
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Argenziano 2012
Reason for exclusion EXCLUDE on reference standard
no follow-up of test negatives
 
Argenziano 2014
Reason for exclusion EXCLUDE on 2x2 data
 
Armstrong 2011
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Reason for exclusion EXCLUDE on reference standard
No reference standard results presented for the screened lesions; just compares
naked eye judgements with dermoscopy
 
Ascierto 1998
Reason for exclusion EXCLUDE on 2x2 data
the data presented does not contribute to the review
EXCLUDE duplicate or related publication Data included in Ascierto 2003
 
Ascierto 2000
Reason for exclusion EXCLUDE on 2x2 data
EXCLUDE but contact authors
For excised lesions, study cross-tabulates ELM high/very high risk classification
against some histological classification (Table 2). Number D+ = 580 (2x2: 504, 79, 76,
2072); 580 not mentioned anywhere else in paper [contacted 10/05/2016 and
24/06/2016]
 
Ascierto 2003
Reason for exclusion EXCLUDE not a primary study
 
Ascierto 2010
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Badertscher 2015
Reason for exclusion EXCLUDE on 2x2 data
 
Bafounta 2001
Reason for exclusion EXCLUDE not a primary study
systematic review
 
Bajaj 2016
Reason for exclusion EXCLUDE on reference standard
unclear ref standard for benign diagnoses 
 
Banky 2005
Reason for exclusion EXCLUDE on target condition
EXCLUDE on index test
 
Barzegari 2005
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Basarab 1996
Reason for exclusion EXCLUDE on study population
not all suspected of skin cancer
EXCLUDE on 2x2 data
 
#165 Visual examination and dermoscopy, alone or in combination, for the diagnosis of keratinocyte skin cancers in ad...
90 / 231
Bauer 2000
Reason for exclusion EXCLUDE on index test
Does not provide 2x2 data for visual inspection alone
 
Bauer 2005
Reason for exclusion EXCLUDE on index test
follow-up/monitoring study
 
Bauer 2006
Reason for exclusion EXCLUDE on index test
dermoscopy used to improve histopathology diagnosis
 
Becker 1954
Reason for exclusion EXCLUDE not a primary study
 
Benati 2015
Reason for exclusion EXCLUDE if individual lesion characteristics
 
Benelli 1999
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Benelli 2000
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Benelli 2000a
Reason for exclusion EXCLUDE on 2x2 data
only inter-rater reliability data given (n=25); authors have published much larger
evaluations of 7FFM and ABCD
 
Benelli 2001
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Benvenuto-Andrade 2006
Reason for exclusion EXCLUDE on 2x2 data
diagnostic confidence rather than accuracy
 
Benvenuto-Andrade 2007
Reason for exclusion EXCLUDE on 2x2 data
agreement on lesion characterisation; not test accuracy
 
Binder 1994
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Binder 1995
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Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Binder 1997
Reason for exclusion EXCLUDE on 2x2 data
training study; only ROC curves/AUC presented pre and post-training
EXCLUDE but contact authors [contacted 10-5-16 and 24-6-16]
 
Binder 1999
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Blum 2003
Reason for exclusion EXCLUDE not a primary study
 
Blum 2003a
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Blum 2003b
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Blum 2004
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Blum 2004a
Reason for exclusion EXCLUDE not a primary study
comment paper
 
Blum 2004b
Reason for exclusion EXCLUDE not a primary study
letter
EXCLUDE Letter only; limited data presented - evaluates '3-colour' rule as developed
By MacKie 1992 (excluded as assessment of individual lesion features only)
 
Blum 2004c
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Blum 2004d
Reason for exclusion EXCLUDE not a primary study
letter
 
Blum 2006
Reason for exclusion EXCLUDE on target condition
differentiates melanocytic from non-melanocytic lesions only 
 
Blum 2011
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Reason for exclusion EXCLUDE on study population
mucosal lesions only
 
Blum 2014
Reason for exclusion EXCLUDE on sample size
case studies
 
Boespflug 2015
Reason for exclusion EXCLUDE on study population
study aim is estimate the efficacy of an online spaced educational training for
dermoscopy
 
Bolognia 1990
Reason for exclusion EXCLUDE on reference standard
no ref standard diagnosis for index test negatives
 
Bono 1996
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Bono 2001
Reason for exclusion EXCLUDE on 2x2 data
aim of the study is to determine what features are present in amelanotic cutaneous
melanoma
 
Bono 2002
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Bono 2002a
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Bono 2006
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Borsari 2010
Reason for exclusion EXCLUDE if individual lesion characteristics
EXCLUDE but contact authors
Paper focuses on diagnostic prediction of dermoscopic island for early melanoma,
however the Methods describe the calculation of the total dermoscopy score and the
7-point checklist score; mean scores on each checklist per lesion type are then
presented [no reply from authors]
 
Borsari 2015
Reason for exclusion EXCLUDE if individual lesion characteristics
 
Borve 2012
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Reason for exclusion EXCLUDE on study population
includes participants without skin lesions
EXCLUDE on sample size
<5 BCC
 
Bourne 2012
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Bowns 2006
Reason for exclusion EXCLUDE on index test; teledermatology study
 
Braun 2000
Reason for exclusion EXCLUDE if derivation study
this is a pilot study on the new "wobble sign" in ELM no training/test sets used
 
Braun 2007
Reason for exclusion EXCLUDE if individual lesion characteristics
 
Braun-Falco 1990
Reason for exclusion EXCLUDE on 2x2 data
Not a test accuracy study
 
Broganelli 2005
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Brown 2000
Reason for exclusion EXCLUDE not a primary study
systematic review 
 
Brown 2009
Reason for exclusion EXCLUDE on test observer
lay persons
 
Buhl 2012
Reason for exclusion EXCLUDE on index test
follow up/monitoring
EXCLUDE duplicate or related publication
same patients as Haenssle 2010 #191
 
Burki 2015
Reason for exclusion EXCLUDE not a primary study
 
Burr 2015
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Reason for exclusion EXCLUDE not a primary study
 
Burton 1998
Reason for exclusion EXCLUDE on reference standard
can only get 2x2 data for referral accuracy
EXCLUDE on 2x2 data
 
Bystryn 2003
Reason for exclusion EXCLUDE not a primary study
letter
 
Cabrijan 2008
Reason for exclusion EXCLUDE on 2x2 data
can't get 2x2; reports % correct diagnoses for each different lesion classification and
not % misdiagnosed as melanoma or melanomas missed 
EXCLUDE but contact authors
Study states "Dermatoscopic diagnosis were conformable with pathohistological
diagnosis in 75 cases (72.82%) out of 103. The highest conformation was in
diagnosing melanoma, in 5 out of 6 cases (83.3%)." which would give us sensitivity; do
you have data on numbers mis classified as melanoma, i.e false positives? [author
replied 5-7-16 with some data but not sufficient to allow 2x2]
 
Canpolat 2011
Reason for exclusion EXCLUDE if derivation study
looks at dermoscopic characteristics of acral lesions; only 4 suspicious lesions excised
 
Cardenas 2009
Reason for exclusion EXCLUDE on study population
Includes participants with palpable lesions; not all suspected of having skin cancer
 
Carli 1994
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Carli 1998
Reason for exclusion EXCLUDE on sample size
se/sp data are based on sample with only 4 MM
 
Carli 2000
Reason for exclusion EXCLUDE on target condition
only lesions histologically classified as common naevi or naevi with architectural
disorder with/without cytological atypia were considered for the study.
 
Carli 2003
Reason for exclusion EXCLUDE on reference standard
Only 39/1042 with ref test
 
Carli 2003a
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Reason for exclusion EXCLUDE on sample size
 
Carli 2003b
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Carli 2003c
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Carli 2004
Reason for exclusion EXCLUDE on sample size
<5 MM per arm
EXCLUDE on 2x2 data
 
Carli 2004a
Reason for exclusion EXCLUDE on index test; can only estimate 2x2 for the full time period 1997 to 2001
across all observers, however dermoscopy was only introduced routinely in 1998 so
some diagnoses prior to that will have been with visual inspection alone, and
observers were classed as dermoscopy ’users’ (those working in pigmented lesion
clinics) and nonusers (general dermatology).
EXCLUDE but contact authors
Author passed away; unable to make contact with co-authors
 
Carli 2004b
Reason for exclusion EXCLUDE on index test
'Clinical diagnosis' - Dataset covers 1997-2001, but dermoscopy routinely introduced
1998; authors contacted but no response. 
 
Carli 2005
Reason for exclusion EXCLUDE on 2x2 data
EXCLUDE but contact authors
Study presents % MM correctly classified by naked eye +/- dermoscopy but doesn't
give any detail on FPs, is thisavailable anywhere and/or are these lesions included in
any subsequent publications? Author passed away; unable to make contact with co-
authors
 
Carlos-Ortega 2007
Reason for exclusion EXCLUDE on 2x2 data
Gives se/sp for visual inspection and dermoscopy in the English abstract. 68
patients/70 lesions were included but only 36 seem to have had visual inspection
results and all underwent dermoscopy. Two observers performed each test blinded to
each other. Table I gives 22 with BCC and 11 with melanoma overall (no. D+ not
reported for those with VI results), but using either or both of these numbers with the
se/sp provided does not give the same PPV and NPV as given by the authors
EXCLUDE but contact authors
data not clearly presented for 2x2; translator suggested alternative but still does not
work out to what is in paper; tried contacting authors twice, no reply as of 28-07-16;
 
Carrera 2016
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Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Carroll 1998
Reason for exclusion EXCLUDE if derivation study
Derivation study; proposes new dermoscopic criteria for dx of BCC
EXCLUDE on 2x2 data
 
Chen 2001
Reason for exclusion EXCLUDE not a primary study
Systematic review comparing PCP accuracy with dermatologist accuracy. 
 
Chen 2006
Reason for exclusion EXCLUDE on 2x2 data
only given AUC
 
Chen 2013
Reason for exclusion EXCLUDE on test observer
 
Chiaravalloti 2014
Reason for exclusion EXCLUDE on study population
Includes melanoma only
 
Ciudad-Blanco 2014
Reason for exclusion EXCLUDE on study population
Includes melanoma only
EXCLUDE if individual lesion characteristics
EXCLUDE on 2x2 data
 
Collas 1999
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Coras 2003
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Cornell 2015
Reason for exclusion EXCLUDE on test observer
 
Cox 2008
Reason for exclusion EXCLUDE on reference standard
Se and sp estimates for diagnosis of melanoma for both the seven-point checklist and
the revised (10-point) checklist; reference standard not reported for any of the 381
TWR referrals for melanoma
EXCLUDE but contact authors
Author contacted 10/05/16; co-author contacted 24-6-16
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Cristofolini 1994
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Cristofolini 1997
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Dal Pozzo 1999
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
de Giorgi 2006
Reason for exclusion EXCLUDE on sample size
<5 cases of participants with a final melanoma diagnosis 
 
De Giorgi 2011
Reason for exclusion EXCLUDE duplicate or related publication
Assesses same lesions as in Carli 2003b but different observers
 
de Giorgi 2012
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
de Troya-Martin 2008
Reason for exclusion EXCLUDE on study population
Only MM included
 
DeCoste 1993
Reason for exclusion EXCLUDE on 2x2 data
Not given the total number of D+/D- or total number of lesions included. Just given the
sens/spec values 
 
Delfino 1997
Reason for exclusion EXCLUDE if individual lesion characteristics
EXCLUDE if derivation study
EXCLUDE on 2x2 data
only reports association of each characteristics with D+/D-, not 2x2
 
Di Carlo 2014
Reason for exclusion xxxxxxxxxxx
 
Di Chiacchio 2010
Reason for exclusion EXCLUDE on target condition
Excluding nail bed melanoma
EXCLUDE on 2x2 data
There is insufficient data to extract for a 2x2 table
 
di Meo 2016
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Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Di Stefani 2007
Reason for exclusion EXCLUDE on sample size
<5 malignant
 
Dolianitis 2005
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Dreiseitl 2009
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Duff 2001
Reason for exclusion EXCLUDE on index test
Does not evaluate visual inspection alone
 
Dummer 1993
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Dummer 1995
Reason for exclusion EXCLUDE if individual lesion characteristics
 
Edmondson 1999
Reason for exclusion EXCLUDE on reference standard
It seems that the reference standard here is expert diagnosis. This is not a
teledermatology paper 
 
Elwan 2016
Reason for exclusion EXCLUDE on sample size
EXCLUDE if derivation study
EXCLUDE on 2x2 data
 
Emmons 2011
Reason for exclusion EXCLUDE on 2x2 data
not test accuracy study; promoting primary prevention
 
Engelberg 1999
Reason for exclusion EXCLUDE on sample size
only 1 confirmed melanoma and 3 BCC
 
English 2003
Reason for exclusion EXCLUDE on 2x2 data
no accuracy data given 
 
English 2004
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Reason for exclusion EXCLUDE on 2x2 data
no accuracy data
 
Fabbrocini 2008
Reason for exclusion EXCLUDE on 2x2 data
there isn't sufficient data provided for each index test to populate 2x2 table 
EXCLUDE but contact authors
As we can only include DTA studies - Do you have a cross tabulation of each
clinician's diagnosis (e.g. at threshold of >=3 on 7 point checklist) against the
histological diagnosis and/or a cross tabulation of the remote diagnosis against the
Face to Face diagnoses? [author reply; 30-6-16 cannot access data needed]
 
Feci 2015
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Federman 1995
Reason for exclusion EXCLUDE on 2x2 data
Not test accuracy
 
Feldmann 1998
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Ferrara 2002
Reason for exclusion EXCLUDE on index test
this study looks at histopathological and dermoscopic disagreements not necessarily
looking at how well dermoscopy differentiates between benign and malignant
diagnosis
 
Ferrari 2015
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Ferris 2015
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Fidalgo 2003
Reason for exclusion EXCLUDE on 2x2 data
EXCLUDE duplicate or related publication
Appears to be superseded by Serrao 2006
EXCLUDE but contact authors
Paper provides % of MM and of DN with DNAOS scores of >=5.5 and >7, is it possible
for you to provide the same information for the remaining 127 lesions in the study?
Also can you advise as to whether any of the 247 lesions included in this study,
overlap with the 652 reported in Serrao 2006 (#1144)? [author contacted 10-5-16;
24-06-16]
 
Fikrle 2013
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Reason for exclusion EXCLUDE on reference standard
Follow up study <50% of study participants have their final diagnosis reached by
histopathology.
 
Freeman 1963
Reason for exclusion EXCLUDE on 2x2 data
Only gives % correct for each lesion type
EXCLUDE but contact authors
Tables 2 and 3 appear to give % correct diagnoses per lesion type, but does not give
data on numbers misclassified as melanoma, or other malignancy, i.e. FPs. Author
responded; paper too old, cannot provide data
 
Friedman 1985
Reason for exclusion EXCLUDE not a primary study
 
Friedman 2008
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Fruhauf 2012
Reason for exclusion EXCLUDE on reference standard
35/219 underwent histology; 13 followed-up; 171 expert clinical Dx
 
Fueyo-Casado 2009
Reason for exclusion EXCLUDE on reference standard
<50% of the study population received histology as a test. No information given on
those who were followed up. 
 
Funt 1963
Reason for exclusion EXCLUDE on index test
EXCLUDE on 2x2 data
No 2x2 data
 
Gachon 2005
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Gerbert 1996
Reason for exclusion EXCLUDE on target condition
No breakdown of final diagnoses for included lesions
EXCLUDE on 2x2 data
Only gives % correct for each lesion type; not sens/spec
 
Gerbert 1998
Reason for exclusion EXCLUDE on 2x2 data
 
Gereli 2010
#165 Visual examination and dermoscopy, alone or in combination, for the diagnosis of keratinocyte skin cancers in ad...
101 / 231
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Giacomel 2005
Reason for exclusion EXCLUDE on study population
Only BCC included
 
Giacomel 2014
Reason for exclusion EXCLUDE on sample size
 
Giannotti 2004
Reason for exclusion EXCLUDE not a primary study
a review
 
Gill 2015
Reason for exclusion EXCLUDE on sample size
EXCLUDE if derivation study
 
Gilmore 2009
Reason for exclusion EXCLUDE if derivation study
Principle of lacunarity has been looked at before but not this particular
application/approach to it
EXCLUDE on reference standard
It is possible to get 2x2 for 'standard dermoscopy criteria' however dermoscopy
negative were not excised and assumed benign; 201/312 underwent excision so
theoretically eligible
 
Gilmore 2010
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Glud 2009
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Grana 2003
Reason for exclusion EXCLUDE on index test
EXCLUDE if individual lesion characteristics
only looking at lesion border
 
Green 1991
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Green 1994
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Grichnik 2003
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Reason for exclusion EXCLUDE on sample size
 
Grichnik 2004
Reason for exclusion EXCLUDE not a primary study
Editorial
 
Grimaldi 2009
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Grob 1998
Reason for exclusion EXCLUDE not a primary study
 
Guibert 2000
Reason for exclusion EXCLUDE on reference standard
Not designed as an accuracy study only observational. Can't get 2x2 data >50% of
study participants did not recieve histology as ref standard. 
 
Guillod 1996
Reason for exclusion EXCLUDE if derivation study
 
Gunduz 2003
Reason for exclusion EXCLUDE on sample size
case study
 
Gutierrez 2013
Reason for exclusion EXCLUDE on index test
test to improve histopathology diagnosis
 
Haenssle 2006
Reason for exclusion EXCLUDE on index test
[surveillance study estimating accuracy of different approaches to follow-up]
 
Haenssle 2010
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Haenssle 2010a
Reason for exclusion EXCLUDE on 2x2 data
Does not report specificity
EXCLUDE duplicate or related publication
same patients as Haenssle 2010 #191
 
Hallock 1998
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Reason for exclusion EXCLUDE on index test
'clinical diagnosis'; dermoscopy used for 3 of 4 years
 
Haniffa 2007
Reason for exclusion EXCLUDE on reference standard
looks like approximately 20% of patients received a final diagnosis by histology. 179
biopsies were performed. Total sample was 881 lesions 
 
Har-Shai 2001
Reason for exclusion EXCLUDE on index test
'clinical diagnosis'
 
Haspeslagh 2016
Reason for exclusion EXCLUDE if individual lesion characteristics
EXCLUDE on 2x2 data
 
Hauschild 2014
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Heal 2008
Reason for exclusion EXCLUDE on 2x2 data
Sensitivities and PPVs are given so theoretically a 2x2 could be worked out but the
numbers do not appear to work out 
Author response; the 2x2 table the Cochrane researchers want to create is not
possible for our results, because sensitivity and PPV are based on different sample
sizes. 
 
Healsmith 1994
Reason for exclusion EXCLUDE on reference standard
Benign lesions described as 'clinically diagnosed' rather than histology/follow-up
 
Henning 2007
Reason for exclusion EXCLUDE if derivation study
First application of CASH algorithm
 
Henning 2008
Reason for exclusion Exclude is a derivation study
 
Herschorn 2012
Reason for exclusion EXCLUDE not a primary study
systematic review
 
Higgins 1992
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Reason for exclusion EXCLUDE on study population
Includes only benign lesions
EXCLUDE on sample size
No melanomas
EXCLUDE on 2x2 data
No malignant cases
 
Hirata 2011
Reason for exclusion EXCLUDE on target condition
EXCLUDE on index test
 
Hoffmann 2003
Reason for exclusion EXCLUDE if derivation study
Uses leave one out cross validation procedure
EXCLUDE on 2x2 data
Only giving ROC values not able to extract a 2x2 table 
 
Hoorens 2016
Reason for exclusion EXCLUDE on index test
EXCLUDE on reference standard
No info on numbers undergoing histology; and no follow-up reported for benign
appearing lesions
EXCLUDE on 2x2 data
 
Huang 1996
Reason for exclusion EXCLUDE if individual lesion characteristics
Border irregularity not overall dx
EXCLUDE on 2x2 data
 
Hubener 1956
Reason for exclusion EXCLUDE on 2x2 data
 
Ishioka 2009
Reason for exclusion EXCLUDE ON INDEX TEST - include for teledermatology only
 
Iyatomi 2006
Reason for exclusion EXCLUDE if derivation study
uses leave one out procedure and same lesions and tumour extraction method as
Iyatomi 2006
EXCLUDE on 2x2 data
 
Iyatomi 2008
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Reason for exclusion EXCLUDE if derivation study
the performance was evaluated by averaging both combinations (training and test
sets) they did not present the data separately; uses leave one out procedure
EXCLUDE on 2x2 data
Not test accuracy; compares automated with manual extraction of tumour area
 
Jamora 2003
Reason for exclusion EXCLUDE on reference standard
no referene standrd for index test negatives
 
Janda 2014
Reason for exclusion EXCLUDE on sample size
only one case of melanoma, one case of BCC and one of SCC
 
Jensen 2015
Reason for exclusion EXCLUDE not a primary study
comment paper
 
Johr 2002
Reason for exclusion EXCLUDE not a primary study
 
Jolliffe 2001
Reason for exclusion EXCLUDE on index test
Provides data for clinical diagnosis (including dermoscopy for some cases)
 
Jonna 1998
Reason for exclusion EXCLUDE on 2x2 data
only included index test positives to get PPV, not worth author contact on this one
 
Kaddu 1997
Reason for exclusion EXCLUDE on sample size
Sample size <5; not test accuracy
 
Kawabata 1998
Reason for exclusion EXCLUDE if derivation study
aim of the study is to correlate findings between dermoscopy and histology findings of
acral melanoma
EXCLUDE on 2x2 data
not test accuracy
 
Kawabata 2001
Reason for exclusion EXCLUDE on study population MM of the nail bed
 
Keefe 1990
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Reason for exclusion EXCLUDE on reference standard
Only 28% (60/214) of non melanoma group had excision
 
Kefel 2012
Reason for exclusion EXCLUDE if derivation study
no test set, first use of polarised light dermoscopy, various neural networks tested
EXCLUDE on 2x2 data
 
Kelly 1986
Reason for exclusion EXCLUDE on target condition
Can't disaggregate the severely dysplastic/in situ MM
EXCLUDE on sample size
unclear whether >5 in situ melanoma
 
Kenet 1994
Reason for exclusion EXCLUDE not a primary study
EXCLUDE on 2x2 data
not an accuracy study 
 
Kittler 1998
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Kittler 1999
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Kittler 2001
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Kittler 2002
Reason for exclusion EXCLUDE not a primary study
systematic review
 
Kittler 2006
Reason for exclusion EXCLUDE conference abstract
 
Koga 2011
Reason for exclusion EXCLUDE on reference standard
~23% of patients have their final diagnosis reached by histopathology 43/191
 
Koh 1990
Reason for exclusion EXCLUDE on reference standard
screening study; no adequate reference standard
 
Kopf 1975
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Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Korotkov 2012
Reason for exclusion EXCLUDE not a primary study
narrative review
 
Krahn 1998
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Kreusch 1992
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Kroemer 2011
Reason for exclusion EXCLUDE on index test
Provides data for clinical diagnosis (including dermoscopy for some cases)
 
Krol 1991
Reason for exclusion EXCLUDE on reference standard
No follow up reported for those who were test negative
 
Kurvers 2015
Reason for exclusion EXCLUDE on index test
Collective intelligence - majority rule and quorum rule applied to large number of test
interpreter decisions
EXCLUDE duplicate or related publication
re-analyses data from 2 previously published studies to determine whether collective
intelligence (i.e majority rules or quorum rules across a large number of observers)
imporves test accuracy. We have excluded one of these studies as the number of
melanomas is not provided ( Argenziano 2003 ) and included the other in dermoscopy
review ( Zalaudek 2006 ).
 
Kvedar 1997
Reason for exclusion EXCLUDE on study population
Not all suspected of skin cancer
 
Lallas 2015
Reason for exclusion EXCLUDE if derivation study
Develops new algorithm and does not use separate training/test sets of lesions
 
Langley 2001
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Langley 2007
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Lechner 2015
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Reason for exclusion EXCLUDE not a primary study
Erratum
 
Lewis 1999
Reason for exclusion EXCLUDE on 2x2 data
Study appears to meet all eligibility criteria but disease prevalence not given alongside
se/sp
EXCLUDE but contact authors
Authors contacted 10/05/2016; email returned
 
Liebman 2011
Reason for exclusion EXCLUDE not a primary study
comment
 
Liebman 2012
Reason for exclusion EXCLUDE not a primary study
comment
 
Lindelöf 1994
Reason for exclusion EXCLUDE on study population
only malignant melanoma 
EXCLUDE on 2x2 data
not enough information given to derive a 2x2 table. only given for a sample of 50
patients who had a strong suspicion of melanoma clinically. Do not know what
happened to those with no suspicion clinically 
 
Lipoff 2008
Reason for exclusion EXCLUDE on target condition
study does not differentiate MM from benign/other but looks to identify lesion
characteristics that might help id those at risk for MM
 
Liu 2012
Reason for exclusion EXCLUDE if derivation study
ásymmetry detection; 10-fold cross validation
EXCLUDE on 2x2 data
 
Lorentzen 2000
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Luttrell 2012
Reason for exclusion EXCLUDE on test observer
Accuracy data only given for lay-persons not interested in this population of test
observers
 
Machet 2005
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Reason for exclusion EXCLUDE on study population
**[Note this is a staging study]
 
MacKenzie-Wood 1998
Reason for exclusion EXCLUDE on study population
only malignant diagnosis
 
MacKie 1971
Reason for exclusion EXCLUDE on 2x2 data
only gives % with correct diagnosis rather than numbers misclassified as malignant
 
MacKie 1990
Reason for exclusion EXCLUDE not a primary study
 
MacKie 1991
Reason for exclusion EXCLUDE not a primary study
letter
 
MacKie 2002
Reason for exclusion EXCLUDE if individual lesion characteristics
presence of 3 or more colours on dermoscopy
 
Mahendran 2005
Reason for exclusion EXCLUDE on index test
Face to face is 'clinical diagnosis', i.e. visual inspection +/- use of dermoscopy
 
Mahon 1997
Reason for exclusion EXCLUDE not a primary study
a summary of a comparison of two screening checklists
 
Malvehy 2014
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Marghoob 1995
Reason for exclusion EXCLUDE not a primary study
letter
 
Marghoob 2007
Reason for exclusion EXCLUDE not a primary study
 
Marghoob 2010
Reason for exclusion EXCLUDE not a primary study
 
Massi 2001
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Reason for exclusion EXCLUDE if individual lesion characteristics
 
Mayer 1997
Reason for exclusion EXCLUDE not a primary study
systematic review
 
McCarthy 1995
Reason for exclusion EXCLUDE not a primary study
leaflet
 
McGovern 1992
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Menzies 1996
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Menzies 1996a
Reason for exclusion EXCLUDE if individual lesion characteristics
only given the SE/SP of individual characteristics; lesions make up the training set for 
Menzies 1996 (#1971)
 
Menzies 1999
Reason for exclusion EXCLUDE not a primary study
 
Menzies 2001
Reason for exclusion EXCLUDE on index test
monitoring purposes
 
Menzies 2005
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Menzies 2008
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Menzies 2009
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Menzies 2011
Reason for exclusion EXCLUDE on index test
surveillance study; data used to id factors predictive of lesion changes
 
Menzies 2013
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
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Moffatt 2006
Reason for exclusion EXCLUDE on index test
'clinical diagnosis'
 
Mohammad 2015
Reason for exclusion EXCLUDE on study population
only includes BCC
 
Morales Callaghan 2008
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Morrison 2001
Reason for exclusion EXCLUDE on 2x2 data
Study gives % correct diagnosis within each histology group and then gives the %
‘correct’ diagnosis of skin cancer as 22% for FP and 87% for dermatologist. But these
statistics appear to have been reached by taking the mean of the % correct diagnoses
across the malignant groups and do not equate to sensitivity. i.e. If you take the mean
of the FP correct (%) for the 4 malignant groups you get: (40+22+25+0)/4 = 21.75%
and then the same for the dermatologist correct (%) column:
(95+77+75+100)/4=86.75% 
 
Morton 1998
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Mun 2016
Reason for exclusion EXCLUDE on reference standard
Only 37% of benign group underwent adequate reference standard
 
Nachbar 1994
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Nathansohn 2007
Reason for exclusion EXCLUDE on 2x2 data
Not test accuracy; follow-up study
 
Nilles 1994
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Osborne 1998
Reason for exclusion EXCLUDE on reference standard
not clear what the ref standard is 
EXCLUDE on 2x2 data
 
Osborne 1999
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Reason for exclusion EXCLUDE on study population
Only patients with melanoma included
 
Pagnanelli 2003
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Pan 2008
Reason for exclusion EXCLUDE if derivation study
looking to id characteristics assoc with superficial BCC; 2x2 could be extracted for
combination of 3 selected characteristics. Dermoscopic features selected based on
prior studies but only patients with 3 diagnoses included: BCC, intra-ep carcinoma and
psoriasis
 
Panasiti 2009
Reason for exclusion EXCLUDE if individual lesion characteristics
EXCLUDE on reference standard
Of the 1543 lesions analysed on 321 received histopathology diagnosis. The accuracy
data is based on this (only 20%) not sure what happened to the 80% of participants as
no mention of follow up is mentioned. 
 
Parslew 1997
Reason for exclusion EXCLUDE on study population
Not all suspected of skin cancer
 
Pazzini 1996
Reason for exclusion EXCLUDE on 2x2 data
 
Pehamberger 1987
Reason for exclusion EXCLUDE on 2x2 data
Not test accuracy. This is a descriptive paper defining dermoscopic criteria. It is not a
study testing accuracy of dermoscopy. From the authors final sign off it looks like part
2 of this paper may have details on accuracy ( Steiner 1987 ).
 
Pellacani 2002
Reason for exclusion EXCLUDE not a primary study
 
Pellacani 2006
Reason for exclusion EXCLUDE if derivation study
looks at detection of asymmetry between clinicians and computer
EXCLUDE on 2x2 data
2x2 could be derived for overall asymmetry or border cut-off but not overall diagnosis
 
Pellacani 2007
Reason for exclusion EXCLUDE if individual lesion characteristics
EXCLUDE if derivation study
looking at blue hue
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Pellacani 2009
Reason for exclusion EXCLUDE on target condition
focus is on identifying Spitz nevi from melanoma and ‘clark’ naevi and it is looking to
derive useful RCM characteristics. Although some data is given in the text for an RCM
score of >3 it is difficult to work out which are FP and which FN. 
 
Perednia 1992
Reason for exclusion EXCLUDE on 2x2 data
Not test accuracy
 
Peris 2002
Reason for exclusion EXCLUDE on study population
only patients with BCC diagnosis included
 
Perrinaud 2007
Reason for exclusion EXCLUDE on index test
Does not provide data for visual inspection alone
 
Phan 2010
Reason for exclusion EXCLUDE on 2x2 data
Not test accuracy investigating dermoscopic features of acral melanoma including of
the nail apparatus; no accuracy data given
 
Piccolo 2000
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Piccolo 2002
Reason for exclusion EXCLUDE not a primary study
EXCLUDE on 2x2 data
not enough data to populate 2x2 table. No breakdown of index test results and ref
standard. 
 
Piccolo 2002a
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Piccolo 2004
Reason for exclusion EXCLUDE on index test; include for teledermatology anyway
 
Piccolo 2006
Reason for exclusion EXCLUDE on sample size
3 MMs, but also 1 lentigo and 14 dysplastic nevus; data not presented to allow se/sp
estimation
EXCLUDE if individual lesion characteristics
EXCLUDE if derivation study
Derivation for hypoluminescence microscopy; 
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Piccolo 2014
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Pizzichetta 2001
Reason for exclusion EXCLUDE on study population
population in study only those with malignant disease
 
Pizzichetta 2001a
Reason for exclusion EXCLUDE on 2x2 data
Observer agreement only
 
Pizzichetta 2002
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Pizzichetta 2004
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Pizzichetta 2007
Reason for exclusion EXCLUDE on study population
Only patients with melanoma included
 
Pizzichetta 2010
Reason for exclusion EXCLUDE on sample size
case study
 
Pizzichetta 2013
Reason for exclusion EXCLUDE if individual lesion characteristics
presence of negative pigmented network
 
Pralong 2012
Reason for exclusion EXCLUDE on study population
only melanoma pts included
 
Provost 1998
Reason for exclusion EXCLUDE on 2x2 data
Not test accuracy; only reports concordance
 
Pupelli 2013
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Quereux 2011
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Reason for exclusion EXCLUDE on index test
self-administered questions to patients attending a GP surgery before their
appointment to determine whether they are at high risk of melanoma--which is meant
to highlight to the GP which patient to examine during their consultation
 
Rader 2014
Reason for exclusion EXCLUDE if individual lesion characteristics
EXCLUDE on 2x2 data
 
Rajpara 2009
Reason for exclusion EXCLUDE not a primary study
Systematic review
 
Rallan 2006
Reason for exclusion EXCLUDE on index test
No data can be extracted for visual inspection alone
 
Rampen 1988
Reason for exclusion EXCLUDE on study population
Only melanoma included
 
Rao 1997
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Reeck 1999
Reason for exclusion EXCLUDE on study population
Only includes index test negatives; i.e. those considered benign by referring clinician
EXCLUDE on target condition
 
Reggiani 2015
Reason for exclusion EXCLUDE not a primary study
systematic review kerationcyte skin cancer
 
Riddell 1961
Reason for exclusion EXCLUDE on study population
All malignant
 
Rigel 1993
Reason for exclusion EXCLUDE not a primary study
 
Rigel 1997
Reason for exclusion EXCLUDE not a primary study
 
Rigel 2012
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Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Robati 2014
Reason for exclusion EXCLUDE on reference standard
no follow-up of patients not referred to dermatology clinics, who did not recieve
histopathology 
 
Robinson 2010
Reason for exclusion EXCLUDE on index test
self examination
 
Ronger 2002
Reason for exclusion EXCLUDE if individual lesion characteristics
 
Rosado 2003
Reason for exclusion EXCLUDE not a primary study
Systematic Review
 
Rosendahl 2012
Reason for exclusion EXCLUDE if individual lesion characteristics
 
Rosendahl 2012a
Reason for exclusion EXCLUDE not a primary study
 
Rossi 2000
Reason for exclusion EXCLUDE on reference standard
Unclear reference standard in disease negative
 
Roush 1986
Reason for exclusion EXCLUDE on target condition
only dysplastic nevus
 
Rubegni 2002
Reason for exclusion EXCLUDE not a primary study
 
Rubegni 2005
Reason for exclusion EXCLUDE not a primary study
Editorial 
 
Rubegni 2010
Reason for exclusion EXCLUDE if derivation study
uses leave one out procedure 
EXCLUDE on 2x2 data
 
Rubegni 2012
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Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Rubegni 2016
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Sahin 2004
Reason for exclusion EXCLUDE if individual lesion characteristics
EXCLUDE on 2x2 data
no accuracy data given, study looking at dermoscopic features of LM
 
Saida 2002
Reason for exclusion EXCLUDE if individual lesion characteristics
Decsriptive study looking at presence (%) of certain features. Not looking at accuracy.
Has paragraph on diagnostic value of this specific feature quoting sens & spec but this
is based upon unpublished observations and the data is not given in this paper.
 
Saida 2004
Reason for exclusion EXCLUDE if individual lesion characteristics
 
Sakakibara 2010
Reason for exclusion EXCLUDE if individual lesion characteristics
only looking at different vascular structures 
 
Salerni 2011
Reason for exclusion EXCLUDE on sample size
<5 cases 
 
Salerni 2012
Reason for exclusion EXCLUDE on index test
surveillance study
EXCLUDE on 2x2 data
 
Salerni 2013
Reason for exclusion EXCLUDE not a primary study
systematic review of surveillance with digital dermoscopy
 
Salvio 2011
Reason for exclusion EXCLUDE not a primary study
EXCLUDE on sample size
 
Sanchez-Martin 2012
Reason for exclusion EXCLUDE on study population
Only BCC cases 
 
Savk 2004
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Reason for exclusion EXCLUDE not a primary study
letter
 
Sawada 2013
Reason for exclusion EXCLUDE not a primary study
 
Sboner 2003
Reason for exclusion EXCLUDE if derivation study
describes 10-fold cross-validation process for training/testing classifier
 
Sboner 2004
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Schindewolf 1994
Reason for exclusion EXCLUDE on index test
evaluates CAD not VI
 
Schmoeckel 1987
Reason for exclusion EXCLUDE not a primary study
 
Schulz 2001
Reason for exclusion EXCLUDE on target condition
Melanoma metastases
 
Scope 2008
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Scope 2015
Reason for exclusion EXCLUDE not a primary study
 
Segura 2009
Reason for exclusion EXCLUDE on index test; RCM evaluation
 
Seidenari 1998
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Seidenari 2004
Reason for exclusion EXCLUDE on 2x2 data
No data to populate 2x2 table just ROC curve values given. 
EXCLUDE but contact authors
TABLE 5 provides AUC values for each diagnosis for both formats and observers; we
are particularly interested in accuracy for the diagnosis of melanoma, are you able to
provide data in 2x2 format , e.g. for melanoma 'certain' against final diagnosis and for
melanoma 'certain or fairly certain' against final diagnosis? [no reply from authors]
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Seidenari 2005
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Seidenari 2006
Reason for exclusion EXCLUDE on study population
assessing best means of follow-in up patients with previous melanoma - total body
exam versus only lesions >2cm. No melanoma identified
 
Seidenari 2006a
Reason for exclusion EXCLUDE if individual lesion characteristics
looks like this study is only looking at asymmetry judgement
 
Seidenari 2007
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Seidenari 2012
Reason for exclusion EXCLUDE if individual lesion characteristics
looks at indvdl lesion chars to distinguish Mel in situ, also gives mean ABCD and
seven point scores
EXCLUDE on 2x2 data
EXCLUDE but contact authors
Table 3 provides mean ABCD and seven point checklist scores, are you able to
provide us with a cross tabulation of results with each checklist at 'standard' thresholds
against final diagnosis? e.g. ABCD >4.75 and >5.45 for MIS and benoign groups 7-
point checklist: presence >=2 chars and >=3 chars? [no reply]
 
Seidenari 2013
Reason for exclusion EXCLUDE on index test
 
Serrao 2006
Reason for exclusion EXCLUDE on index test; include for CAD review only
 
Sgouros 2014
Reason for exclusion EXCLUDE on index test; include for CAD review only
 
Shakya 2012
Reason for exclusion EXCLUDE on target condition
SCC in situ is not included in target condition
 
Shariff 2010
Reason for exclusion EXCLUDE on reference standard
 
Shitara 2014
Reason for exclusion EXCLUDE if individual lesion characteristics
 
Shitara 2015
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Reason for exclusion EXCLUDE on study population
includes only melanoma
 
Skvara 2005
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Sondak 2015
Reason for exclusion EXCLUDE not a primary study
comment paper 
 
Soyer 1987
Reason for exclusion EXCLUDE on 2x2 data
not test accuracy
 
Soyer 1995
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Soyer 2001
Reason for exclusion EXCLUDE not a primary study
editorial
 
Soyer 2004
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Stanganelli 1998
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Stanganelli 1998a
Reason for exclusion EXCLUDE on 2x2 data
can't derive specificity; only gives 'exact diagnoses for MM and 2 benign categories
and not number benign misdiagnosed as MM
 
Stanganelli 1999
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Stanganelli 2005
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Stanganelli 2015
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Stanley 2003
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Reason for exclusion EXCLUDE if individual lesion characteristics
fuzzy histogram is based on the lesion's colour, which is an individual lesion
characteristic
 
Stathopoulos 2015
Reason for exclusion EXCLUDE on 2x2 data
only includes index test positive patients, i.e. no FN or TN results
 
Steiner 1993
Reason for exclusion EXCLUDE if individual lesion characteristics
EXCLUDE if derivation study
 
Stephens 2013
Reason for exclusion EXCLUDE on sample size
 
Stoecker 2009
Reason for exclusion EXCLUDE if derivation study
translucency
EXCLUDE on 2x2 data
data presented only as ROC curve and AUC
 
Stoecker 2011
Reason for exclusion EXCLUDE if individual lesion characteristics
EXCLUDE if derivation study
Uses leave one out
EXCLUDE on 2x2 data
data presented only as ROC curve and AUC
 
Stolz 1994
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Stolz 2002
Reason for exclusion EXCLUDE not a primary study
 
Stratigos 2007
Reason for exclusion EXCLUDE on reference standard
EXCLUDE on 2x2 data
 
Stricklin 2011
Reason for exclusion EXCLUDE if individual lesion characteristics
 
Strumia 2003
Reason for exclusion EXCLUDE conference abstract; letter only
 
Tan 2009
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Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Tandjung 2015
Reason for exclusion EXCLUDE on target condition
'Malignant' includes: AK, Bowen's, dysplastic nevus, lentigo maligna, SCC, BCC, MM,
keratoacanthoma
EXCLUDE on index test
GPs sent images for telederm opinion; then free to send for biopsy or not; results
shown are only for those that wer biopsied, according to TD advice
 
Tasli 2012
Reason for exclusion EXCLUDE not a primary study
systematic review looking at frequency of publications ion dermoscopy
 
Teban 2003
Reason for exclusion EXCLUDE on study population
classification of Clark nevi into 12 types
EXCLUDE on 2x2 data
No 2x2 data; classification of Clark nevi into 12 types
 
Tenenhaus 2010
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Terrill 2009
Reason for exclusion EXCLUDE on index test
Whole body skin examination after patients referred on for further assessment by a
specialist
EXCLUDE on 2x2 data
 
Terstappen 2007
Reason for exclusion EXCLUDE on study population
Includes only BCC - looking for BCC chars on Siascope
EXCLUDE if derivation study
Derivation study; first application of Siascope to pigmented BCC; 21/25 lesions were
BCCs
 
Terushkin 2010
Reason for exclusion EXCLUDE on sample size
Only 2 invasive SCC
EXCLUDE on 2x2 data
 
Terushkin 2010a
Reason for exclusion EXCLUDE on 2x2 data
Not test accuracy - reports final diagnoses of those excised over a number of time
periods and benign-malignant ratio
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Thomas 1998
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Thomson 2005
Reason for exclusion EXCLUDE not a primary study
letter
 
Torrey 1941
Reason for exclusion EXCLUDE on target condition
includes non-cutaneous lesions
 
Tromme 2012
Reason for exclusion EXCLUDE on reference standard
Inadequate ref test for disease negatives; expert dx only
 
Troyanova 2003
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Tschandl 2012
Reason for exclusion EXCLUDE on index test
Differentiating melanocytic from non-melanocytic lesions
 
Tschandl 2015
Reason for exclusion EXCLUDE on test observer
medical students
 
Unlu 2014
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
van der Leest 2011
Reason for exclusion EXCLUDE on reference standard
Inadequate ref test for test negatives; expert dx only
 
van der Rhee 2010
Reason for exclusion EXCLUDE on reference standard
<50% of disease negative have an adequate reference standard
 
van der Rhee 2011
Reason for exclusion EXCLUDE on sample size
<5 cases
 
Vasili 2010
Reason for exclusion EXCLUDE conference abstract
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Verduzco-Martinez 2013
Reason for exclusion EXCLUDE on study population
Only BCC
 
Vestergaard 2008
Reason for exclusion EXCLUDE not a primary study
systematic review; check reference list
 
Viglizzo 2004
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Wagner 1985
Reason for exclusion EXCLUDE on 2x2 data
 
Walter 2010
Reason for exclusion EXCLUDE not a primary study
clinical trial protocol
 
Walter 2012
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Walter 2013
Reason for exclusion EXCLUDE on reference standard
Final diagnosis reached by histology or expert opinion; no FU of non-excised lesions
reported in this paper. The Walter 2012 trial report does report follow-up for enough
benign lesions for control arm (weighted 7PCL) data to be included. Authors contacted
and confirmed calculations (02/03/16).
 
Wang 2008
Reason for exclusion EXCLUDE on 2x2 data
Not test accuracy; no details of misdiagnoses of benign lesions as malignant 
 
Warshaw 2009
Reason for exclusion EXCLUDE on 2x2 data
EXCLUDE duplicate or related publication
Subgroup of participants from Warshaw 2010
EXCLUDE but contact authors
Study presents diagnostic accuracy of teledermatology and clinic diagnosis in
comparison to histopathology; we need the underlying 2x2 contingency tables [see 
Warshaw 2010 for author response]
 
Warshaw 2009a
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Reason for exclusion EXCLUDE on 2x2 data
EXCLUDE duplicate or related publication
Subgroup of participants from Warshaw 2010
EXCLUDE but contact authors
Study presents diagnostic accuracy of teledermatology and clinic diagnosis in
comparison to histopathology; we need the underlying 2x2 contingency tables [see 
Warshaw 2010 for author response]
 
Warshaw 2010
Reason for exclusion EXCLUDE on 2x2 data
EXCLUDE but contact authors
Study presents diagnostic accuracy of teledermatology and clinic diagnosis in
comparison to histopathology [author only able to provide numbers test positive and
negative for melanoma and not for the final 2 cells of the 2x2; data provided showed
higher sensitivity for melanoma as the primary diagnosis rather than as the ‘aggregate’
diagnosis and the 2x2 using the authors data and the accuracy figures from the paper
showed more T+ from the primary diagnosis as opposed to the aggregate
 
Warshaw 2010a
Reason for exclusion EXCLUDE on 2x2 data
As per Warshaw 2009 ; this 2010npaper presents combined data for pigmented and
nonpigmented lesions
 
Weismann 2002
Reason for exclusion EXCLUDE not a primary study
 
Wells 2012
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Westbrook 2006
Reason for exclusion EXCLUDE on 2x2 data
 
Westerhoff 2000
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Whitaker-Worth 1998
Reason for exclusion EXCLUDE on study population
EXCLUDE on test observer
mixed medical student/clinicians
EXCLUDE on 2x2 data
not test accuracy study
 
Whited 1998
Reason for exclusion EXCLUDE on sample size
 
Wilkes 2010
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Reason for exclusion EXCLUDE not a primary study
 
Williams 1991
Reason for exclusion EXCLUDE on 2x2 data
 
Winkelmann 2015
Reason for exclusion EXCLUDE duplicate or related publication
 
Winkelmann 2015a
Reason for exclusion EXCLUDE duplicate or related publication
 
Winkelmann 2016
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Wolf 1998
Reason for exclusion EXCLUDE on index test
clinical diagnosis study; Test clearly described - "concerning the clinical diagnosis, we
were not able to ascertain from the clinical data sheet whether the referring physicians
used additional diagnostics techniques such as dermoscopy"
 
Yadav 1993
Reason for exclusion EXCLUDE on 2x2 data
Not test accuracy
 
Yamaura 2005
Reason for exclusion EXCLUDE if derivation study
gene amplification in acral lesions
 
Yelamos 2016
Reason for exclusion EXCLUDE not a primary study
commentary on Guitera 2016
 
Yoo 2015
Reason for exclusion EXCLUDE conference abstract
 
Youl 2007
Reason for exclusion EXCLUDE on index test; evaluates 'clinical diagnosis'
EXCLUDE but contact authors; author replied - dermoscopy used in some but not all
lesions
 
Youl 2007a
Reason for exclusion EXCLUDE on index test; evaluates 'clinical diagnosis'
EXCLUDE but contact authors; author replied - dermoscopy used in some but not all
lesions
 
Zaballos 2013
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Reason for exclusion EXCLUDE on study population
They do not have enough benign cases to include as full report. 
 
Zalaudek 2010
Reason for exclusion EXCLUDE not a primary study
Editorial
 
Zaumseil 1983
Reason for exclusion EXCLUDE on target condition; does not present data for detection of BCC or cSCC
 
Zell 2008
Reason for exclusion EXCLUDE on sample size
case study
 
Zortea 2014
Reason for exclusion EXCLUDE if derivation study
Although data are divided into training and test sets, the test set data is used more
than once over 20 realisations of each model, especially the melanomas, for which the
same 10 are used in each realisation
 
Zou 2001
Reason for exclusion EXCLUDE not a primary study
Study uses results from Stolz 1994
EXCLUDE on 2x2 data
Just showing ROC curves
 
Footnotes
Characteristics of studies awaiting classification 
Footnotes
Characteristics of ongoing studies 
Footnotes
Summary of results tables
1 Summary of findings table
Question: What is the diagnostic accuracy of dermoscopy, in comparison to visual inspection, for the detection ofkeratinocyte skin cancer in adults?
Population: 
Adults with skin lesions: suspicious for keratinocyte skin cancers, basal cell carcinoma (BCC) or
cutaneous squamous cell carcinoma (cSCC) (e.g. non-pigmented lesions); suspicious for any skin cancer,
including melanoma (e.g. those with pigmented lesions only or mixed populations of pigmented and non-
pigmented lesions); or those at high risk of developing keratinocyte skin cancer.
Index test: 
Dermoscopy with or without the use of any established algorithms or checklist to aid diagnosis, including:
in-person evaluations (face-to-face diagnosis), and image-based evaluations (diagnosis based on
assessment of a dermoscopic image).
Comparator test Visual inspection including: in-person evaluations, and image-based evaluations (diagnosis based onassessment of a clinical image).
Primary Target
condition: BCC or cSCC
Reference
standard: Histology with or without long term follow-up
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Question: What is the diagnostic accuracy of dermoscopy, in comparison to visual inspection, for the detection ofkeratinocyte skin cancer in adults?
Action: If accurate, negative results will stop patients having unnecessary excision or biopsy of skin lesions;positive results could inform the use of nonsurgical management options
  Number of studies Total lesions Total malignancies
Quantity of
evidence 24
Visual Inspection: 8805
Dermoscopy: 6855
Visual Inspection: 2579
Dermoscopy: 1444
Limitations 
Risk of bias: (in-
person (14);
image-based
(12))
Potential risk of bias for patient selection from use of case-control type design (3 image-based),
inappropriate exclusion criteria (3; 2) or lack of detail (8; 4). All visual inspection and dermoscopy
interpretation considered blinded to reference standard diagnosis. Visual Inspection risk of bias not clear
due to thresholds not clearly pre-specified (8; 4). Threshold pre-specification better reported for
dermoscopy (6; 6). Low risk for reference standard (13; 11); high risk from use of expert diagnosis or
>20% of benign lesions with no histology (1; 1). High risk for participant flow due to differential verification
(1; 1), and exclusions following recruitment (5; 6); timing of tests was not mentioned in (7; 7).
Applicability of
evidence to
question: (in-
person (14);
image-based
(12))
High concern for participants (14; 12) due to restriction to those with histopathology results (13;11) and
including multiple lesions per participant (9; 2). High concern for Visual Inspection (7; 4) from lack of
description of diagnostic thresholds. High concern for dermoscopy (3; 9) from no description of diagnostic
thresholds (2; 4) or reporting of average or consensus diagnoses (2; 7). Dermoscopic image interpretation
blinded to clinical images (10 image-based). Unclear applicability of reference standard due to insufficient
information concerning the expertise of the histopathologist (13; 11).
FINDINGS: 
Twenty-four studies were included. Fourteen studies reported data for in-person visual inspection (n = 11) or in-person
dermoscopy (n = 8); twelve studies reported data for image-based visual inspection (n = 4) or image-based dermoscopy (n
= 10). Two studies report both in-person and image-based data. The findings presented are based on results for the twenty-
one studies reporting data for BCC alone or for cSCC alone. Due to the observed heterogeneity between studies, the
results presented are points estimated from summary ROC curves rather than average sensitivity and specificity operating
points. These are presented for illustrative purposes and should not be quoted as the actual performance of visual
inspection or dermoscopy. Analyses of studies by degree of prior testing were not undertaken due to a lack of relevant
information provided in the study publications, the majority of studies apparently conducted in referred populations, and
small study subgroups. There was not enough evidence to assess the use of algorithms or structured checklists for
dermoscopy (or visual inspection).
Test (for BCC): In-person visual inspection alone versus visual inspection plus dermoscopy for the detection of BCC – anyalgorithm or threshold 
Data analysed 
Visual inspection 8 datasets - 7017 lesions; 1586 cases
Dermoscopy 7 datasets - 4683 lesions; 363 cases
Resultsa Sensitivity Fixed specificity Fixed sensitivity Specificity 
Visual inspection 79%
80% 80%
77%
Dermoscopy 93% 99%
Numbers applied to a hypothetical cohort of 1000 lesionsb
  TP FN FP TN TP FN FP TN
At a prevalence
of 10%
VI: 79
D: 93 ↑ 14
VI: 21
D: 7 ↓ 14
180 720 80 20
VI: 207
D: 9 ↓198
VI: 693
D: 891 ↑198
At a prevalence
of 17%
VI: 134
D: 158 ↑24
VI: 36
D: 12 ↓
24
166 664 136 34
VI: 191
D: 8 ↓183
VI: 639
D: 822 ↑183
At a prevalence
of 53%
VI: 419
D: 493 ↑
74
VI: 111
D: 37 ↓
74
94 376 424 106
VI: 108
D: 5 ↓103
VI: 362
D: 465 ↑103
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Question: What is the diagnostic accuracy of dermoscopy, in comparison to visual inspection, for the detection ofkeratinocyte skin cancer in adults?
Consistency:
Wide range in prevalence of BCC; includes pigmented and non-pigmented lesion populations and
participants suspected of BCC or suspected of any malignancy, including melanoma. Sensitivities highly
heterogeneous, particularly for visual inspection evaluations. Specificity for BCC lower in studies of non-
pigmented lesions.
Test (for BCC): Image-based visual inspection alone versus visual inspection plus dermoscopy for the detection of BCC –any algorithm or threshold 
Data analysed
Visual inspection 4 datasets - 853 lesions; 156 cases
Dermoscopy 9 datasets - 2271 lesions; 737 cases
Results* Sensitivity Fixed specificity Fixed sensitivity Specificity
Visual inspection 85%
80% 80%
87%
Dermoscopy 93% 96%
Numbers applied to a hypothetical cohort of 1000 lesionsc
  TP FN FP TN TP FN FP TN
At a prevalence
of 11%
VI: 94
D: 102 ↑ 8
VI: 16
D: 8 ↓ 8
178 712 88 22
VI: 116
D: 36 ↓80
VI: 774
D: 854 ↑80
At a prevalence
of 16%
VI: 136
D: 149 ↑13
VI: 24
D: 11 ↓
13
168 672 128 32
VI: 109
D: 34 ↓75
VI: 731
D: 806 ↑75
At a prevalence
of 47%
VI: 400
D: 437 ↑
37
VI: 70
D: 33 ↓
37
106 424 376 94
VI: 69
D: 21 ↓48
VI: 461
D: 509 ↑48
Consistency: Wide range in prevalence of BCC; includes mixed populations, as for in-person evaluations. Sensitivitieshighly heterogeneous for visual inspection evaluations.
Test (for cSCC): Visual inspection or dermoscopy for the detection of cSCC 
  Datasets Lesions Cases Sensitivity (95%CIs) Specificity (95%CI)
Visual
inspection (in-
person)
2 2684 538 57% (53%, 61%) 79% (77%, 81%)
Dermoscopy
(image-based) 2 717 119 55% (29%, 79%) 84% (32%, 98%)
Footnotes
aNumbers for a hypothetical cohort of 1000 lesions are presented for two illustrative examples of points on the SROC curves:
firstly for the sensitivities of tests at fixed specificities of 80%; and secondly for the specificities of tests at fixed sensitivities of
80%.
bNumbers estimated at 25th, 50th (median) and 75% percentiles of BCC prevalence observed across 11 studies reporting in-
person evaluations of visual inspection (reported in 8 studies) or visual inspection plus dermoscopy (reported in 7 studies).
cNumbers estimated at 25th, 50th (median) and 75% percentiles of BCC prevalence observed across 11 studies reporting
image-based diagnosis using clinical photographs (reported in 4 studies) or dermoscopic images (reported in 9 studies)
Additional tables 
1 Comparison of visual inspection and dermoscopy for detection of BCC
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Test DatasetsLesions
(BCCs)
DOR
(95% CI)
Specificity at 80%
sensitivity
Sensitivity at 80%
specificity
Relative
DOR
(95% CI)
P value
(LR)a
P value
(Wald)b
In-person evaluations
Visual inspection 8 7017
(1586)
19.9
(7.8,
51.2)
77% 79% 8.2
(3.5, 19.3)
< 0.001 < 0.0001
Visual inspection
+Dermoscopy
7 4683
(363)
164
(56.8,
475)
99% 93%
In-person evaluations (direct studies)
Visual inspection 4 3974
(257)
12.8
(3.3,
48.8)
36% 71% 7.5
(2.7, 21.3)
< 0.001 0.0001
Visual inspection
+Dermoscopy
4 3974
(258)
96.2
(21.1,
439)
97% 87%
Image-based evaluations
Visual inspection
(clinical images)
4 853
(156)
26.8
(11.9,
60.4)
87% 85% 3.9
(1.2, 5.0)
0.006 0.025
Dermoscopic images 9 2271
(737)
75.7
(21.3,
269)
96% 93%
Image-based evaluations (direct studies)
Visual inspection
(clinical images)
2 516
(82)
81.1
(39.1,
168)
95%c 95%c Not
estimable
Not
estimable
Not
estimable
Dermoscopic images 2 516
(79)
275.5
(112,
678)
99%c 99%c
Footnotes
BCC - basal cell carcinoma; DOR - diagnostic odds ratio; RDOR - relative diagnostic odds ratio; CI - confidence interval; LR -
likelihood ratio
atests whether there is a difference in test performance between defined groups in terms of either DOR or threshold
btests the significance of the difference in DOR between defined groups at a particular SROC curve intercept value
ccomputed assuming symmetric SROC curve
2 Investigations of sources of heterogeneity for studies of visual inspection for detection of BCC
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Test DatasetsLesions
(BCCs)
DOR
(95% CI)
Specificity at 80%
sensitivity
Sensitivity at 80%
specificity
Relative
DOR
(95% CI)
P
value
(LR)a
P value
(Wald)b
Difference in-person and image based
In-
person
8 7017
(1586)
11.9
(4.4,
32.2)
64% 74% 0.45
(0.26, 9.2)
0.88 0.62
Image 4 853
(156)
18.5
(4.3,
80.6)
78% 79%
Prevalence 
0-25% 6 4643
(168)
50.5
(17.1,
149)
94% 91% 9.7
(2.3, 40.8)
0.002 0.002
>25% 6 3227
(1574)
5.2
(2.3,
11.7)
50% 60%
Footnotes
BCC - basal cell carcinoma; DOR - diagnostic odds ratio; RDOR - relative diagnostic odds ratio; CI - confidence interval; LR -
likelihood ratio
atests whether there is a difference in test performance between defined groups in terms of either DOR or threshold
btests the significance of the difference in DOR between defined groups at a particular SROC curve intercept value
3 Investigations of sources of heterogeneity for studies of dermoscopy for detection of BCC
Test DatasetsLesions
(cases)
DOR
(95% CI)
Specificity at 80%
sensitivity
Sensitivity at 80%
specificity
Relative
DOR
(95% CI)
P
value
(LR)a
P value
(Wald)b
Difference in person and image based
In person 7 4683
(363)
388
(68.6,
2194)
100% 96% 4.0
(0.46, 33.8)
0.39 0.21
Image 9 2271
(737)
98.2
(21.6,
446)
98% 91%
Use of an algorithm
No
algorithm
9 5427
(338)
371
(86.9,
1587)
100% 98% 7.8
(0.90, 68.2)
0.004 0.06
Any
algorithm
7 1527
(762)
47.4
(10.2,
219)
94% 90%
Prevalence (in-person studies)
0-25% 9 5524 (349) 309
(69.2,
1380)
100% 97% 4.5
(0.49, 41.8)
0.04 0.18
>25% 7 1430
(751)
68.4
(13.2,
356)
96% 91%
Footnotes
BCC - basal cell carcinoma; DOR - diagnostic odds ratio; RDOR - relative diagnostic odds ratio; CI - confidence interval; LR -
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likelihood ratio
atests whether there is a difference in test performance between defined groups in terms of either DOR or threshold
btests the significance of the difference in DOR between defined groups at a particular SROC curve intercept value
4 Algorithm and threshold analysis for each definition of the target condition
Target condition
Test
No
Datasets
Lesions
(Cases)
Pooled
Sensitivity
(95% CI)
Pooled Specificity
(95% CI)
No
studies
Lesions
(Cases)
Pooled
Sensitivity
(95% CI)
Pooled
Specificity 
(95% CI)
a. BCC – Visual
inspection
IN-PERSON IMAGE-BASED
No algorithm at any
threshold
7 3645
(1543)
0.68 (0.48,
0.83)
0.82 (0.55, 0.95) 4 853
(156)
0.71 (0.51,
0.86)
0.92 (0.76,
0.98)
No algorithm at BCC
possible
1 141 (82) 0.89 (0.80,
0.95)
0.37 (0.25, 0.51) 1 105 (58) 0.78 (0.65,
0.87)
0.38 (0.25,
0.54)
ABCD threshold not
reported
1 3372 (43) 0.49 (0.33,
0.65)
1.00 (1.00, 1.00) - - - -
Schwartzberg algorithm 1 141 (82) 0.89 (0.80,
0.95)
0.37 (0.25, 0.51) - - - -
b. BCC – Dermoscopy IN-PERSON IMAGE-BASED
No algorithm threshold
not reported
2 648 (79) 0.92 (0.84,
0.97)
0.97 (0.95, 0.98) 2 313
(121)
0.85 (0.78,
0.90)
0.93 (0.88,
0.96)
Pattern analysis 2 3628 (48) 0.79 (0.65,
0.88)
1.00 (1.00, 1.00) 2 582 (85) 0.89 (0.81,
0.94)
0.98 (0.96,
0.99)
3 point at >=2 1 61 (27) 1.00 (0.87,
1.00)
0.97 (0.85, 1.00) 1 150 (18) 0.89
(0.65,0.99)
0.72 (0.63,
0.79)
Two step algorithm 2 346 (209) 0.86 (0.76,
0.92)
0.55 (0.46, 0.63) - - - -
Menzies for BCC (new) - - - - 1 213 (71) 0.97 (0.90,
1.00)
0.92 (0.87,
0.96)
Menzies for BCC
(revised)
- - - - 1 300
(150)
0.95 (0.91,
0.98)
0.87 (0.81,
0.92)
New SWS at >=1 - - - - 1 457
(287)
0.54 (0.48,
0.60)
0.50 (0.42,
0.58)
Chaos/clues - - - - 1 463 (72) 0.99
(0.93,1.00)
0.55 (0.50,
0.60)
c. cSCC – Visual
inspection
IN-PERSON IMAGE-BASED
No algorithm at
threshold NR
2 2684
(538)
0.59 (0.42,
0.82) 0.79 (0.77, 0.81)
       
d. cSCC – Dermoscopy IN-PERSON IMAGE-BASED
No algorithm at
threshold NR
- - - - 1 260 (13) 0.77 (0.46,
0.95)
0.97 (0.94,
0.99)
SWS at >1 char - - - - 1 457
(106)
0.42 (0.32,
0.51)
0.49 (0.43,
0.54)
e. Any – Visual
inspection
IN-PERSON IMAGE-BASED
No algorithm at
threshold NR
4 3533
(1968)
0.91 (0.79,
0.96)
0.61 (0.25, 0.87) 2 517
(124)
0.77 (0.68,
0.83)
0.84 (0.80,
0.87)
ABCD at threshold NR 1 85 (53) 0.57 (0.42,
0.70)
0.50 (0.32, 0.68) - - - -
f. Any – Dermoscopy IN-PERSON IMAGE-BASED
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Target condition
Test
No
Datasets
Lesions
(Cases)
Pooled
Sensitivity
(95% CI)
Pooled Specificity
(95% CI)
No
studies
Lesions
(Cases)
Pooled
Sensitivity
(95% CI)
Pooled
Specificity 
(95% CI)
a. BCC – Visual
inspection
IN-PERSON IMAGE-BASED
No algorithm at
threshold NR
1 200 (46) 0.98 (0.88,
1.00)
0.98 (0.94, 1.00) 3 393
(187)
0.89 (0.84,
0.93)
0.79 (0.73,
0.84)
No algorithm at excise - - - - 1 260
(140)
0.95 (0.90,
0.98)
0.53 (0.44,
0.62)
Pattern analysis - - - - 1 463
(104)
0.79 (0.70,
0.86)
0.88 (0.85,
0.91)
3 point at >=2 1 77 (39) 0.85 (0.69,
0.94)
0.26 (0.13, 0.43) - - - -
Menzies for BCC
(revised)
- - - - 1 213
(142)
0.95 (0.90,
0.98)
0.92 (0.83,
0.97)
SWS - - - - 1 457
(414)
0.50 (0.45,
0.55)
0.63 (0.47,
0.77)
Chaos/Clues         1 463
(104)
0.92 (0.85,
0.97)
0.58 (0.53,
0.63)
Footnotes
BCC - basal cell carcinoma; CI - confidence interval; SWS - shiny white streaks; NR - not reported
5 Comparison of visual inspection and dermoscopy for the detection of cSCC
Test DatasetsLesions
(cSCC)
DOR
(95% CI)
 
Summary sensitivity
Summary 
specificity
In-person evaluations
Visual inspection 2 2684
(538)
5.0
(4.1, 6.1)
0.57
(0.53, 0.61)
0.79
(0.77, 0.81)
Visual inspection
+Dermoscopy
 
0
- - - -
Image based evaluations
Visual inspection (clinical images) 0 - - - -
Dermoscopic images 2 717
(119)
6.5
(0.45, 93.2)
0.55
(0.29, 0.79)
0.84
(0.32, 0.98)
Footnotes
cSCC - cutaneous squamous cell carcinoma; DOR - diagnostic odds ratio; CI - confidence interval
6 Comparison of visual inspection and dermoscopy for the detection of any skin cancer
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Test DatasetsLesions
(cases)
DOR
(95%
CI)
Specificity at 80%
sensitivity
Sensitivity at 80%
specificity
Relative
DOR
(95% CI)
P
value
(LR)a
P value
(Wald)
b
In-person evaluations
Visual inspection 5 3618
(2021)
28.7
(5.0,
166)
88% 84% NE NE NE
Visual inspection
+Dermoscopy
2 277
(85)
126
(9.1,
1751)
NE NE
Image based evaluations
Visual inspection (clinical
images)
2 517
(124)
16.3
(4.4,
59.9)
79% 78% 1.5
(0.76, 3.0)
0.50 0.24
Dermoscopic images 6 1526
(847)
24.5
(7.6,
79.3)
84% 86%
Footnotes
DOR - diagnostic odds ratio; RDOR - relative diagnostic odds ratio; CI - confidence interval; LR - likelihood ratio; NE – not
estimated; data not estimated due to extreme differences in results between the two studies of dermoscopy added to visual
inspection
atests whether there is a difference in test performance between defined groups in terms of either DOR or threshold
btests the significance of the difference in DOR between defined groups at a particular SROC curve intercept value
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Classification pending references
Data and analyses 
Data tables by test
Test StudiesParticipants
1 BCC-Visual Inspection (in-person) 8 7017
2 BCC-Visual Inspection (image-based) 4 853
3 BCC-VI+Dermoscopy (in-person) 7 4683
4 BCC-Dermoscopy alone (image-based) 9 2271
5 BCC-VI - no algorithm at any threshold (in-person) 7 3645
6 BCC-VI - no algorithm at BCC possible (in-person) 1 141
7 BCC-VI - ABCD at threshold NR (in-person) 1 3372
8 BCC-VI - Schwartzberg algorithm (in-person) 1 141
9 BCC-VI - no algorithm at any threshold (image-based) 4 853
10 BCC-VI - no algorithm at BCC possible (image-based) 1 105
11 BCC- VI+Dermoscopy no algorithm at NR (in-person) 2 648
12 BCC-VI+Dermoscopy pattern analysis_obs_dx (in-person) 2 3628
13 BCC- VI+Dermoscopy 3 point at >= (in-person) 1 61
14 BCC-VI+Dermoscopy Two step_obs_dx (in-person) 2 346
15 BCC-Dermoscopy - no algorithm at any threshold (image-based) 2 313
16 BCC-Dermoscopy - pattern analysis at NR (image-based) 2 582
17 BCC-Dermoscopy - Menzies for BCC(rev)_obsdx (image-based) 1 300
18 BCC-Dermoscopy - Menzies for BCC(new) - 1 char absent&>=1 other +ve (image-based)1 213
19 BCC-Dermoscopy - 3 point checklist at >= 2 (image-based) 1 150
20 BCC-Dermoscopy - new SWS at >=1 (image-based) 1 457
21 BCC-Dermoscopy - Chaos/clues (image-based) 1 463
22 cSCC-Visual inspection (in-person) 2 2684
23 cSCC-Dermoscopy alone (image-based) 2 717
24 cSCC-VI - no algorithm at NR (in-person) 2 2684
25 cSCC-Dermoscopy - no algorithm at NR (image-based) 1 260
26 cSCC-Dermoscopy - SWS at >1 char (image-based) 1 457
27 Any -Visual inspection (in-person) 5 3618
28 Any -Visual inspection (image-based) 2 517
29 Any -VI+Dermoscopy (in-person) 2 277
30 Any-Dermoscopy alone (image-based) 6 1526
31 KER-VI - no algorithm at NR (in-person) 4 3533
32 KER-VI - ABCD at NR (in-person) 1 85
33 KER-VI - no algorithm at NR (image-based) 2 517
34 KER- VI+Dermoscopy no algorithm at NR (in-person) 1 200
35 KER-VI+Dermoscopy - 3 point at >=2 (in-person) 1 77
36 KER-Dermoscopy - no algorithm at any threshold (image-based) 3 393
37 KER-Dermoscopy - no algorithm at excise (image-based) 1 260
38 KER- Dermoscopy - pattern at NR (image-based) 1 463
39 KER-Dermoscopy- SWS (image-based) 1 457
40 KER-Dermoscopy - Chaos/Clues (image-based) 1 463
41 KER-Dermoscopy - Menzies for BCC(rev)_obsdx (image-based) 1 213
42 BCC-VI - experience - high (in-person) 3 615
43 BCC-VI - experience - mixed (in-person) 2 2684
44 BCC-VI - experience - NR (in-person) 3 3718
45 BCC-VI - experience - high (image-based) 2 158
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Test StudiesParticipants
46 BCC-VI - experience - mixed (image-based) 1 232
47 BCC-VI - experience - NR (image-based) 1 463
48 BCC-VI+Dermoscopy - experience - high (in-person) 2 704
49 BCC-VI+Dermsocopy - experience - NR (in-person) 5 3979
50 BCC-Dermoscopy - experience - high (image-based) 3 428
51 BCC-Dermoscopy - experience - mixed (image-based) 1 150
52 BCC-Dermoscopy - experience - trained (image-based) 1 457
53 BCC-Dermoscopy - experience - NR (image-based) 4 1236
54 BCC-VI - qualification - Consultant expert (in-person) 4 668
55 BCC-VI - qualification - Consultant (in-person) 3 3719
56 BCC-VI - qualification - Mixed (Secondary care) (in-person) 2 2684
57 BCC-VI - qualification - Consultant expert (image-based) 1 463
58 BCC-VI - qualification - Consultant (image-based) 1 105
59 BCC-VI+Dermoscopy - qualification - Consultant expert (in-person) 3 1167
60 BCC-VI+Dermoscopy - qualification - Consultant (in-person) 4 3748
61 BCC-Dermoscopy - qualification - Consultant expert (image-based) 4 728
62 BCC-Dermoscopy - qualification - Consultant (image-based) 2 473
63 BCC-Dermoscopy - qualification - Resident (image-based) 1 457
64 BCC-Dermoscopy - qualification - Mixed (dermoscopy trained) (image-based) 1 150
65 cSCC-VI - experience - mixed (in-person) 1 2582
66 cSCC-VI - experience - NR (in-person) 1 102
67 cSCC-Dermoscopy - experience - trained (image-based) 1 457
68 cSCC-Dermoscopy - experience - NR (image-based) 1 260
73 KER-VI - experience - high (in-person) 1 769
74 KER-VI - experience - mixed (in-person) 1 2582
75 KER-VI - experience - NR (in-person) 3 267
76 KER-VI - experience - high (image-based) 1 54
77 KER-VI - experience - NR (image-based) 1 463
78 KER-VI+Dermoscopy - experience - trained (in-person) 1 77
80 KER-VI+Dermoscopy - experience - NR (in-person) 1 200
81 KER-Dermoscopy - experience - high (image-based) 1 53
82 KER-Dermoscopy - experience - trained (image-based) 1 457
83 KER-Dermoscopy - experience - NR (image-based) 4 1016
Figures
Figure 1
Caption
Sample photograph of superficial spreading melanoma(left), BCC (centre) and SCC (right)
Figure 2
#165 Visual examination and dermoscopy, alone or in combination, for the diagnosis of keratinocyte skin cancers in ad...
174 / 231
Caption
Dermatoscope
Figure 3
Caption
Sample dermoscopic images of melanoma (left), BCC (centre) and SCC (right)
Figure 4
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Caption
Current clinical pathway for people with skin lesions
Figure 5
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Caption
PRISMA flow diagram.
Figure 6
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Caption
Risk of bias and applicability concerns graph for in-person studies: review authors' judgements about each domain presented
as percentages across included studies
Figure 7
Caption
Risk of bias and applicability concerns summary for in-person evaluations: review authors' judgements about each domain
for each included study
Figure 8
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Caption
Risk of bias and applicability concerns graph for image-based evaluations: review authors' judgements about each domain
presented as percentages across included studies
Figure 9
Caption
Risk of bias and applicability concerns summary for image-based evaluations: review authors' judgements about each
domain for each included study
Figure 10 (Analysis 1) 
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Caption
In-person evaluations of the accuracy of visual inspection and visual inspection plus dermoscopy (VI+Dermoscopy)
according to BCC prevalence and use of a formal algorithm
Figure 11 (Analysis 3) 
Caption
Image-based evaluations of the accuracy of visual inspection and dermoscopy alone according to BCC prevalence and use
of a formal algorithm
Figure 12 (Analysis 1) 
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Caption
Comparison of the accuracy of visual inspection with visual inspection plus dermoscopy (VI+Dermoscopy) for detection of
BCC from in-person studies
Figure 13 (Analysis 2) 
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Caption
Paired comparisons of the accuracy of visual inspection with visual inspection plus dermoscopy for detection of BCC from in-
person studies
Figure 14 (Analysis 3) 
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Caption
Comparison of the accuracy of image-based visual inspection with image-based dermoscopy for detection of BCC
Figure 15 (Analysis 4) 
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Caption
Paired comparisons of the accuracy of visual inspection with visual inspection plus dermoscopy for detection of BCC from
image-based studies
Figure 16 (Analysis 5) 
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Caption
Comparison of the accuracy of visual inspection for detection of BCC between in-person and image-based
Figure 17 (Analysis 6) 
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Caption
Comparison of the accuracy of dermoscopy for detection of BCC between in-person (VI+Dermoscopy) and image-based
(Dermoscopy alone)
Figure 18 (Analysis 13) 
Caption
Evaluations of the accuracy of visual inspection or dermoscopy for detecting invasive melanoma cSCC
Figure 19 (Analysis 16) 
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Caption
Forest plot of tests: 27 Any -Visual inspection (in-person), 29 Any -VI+Dermoscopy (in-person).
Figure 20 (Analysis 17) 
Caption
Forest plot of tests: 28 Any -Visual inspection (image-based), 30 Any-Dermoscopy alone (image-based).
Figure 21 (Analysis 16) 
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Caption
Comparison of the accuracy of visual inspection with visual inspection plus dermoscopy (VI+Dermoscopy) for detection of
any skin cancer (Any). SROC curve estimated only for in-person visual inspection.
Figure 22 (Analysis 17) 
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Caption
Comparison of the accuracy of image-based visual inspection with image-based dermoscopy (Dermoscopy alone) for
detection of any skin cancer (Any)
Figure 23 (Analysis 24) 
Caption
Forest plot of tests: 1 BCC-Visual Inspection (in-person), 2 BCC-Visual Inspection (image-based).
Figure 24 (Analysis 25) 
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Caption
Forest plot of tests: 3 BCC-VI+Dermoscopy (in-person), 4 BCC-Dermoscopy alone (image-based).
Sources of support 
Internal sources
No sources of support provided
External sources
The National Institute for Health Research (NIHR), UK
The NIHR, UK, is the largest single funder of the Cochrane Skin Group
NIHR Systematic Review Programme, UK
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List of reviews  
Estimated number of
studies Diagnosis of melanoma 
1. Visual inspection versus visual inspection plus dermoscopy 120
2. Teledermatology 12
3. Mobile phone applications 2
4. Computer-aided diagnosis: dermoscopy based and spectroscopy based techniques 37
5. Reflectance confocal microscopy 19
6. High frequency ultrasound 3
7. Overview: comparing the accuracy of tests for which sufficient evidence was identified either
alone or in combination –
Diagnosis of keratinocyte skin cancer (basal cell carcinoma and cutaneous squamous cell
carcinoma)
 
8. Visual inspection ± dermoscopy 22
9. Computer aided diagnosis: dermoscopy based and spectroscopy based techniques 3
10. Optical coherence tomography 6
11. Reflectance confocal microscopy 9
12. High frequency ultrasound 1
13. Exfoliative cytology 5
14. Overview: comparing the accuracy of tests for which sufficient evidence was identified either
alone or in combination –
Staging of melanoma  
15. Ultrasound 25 to 30
16. Computer tomography 5 to 10
17. Positron emission tomography or positron emission tomography-computer tomography 20 to 25
18. Magnetic resonance imaging 5
19. Sentinel lymph node biopsy ± high frequency ultrasound 70
20. Overview: comparing the accuracy of tests for which sufficient evidence was identified either
alone or in combination –
Staging of cutaneous squamous cell carcinoma  
21. Imaging tests review 10 to 15
22. Sentinel lymph node biopsy ± high frequency ultrasound 15 to 20
2 Glossary of terms
Term Definition
Atypical intraepidermal
melanocytic variant
Unusual area of darker pigmentation contained within the epidermis that may progress to an
invasive melanoma; includes melanoma in situ and lentigo maligna
Atypical naevi Unusual looking but noncancerous mole or area of darker pigmentation of the skin
BRAF V600 mutation BRAF is a human gene that makes a protein called B-Raf which is involved in the control of
cell growth. BRAF mutations (damaged DNA) occur in around 40% of melanomas, which
can then be treated with particular drugs.
BRAF inhibitors Therapeutic agents which inhibit the serine-threonine protein kinase BRAF mutated
metastatic melanoma.
Breslow thickness A scale for measuring the thickness of melanomas by the pathologist using a microscope,
measured in mm from the top layer of skin to the bottom of the tumour.
Congenital naevi A type of mole found on infants at birth
#165 Visual examination and dermoscopy, alone or in combination, for the diagnosis of keratinocyte skin cancers in ad...
191 / 231
Term Definition
 
Dermoscopy
Whereby a handheld microscope is used to allow more detailed, magnified, examination of
the skin compared to examination by the naked eye alone
False negative An individual who is truly positive for a disease, but whom a diagnostic test classifies them
as disease-free.
False positive An individual who is truly disease-free, but whom a diagnostic test classifies them as having
the disease.
Histopathology/Histology The study of tissue, usually obtained by biopsy or excision, for example under a microscope.
Incidence The number of new cases of a disease in a given time period.
Index test A diagnostic test under evaluation in a primary study
Lentigo maligna Unusual area of darker pigmentation contained within the epidermis which includes
malignant cells but with no invasive growth. May progress to an invasive melanoma
Lymph node Lymph nodes filter the lymphatic fluid (clear fluid containing white blood cells) that travels
around the body to help fight disease; they are located throughout the body often in clusters
(nodal basins).
Melanocytic naevus An area of skin with darker pigmentation (or melanocytes) also referred to as ‘moles’
Meta-analysis A form of statistical analysis used to synthesise results from a collection of individual studies.
Metastases/metastatic disease Spread of cancer away from the primary site to somewhere else through the bloodstream or
the lymphatic system.
Micrometastases Micrometastases are metastases so small that they can only be seen under a microscope.
Mitotic rate Microscopic evaluation of number of cells actively dividing in a tumour.
Morbidity Detrimental effects on health.
Mortality Either (1) the condition of being subject to death; or (2) the death rate, which reflects the
number of deaths per unit of population in relation to any specific region, age group,
disease, treatment or other classification, usually expressed as deaths per 100, 1000,
10,000 or 100,000 people.
Multidisciplinary team A team with members from different healthcare professions and specialties (e.g. urology,
oncology, pathology, radiology, and nursing). Cancer care in the National Health Service
(NHS) uses this system to ensure that all relevant health professionals are engaged to
discuss the best possible care for that patient.
Prevalence The proportion of a population found to have a condition.
Prognostic factors/indicators Specific characteristics of a cancer or the person who has it which might affect the patient’s
prognosis.
Receiver operating
characteristic (ROC) plot
A plot of the sensitivity and 1 minus the specificity of a test at the different possible
thresholds for test positivity; represents the diagnostic capability of a test with a range of
binary test results
Receiver operating
characteristic (ROC) analysis
The analysis of a ROC plot of a test to select an optimal threshold for test positivity
Recurrence Recurrence is when new cancer cells are detected following treatment. This can occur either
at the site of the original tumour or at other sites in the body.
Reference Standard A test or combination of tests used to establish the final or ‘true’ diagnosis of a patient in an
evaluation of a diagnostic test
Reflectance confocal
microscopy (RCM)
A microscopic technique using infrared light (either in a handheld device or a static unit) that
can create images of the deeper layers of the skin
Sensitivity In this context the term is used to mean the proportion of individuals with a disease who
have that disease correctly identified by the study test
Specificity The proportion of individuals without the disease of interest (in this case with benign skin
lesions) who have that absence of disease correctly identified by the study test
Staging Clinical description of the size and spread of a patient’s tumour, fitting into internationally
agreed categories.
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Term Definition
Subclinical (disease) Disease that is usually asymptomatic and not easily observable, e.g. by clinical or physical
examination.
Systemic treatment Treatment, usually given by mouth or by injection, that reaches and affects cancer cells
throughout the body rather than targeting one specific area.
3 Proposed sources of heterogeneity
i. Population characteristics
general versus higher risk populations
patient population: Primary /secondary / specialist unit
lesion suspicion: general suspicion/atypical/equivocal/NR
lesion type: any pigmented; melanocytic
inclusion of multiple lesions per participant
ethnicity
ii. Index test characteristics
the nature of and definition of criteria for test positivity
observer experience with the index test
approaches to lesion preparation (e.g., the use of oil or antiseptic gel for dermoscopy)
iii. Reference standard characteristics
reference standard used
whether histology-reporting meets pathology-reporting guidelines
use of excisional versus diagnostic biopsy
whether two independent dermatopathologists reviewed histological diagnosis
iv. Study quality
consecutive or random sample of participants recruited
index test interpreted blinded to the reference standard result
index test interpreted blinded to the result of any other index test
presence of partial or differential verification bias (whereby only a sample of those subject to the index test are verified by
the reference test or by the same reference test with selection dependent on the index test result)
use of an adequate reference standard
overall risk of bias
4 Final search strategies
Melanoma search strategies to August 2016
Database: Ovid MEDLINE(R) 1946 to August week 3 2016
Search strategy:
1 exp melanoma/
2 exp skin cancer/
3 exp basal cell carcinoma/
4 basalioma$1.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or
adenoma$1 or epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or
keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1
or epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or CSCC or NMSC).ti,ab.
11 keratinocy$.ti,ab.
12 Keratinocytes/
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
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16 photomicrograph$.ti,ab.
17 exp epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 exp diagnosis, computer-assisted/
38 MoleMax.ti,ab.
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 Aura.ti,ab.
44 (optical adj2 scan$).ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 (high adj3 ultraso$).ti,ab.
51 (canine adj2 detect$).ti,ab.
52 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
53 smartphone$.ti,ab.
54 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
55 Mole Detective.ti,ab.
56 Spot Check.ti,ab.
57 (mole$1 adj2 map$).ti,ab.
58 (total adj2 body).ti,ab.
59 exfoliative cytolog$.ti,ab.
60 digital analys$.ti,ab.
61 (image$1 adj3 software).ti,ab.
62 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or
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teledermatoscop$ or tele-dermatoscop$).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (computer adj2 diagnos$).ti,ab.
65 exp sentinel lymph node biopsy/
66 (sentinel adj2 node).ti,ab.
67 nevisense.mp. or HFUS.ti,ab.
68 electrical impedance spectroscopy.ti,ab.
69 history taking.ti,ab.
70 patient history.ti,ab.
71 (naked eye adj (exam$ or assess$)).ti,ab.
72 (skin adj exam$).ti,ab.
73 physical examination/
74 ugly duckling.mp. or UD.ti,ab.
75 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
76 ABCDE.mp. or VOC.ti,ab.
77 clinical accuracy.ti,ab.
78 Family Practice/ or Physicians, Family/ or clinical competence/
79 (confocal adj2 microscop$).ti,ab.
80 diagnostic algorithm$1.ti,ab.
81 checklist$.ti,ab.
82 virtual imag$1.ti,ab.
83 volatile organic compound$1.ti,ab.
84 dog$1.ti,ab.
85 gene expression analy$.ti,ab.
86 reflex transmission imag$.ti,ab.
87 thermal imaging.ti,ab.
88 elastography.ti,ab.
89 or/14-88
90 (CT or PET).ti,ab.
91 PET-CT.ti,ab.
92 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
93 exp Deoxyglucose/
94 deoxy-glucose.ti,ab.
95 deoxyglucose.ti,ab.
96 CATSCAN.ti,ab.
97 exp Tomography, Emission-Computed/
98 exp Tomography, X-ray computed/
99 positron emission tomograph$.ti,ab.
100 exp magnetic resonance imaging/
101 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
102 exp echography/
103 Doppler echography.ti,ab.
104 sonograph$.ti,ab.
105 ultraso$.ti,ab.
106 doppler.ti,ab.
107 magnetic resonance imag$.ti,ab.
108 or/90-107
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109 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
110 "Sensitivity and Specificity"/
111 exp cancer staging/
112 or/109-111
113 108 and 112
114 89 or 113
115 13 and 114
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations 29 August 2016
Search strategy:
1 basalioma$1.ti,ab.
2 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or
adenoma$1 or epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
3 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
4 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or
keratinocyt$).ti,ab.
5 nmsc.ti,ab.
6 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1
or epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
7 (BCC or CSCC or NMSC).ti,ab.
8 keratinocy$.ti,ab.
9 or/1-8
10 dermoscop$.ti,ab.
11 dermatoscop$.ti,ab.
12 photomicrograph$.ti,ab.
13 (epiluminescence adj2 microscop$).ti,ab.
14 (confocal adj2 microscop$).ti,ab.
15 (incident light adj2 microscop$).ti,ab.
16 (surface adj2 microscop$).ti,ab.
17 (visual adj (inspect$ or examin$)).ti,ab.
18 ((clinical or physical) adj examin$).ti,ab.
19 3 point.ti,ab.
20 three point.ti,ab.
21 pattern analys$.ti,ab.
22 ABCD$.ti,ab.
23 menzies.ti,ab.
24 7 point.ti,ab.
25 seven point.ti,ab.
26 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
27 artificial intelligence.ti,ab.
28 AI.ti,ab.
29 computer assisted.ti,ab.
30 computer aided.ti,ab.
31 neural network$.ti,ab.
32 MoleMax.ti,ab.
33 image process$.ti,ab.
34 automatic classif$.ti,ab.
35 image analysis.ti,ab.
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36 SIAscop$.ti,ab.
37 Aura.ti,ab.
38 (optical adj2 scan$).ti,ab.
39 MelaFind.ti,ab.
40 SIMSYS.ti,ab.
41 MoleMate.ti,ab.
42 SolarScan.ti,ab.
43 VivaScope.ti,ab.
44 (high adj3 ultraso$).ti,ab.
45 (canine adj2 detect$).ti,ab.
46 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
47 smartphone$.ti,ab.
48 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
49 Mole Detective.ti,ab.
50 Spot Check.ti,ab.
51 (mole$1 adj2 map$).ti,ab.
52 (total adj2 body).ti,ab.
53 exfoliative cytolog$.ti,ab.
54 digital analys$.ti,ab.
55 (image$1 adj3 software).ti,ab.
56 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or
teledermatoscop$ or tele-dermatoscop$).ti,ab.
57 (optical coherence adj (technolog$ or tomog$)).ti,ab.
58 (computer adj2 diagnos$).ti,ab.
59 (sentinel adj2 node).ti,ab.
60 nevisense.mp. or HFUS.ti,ab.
61 electrical impedance spectroscopy.ti,ab.
62 history taking.ti,ab.
63 patient history.ti,ab.
64 (naked eye adj (exam$ or assess$)).ti,ab.
65 (skin adj exam$).ti,ab.
66 ugly duckling.mp. or UD.ti,ab.
67 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
68 ABCDE.mp. or VOC.ti,ab.
69 clinical accuracy.ti,ab.
70 (Family adj (Practice or Physicians)).ti,ab.
71 (confocal adj2 microscop$).ti,ab.
72 clinical competence.ti,ab.
73 diagnostic algorithm$1.ti,ab.
74 checklist$.ti,ab.
75 virtual imag$1.ti,ab.
76 volatile organic compound$1.ti,ab.
77 dog$1.ti,ab.
78 gene expression analy$.ti,ab.
79 reflex transmission imag$.ti,ab.
80 thermal imaging.ti,ab.
81 elastography.ti,ab.
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82 or/10-81
83 (CT or PET).ti,ab.
84 PET-CT.ti,ab.
85 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
86 deoxy-glucose.ti,ab.
87 deoxyglucose.ti,ab.
88 CATSCAN.ti,ab.
89 positron emission tomograph$.ti,ab.
90 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
91 Doppler echography.ti,ab.
92 sonograph$.ti,ab.
93 ultraso$.ti,ab.
94 doppler.ti,ab.
95 magnetic resonance imag$.ti,ab.
96 or/83-95
97 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
98 96 and 97
99 82 or 98
100 9 and 99
Database: Embase 1974 to 29 August 2016
Search strategy:
1 *melanoma/
2 *skin cancer/
3 *basal cell carcinoma/
4 basalioma$.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$ or adenoma$
or epithelioma$ or lesion$ or malignan$ or nodule$)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or
keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or cscc).mp. or NMSC.ti,ab.
11 keratinocyte.ti,ab.
12 keratinocy$.ti,ab.
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 *epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
#165 Visual examination and dermoscopy, alone or in combination, for the diagnosis of keratinocyte skin cancers in ad...
198 / 231
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 MoleMax.ti,ab.
38 exp diagnosis, computer-assisted/
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 (optical adj2 scan$).ti,ab.
44 Aura.ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 confocal microscop$.ti,ab.
51 (high adj3 ultraso$).ti,ab.
52 (canine adj2 detect$).ti,ab.
53 ((mobile or cell$ or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
54 smartphone$.ti,ab.
55 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
56 Spot Check.ti,ab.
57 Mole Detective.ti,ab.
58 (mole$1 adj2 map$).ti,ab.
59 (total adj2 body).ti,ab.
60 exfoliative cytolog$.ti,ab.
61 digital analys$.ti,ab.
62 (image$1 adj3 software).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or
teledermatoscop$).mp. or tele-dermatoscop$.ti,ab.
65 (computer adj2 diagnos$).ti,ab.
66 *sentinel lymph node biopsy/
67 (sentinel adj2 node).ti,ab.
68 nevisense.ti,ab.
69 HFUS.ti,ab.
70 electrical impedance spectroscopy.ti,ab.
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71 history taking.ti,ab.
72 patient history.ti,ab.
73 (naked eye adj (exam$ or assess$)).ti,ab.
74 (skin adj exam$).ti,ab.
75 *physical examination/
76 ugly duckling.ti,ab.
77 UD sign$.ti,ab.
78 ((physician$ or clinical or physical) adj (exam$ or recog$ or triage)).ti,ab.
79 ABCDE.ti,ab.
80 clinical accuracy.ti,ab.
81 *general practice/
82 (confocal adj2 microscop$).ti,ab.
83 clinical competence/
84 diagnostic algorithm$.ti,ab.
85 checklist$1.ti,ab.
86 virtual image$1.ti,ab.
87 volatile organic compound$1.ti,ab.
88 VOC.ti,ab.
89 dog$1.ti,ab.
90 gene expression analys$.ti,ab.
91 reflex transmission imaging.ti,ab.
92 thermal imaging.ti,ab.
93 elastography.ti,ab.
94 dog$1.ti,ab.
95 gene expression analys$.ti,ab.
96 reflex transmission imaging.ti,ab.
97 thermal imaging.ti,ab.
98 elastography.ti,ab.
99 or/14-93
100 PET-CT.ti,ab.
101 (CT or PET).ti,ab.
102 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
103 exp Deoxyglucose/
104 CATSCAN.ti,ab.
105 deoxyglucose.ti,ab.
106 deoxy-glucose.ti,ab.
107 *positron emission tomography/
108 *computer assisted tomography/
109 positron emission tomograph$.ti,ab.
110 *nuclear magnetic resonance imaging/
111 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
112 *echography/
113 Doppler.ti,ab.
114 sonograph$.ti,ab.
115 ultraso$.ti,ab.
116 magnetic resonance imag$.ti,ab.
117 or/100-116
#165 Visual examination and dermoscopy, alone or in combination, for the diagnosis of keratinocyte skin cancers in ad...
200 / 231
118 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
119 "Sensitivity and Specificity"/
120 *cancer staging/
121 or/118-120
122 117 and 121
123 99 or 122
124 13 and 123
Database: Cochrane Library (Wiley) 2016 searched 30 August 2016 CDSR Issue 8 of 12 2016 CENTRAL Issue 7 of 12 2016
HTA Issue 3 of 4 July 2016 DARE Issue 3 of 4 2015
Search strategy:
#1 melanoma* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyte*
#2 MeSH descriptor: [Melanoma] explode all trees
#3 "skin cancer*"
#4 MeSH descriptor: [Skin Neoplasms] explode all trees
#5 skin near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*)
#6 nmsc
#7 "squamous cell" near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*) near/2 (skin or epiderm* or cutaneous)
#8 "basal cell" near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*)
#9 pigmented near/2 (lesion* or nevus or mole* or naevi or naevus or nevi or skin)
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 dermoscop*
#12 dermatoscop*
#13 Photomicrograph*
#14 MeSH descriptor: [Dermoscopy] explode all trees
#15 confocal near/2 microscop*
#16 epiluminescence near/2 microscop*
#17 incident next light near/2 microscop*
#18 surface near/2 microscop*
#19 "visual inspect*"
#20 "visual exam*"
#21 (clinical or physical) next (exam*)
#22 "3 point"
#23 "three point"
#24 "pattern analys*"
#25 ABDC
#26 menzies
#27 "7 point"
#28 "seven point"
#29 digital near/2 (dermoscop* or dermatoscop*)
#30 "artificial intelligence"
#31 "AI"
#32 "computer assisted"
#33 "computer aided"
#34 AI
#35 "neural network*"
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#36 MoleMax
#37 "computer diagnosis"
#38 "image process*"
#39 "automatic classif*"
#40 SIAscope
#41 "image analysis"
#42 "optical near/2 scan*"
#43 Aura
#44 MelaFind
#45 SIMSYS
#46 MoleMate
#47 SolarScan
#48 Vivascope
#49 "confocal microscopy"
#50 high near/3 ultraso*
#51 canine near/2 detect*
#52 Mole* near/2 map*
#53 total near/2 body
#54 mobile* or smart near/2 phone*
#55 cell next phone*
#56 smartphone*
#57 "mitotic index"
#58 DermoScan or SkinVision or DermLink or SpotCheck
#59 "Mole Detective"
#60 "Spot Check"
#61 mole* near/2 map*
#62 total near/2 body
#63 "exfoliative cytolog*"
#64 "digital analys*"
#65 image near/3 software
#66 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop*
or tele-dermatolog*
#67 "optical coherence" next (technolog* or tomog*)
#68 computer near/2 diagnos*
#69 sentinel near/2 node*
#70 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or
#28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45
or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or
#63 or #64 or #65 or #66 or #67 or #68 or #69
#71 ultraso*
#72 sonograph*
#73 MeSH descriptor: [Ultrasonography] explode all trees
#74 Doppler
#75 CT or PET or PET-CT
#76 "CAT SCAN" or "CATSCAN"
#77 MeSH descriptor: [Positron-Emission Tomography] explode all trees
#78 MeSH descriptor: [Tomography, X-Ray Computed] explode all trees
#79 MRI
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#80 MeSH descriptor: [Magnetic Resonance Imaging] explode all trees
#81 MRI or fMRI or NMRI or scintigraph*
#82 "magnetic resonance imag*"
#83 MeSH descriptor: [Deoxyglucose] explode all trees
#84 deoxyglucose or deoxy-glucose
#85 "positron emission tomograph*"
#86 #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78 or #79 or #80 or #81 or #82 or #83 or #84 or #85
#87 stage* or staging or metasta* or recurrence or sensitivity or specificity or "false negative*" or thickness*
#88 MeSH descriptor: [Neoplasm Staging] explode all trees
#89 #87 or #88
#90 #89 and #86
#91 #70 or #90
#92 #10 and #91
#93 BCC or CSCC or NMCS
#94 keratinocy*
#95 #93 or #94
#96 #10 or #95
#97 nevisense
#98 HFUS
#99 "electrical impedance spectroscopy"
#100 "history taking"
#101 "patient history"
#102 naked next eye near/1 (exam* or assess*)
#103 skin next exam*
#104 "ugly duckling" or (UD sign*)
#105 MeSH descriptor: [Physical Examination] explode all trees
#106 (physician* or clinical or physical) near/1 (exam* or recog* or triage*)
#107 ABCDE
#108 "clinical accuracy"
#109 MeSH descriptor: [General Practice] explode all trees
#110 confocal near microscop*
#111 "diagnostic algorithm*"
#112 MeSH descriptor: [Clinical Competence] explode all trees
#113 checklist*
#114 "virtual image*"
#115 "volatile organic compound*"
#116 dog or dogs
#117 VOC
#118 "gene expression analys*"
#119 "reflex transmission imaging"
#120 "thermal imaging"
#121 elastography
#122 #97 or #98 or #99 or #100 or #101 or #102 or #103 or #104 or #105 or #106 or #107 or #108 or #109 or #110 or #111
or #112 or #113 or #114 or #115 or #116 or #117 or #118 or #119 or #120 or #121
#123 #70 or #122
#124 #96 and #123
#125 #96 and #90
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#126 #125 or #124
#127 #10 and #126
Database: CINAHL Plus (EBSCO) 1937 to 30 August 2016
Search strategy:
S1 (MH "Melanoma") OR (MH "Nevi and Melanomas+")
S2 (MH "Skin Neoplasms+")
S3 (MH "Carcinoma, Basal Cell+")
S4 basalioma*
S5 (basal cell) N2 (cancer* or carcinoma* or mass or masses or tumor* or tumour* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*)
S6 (pigmented) N2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin)
S7 melanom* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt*
S8 nmsc
S9 TX BCC or cscc or NMSC
S10 (MH "Keratinocytes")
S11 keratinocyt*
S12 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11
S13 dermoscop* or dermatoscop* or photomicrograph* or (3 point) or (three point) or ABCD* or menzies or (7 point) or
(seven point) or AI or Molemax or SIASCOP* or Aura or MelaFind or SIMSYS or MoleMate or SolarScan or smartphone* or
DermoScan or SkinVision or DermLink or SpotCheck
S14 (epiluminescence or confocal or incident or surface) N2 (microscop*)
S15 visual N1 (inspect* or examin*)
S16 (clinical or physical) N1 (examin*)
S17 pattern analys*
S18 (digital) N2 (dermoscop* or dermatoscop*)
S19 (artificial intelligence)
S20 (computer) N2 (assisted or aided)
S21 (neural network*)
S22 (MH "Diagnosis, Computer Assisted+")
S23 (image process*)
S24 (automatic classif*)
S25 (image analysis)
S26 SIAScop*
S27 (optical) N2 (scan*)
S28 (high) N3 (ultraso*)
S29 elastography
S30 (mobile or cell or cellular or smart) N2 (phone*) N2 (app or application*)
S31 (mole*) N2 (map*)
S32 total N2 body
S33 exfoliative cytolog*
S34 digital analys*
S35 image N3 software
S36 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop*
or tele-dermatoscop* teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop*
S37 (optical coherence) N1 (technolog* or tomog*)
S38 computer N2 diagnos*
S39 sentinel N2 node
S40 (MH "Sentinel Lymph Node Biopsy")
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S41 nevisense or HFUS or checklist* or VOC or dog*
S42 electrical impedance spectroscopy
S43 history taking
S44 "Patient history"
S45 naked eye
S46 skin exam*
S47 physical exam*
S48 ugly duckling
S49 UD sign*
S50 (physician* or clinical or physical) N1 (exam*)
S51 clinical accuracy
S52 general practice
S53 (physician* or clinical or physical) N1 (recog* or triage)
S54 confocal microscop*
S55 clinical competence
S56 diagnostic algorithm*
S57 checklist*
S58 virtual image*
S59 volatile organic compound*
S60 gene expression analys*
S61 reflex transmission imag*
S62 thermal imaging
S63 S13 or S14 or S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR
S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR
S41 OR S42 OR S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR
S55 OR S56 OR S57 OR S58 OR S59 OR S60 OR S61 OR S62
S64 CT or PET
S65 PET-CT
S66 FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical*
S67 (MH "Deoxyglucose+")
S68 deoxy-glucose or deoxyglucose
S69 CATSCAN
S70 CAT-SCAN
S71 (MH "Deoxyglucose+")
S72 (MH "Tomography, Emission-Computed+")
S73 (MH "Tomography, X-Ray Computed")
S74 positron emission tomograph*
S75 (MH "Magnetic Resonance Imaging+")
S76 MRI or fMRI or NMRI or scintigraph*
S77 echography
S78 doppler
S79 sonograph*
S80 ultraso*
S81 magnetic resonance imag*
S82 S64 OR S65 OR S66 OR S67 OR S68 OR S69 OR S70 OR S71 OR S72 OR S73 OR S74 OR S75 OR S76 OR S77
OR S78 OR S79 OR S80 OR S81
S83 stage* or staging or metasta* or recurrence or sensitivity or specificity or (false negative*) or thickness
S84 (MH "Neoplasm Staging")
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S85 S83 OR S84
S86 S82 AND S85
S87 S63 OR S86
S88 S12 AND S87
Database: Science Citation Index SCI Expanded (Web of Science) 1900 to 30 August 2016
Conference Proceedings Citation Index (Web of Science) 1900 to 1 September 2016
Search strategy:
#1 (melanom* or nonmelanom* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyt*)
#2 (basalioma*)
#3 ((skin) near/2 (cancer* or carcinoma or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma*
or lesion* or malignan* or nodule*))
#4 ((basal) near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*))
#5 ((pigmented) near/2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin))
#6 (nmsc or BCC or NMSC or keratinocy*)
#7 ((squamous cell (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*))
#8 (skin or epiderm* or cutaneous)
#9 #8 AND #7
#10 #9 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#11 ((dermoscop* or dermatoscop* or photomicrograph* or epiluminescence or confocal or "incident light" or "surface
microscop*" or "visual inspect*" or "physical exam*" or 3 point or three point or pattern analy* or ABCDE or menzies or 7
point or seven point or dermoscop* or dermatoscop* or AI or artificial or computer aided or computer assisted or neural
network* or Molemax or image process* or automatic classif* or image analysis or siascope or optical scan* or Aura or
melafind or simsys or molemate or solarscan or vivascope or confocal microscop* or high ultraso* or canine detect* or
cellphone* or mobile* or phone* or smartphone or dermoscan or skinvision or dermlink or spotcheck or spot check or mole
detective or mole map* or total body or exfoliative psychology or digital or image software or optical coherence or
teledermatology or telederm* or teledermoscop* or teledermatoscop* or computer diagnos* or sentinel))
#12 ((nevisense or HFUS or impedance spectroscopy or history taking or patient history or naked eye or skin exam* or
physical exam* or ugly duckling or UD sign* or physician* exam* or physical exam* or ABCDE or clinical accuracy or general
practice or confocal microscop* or clinical competence or diagnostic algorithm* or checklist* or virtual image* or volatile
organic or VOC or dog* or gene expression or reflex transmission or thermal imag* or elastography))
#13 #11 or #12
#14 ((PET or CT or FDG or deoxyglucose or deoxy-glucose or fluorodeoxy* or radiopharma* or CATSCAN or positron
emission or computer assisted or nuclear magnetic or MRI or FMRI or NMRI or scintigraph* or echograph* or Doppler or
sonograph* or ultraso* or magnetic reson*))
#15 ((stage* or staging or metast* or recurrence or sensitivity or specificity or false negative* or thickness*))
#16 #14 AND #15
#17 #16 OR #13
#18 #10 AND #17
Refined by: DOCUMENT TYPES: (MEETING ABSTRACT OR PROCEEDINGS PAPER)
5 Full text inclusion criteria
The title and abstract screening will lead to the retrieval of a large number of full text journal papers and conference abstracts
from which to populate the four sets of test accuracy reviews and the intervention review. The systematic reviews will largely
be carried out sequentially, beginning with the reviews of tests for melanoma diagnosis; however, the full text papers need to
be screened at the beginning of the Programme Grant and papers meeting the inclusion criteria tagged accordingly per
review.
The table below summarises the inclusion criteria to be applied; these will be transferred to an Excel spreadsheet or Google
Forms so that pertinent information can be recorded about each eligible study and reasons for exclusion recorded about
each ineligible study.
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Criterion Inclusion Exclusion
 
Study design
 
For diagnostic and staging reviews
Any study for which a 2×2 contingency table can be
extracted, e.g.
diagnostic case control studies
'cross-sectional' test accuracy study with
retrospective or prospective data collection
studies where estimation of test accuracy was not the
primary objective but test results for both index and
reference standard were available
RCTs of tests or testing strategies where participants
were randomised between index tests and all
undergo a reference standard (i.e. accuracy RCTs)
 
< 5 melanoma cases (diagnosis reviews)
< 10 participants (staging reviews)
Studies developing new criteria for diagnosis
unless a separate 'test set' of images were
used to evaluate the criteria (mainly digital
dermoscopy)
Studies using 'normal' skin as controls
Letters, editorials, comment papers, narrative
reviews
Insufficient data to construct a 2×2 table
Target
condition
 
Melanoma
Keratinocyte skin cancer (or non-melanoma skin
cancer)
BCC or epithelioma
cSCC
 
Studies exclusively conducted in children
Studies of non-cutaneous melanoma or SCC
Population For diagnostic reviews
Adults with a skin lesion suspicious for melanoma, BCC,
or cSCC (other terms include pigmented skin
lesion/nevi, melanocytic, keratinocyte, etc.)
Adults at high risk of developing melanoma skin cancer,
BCC, or cSCC
For staging reviews
Adults with a diagnosis of melanoma or cSCC
undergoing tests for staging of lymph nodes or distant
metastases or both
 
People suspected of other forms of skin cancer
Studies conducted exclusively in children
Index tests For diagnosis
Visual inspection/clinical examination
Dermoscopy/dermatoscopy
Teledermoscpoy
Smartphone/mobile phone applications
Digital dermoscopy/artificial intelligence
Confocal microscopy
Ocular coherence tomography
Exfoliative cytology
High frequency ultrasound
Canine odour detection
DNA expression analysis/gene chip analysis
Other
For staging
CT
PET
PET-CT
MRI
Ultrasound +/fine needle aspiration cytology FNAC
SLNB +/high frequency ultrasound
Other
Any test combination and in any order
Any test positivity threshold
Any variation in testing procedure (e.g. radioisotope used)
 
Sentinel lymph biopsy for therapeutic rather
than staging purposes
Tests to determine melanoma thickness
Tests to determine surgical margins/lesion
borders
Tests to improve histopathology diagnose
LND
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Criterion Inclusion Exclusion
Reference
standard
 
For diagnostic studies
Histopathology of the excised lesion
Clinical follow-up of non-excised/benign appearing
lesions with later histopathology if suspicious
Expert diagnosis (studies should not be included if
expert diagnosis is the sole reference standard)
For studies of imaging tests for staging
Histopathology (via LND or SLMB)
Clinical/radiological follow-up
A combination of the above
For studies of SLNB accuracy for staging
LND of both SLN+ and SLn participants to identify all
diseased nodes
LND of SLN+ participants and follow-up of SLN
participants to identify a subsequent nodal recurrence in
a previously investigated nodal basin
 
For diagnostic studies
Exclude if any disease positive participants
have diagnosis unconfirmed by histology
Exclude if > 50% of disease negative
participants have diagnosis confirmed by expert
opinion with no histology or follow-up
Exclude studies of referral accuracy, i.e.
comparing referral decision with expert
diagnosis, unless evaluations of
teledermatology or mobile phone applications
BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carcinoma; CT: computed tomography; FNAC: fine needle
aspiration cytology; LND: lymph node dissection; MRI: magnetic resonance imaging; PET: positron emission tomography;
PET-CT: positron emission tomography computed tomography; RCT: randomised controlled trial; SCC: squamous cell
carcinoma; SLN+: positive sentinel lymph node; SLn: negative sentinel lymph node; SLNB: sentinel lymph node biopsy.
6 Quality assessment (based on QUADAS-2)
The following tables use text that was originally published in the QUADAS-2 tool by Whiting and colleagues ( Whiting 2011 ).
Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
1) Was a consecutive or random sample of participants or
images enrolled?
Yes – if paper states consecutive or random
No – if paper describes other method of sampling
Unclear – if participant sampling not described
2) Was a case-control design avoided? Yes – if consecutive or random or case-control design
clearly not used
No – if study described as case-control or describes
sampling specific numbers of participants with particular
diagnoses
Unclear – if not described
 
3) Did the study avoid inappropriate exclusions, e.g.,
'difficult to diagnose' lesions not excluded
lesions not excluded on basis of disagreement between
evaluators
Yes – if inappropriate exclusions were avoided
No – if lesions were excluded that might affect test
accuracy, e.g., 'difficult to diagnose' lesions, or where
disagreement between evaluators was observed
Unclear – if not clearly reported but there is suspicion that
difficult to diagnose lesions may have been excluded
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Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
 
4) For between-person comparative studies only (i.e., allocating
different tests to different study participants):
A) were the same participant selection criteria used for those
allocated to each test?
B) was the potential for biased allocation between tests
avoided through adequate generation of a randomised
sequence?
C) was the potential for biased allocation between tests
avoided through concealment of allocation prior to
assignment?
For A)
Yes – if same selection criteria were used for each index
test, No – if different selection criteria were used for each
index test, Unclear – if selection criteria per test were not
described, N/A – if only 1 index test was evaluated or all
participants received all tests
For B)
Yes – if adequate randomisation procedures are
described, No – if inadequate randomisation procedures
are described, Unclear – if the method of allocation to
groups is not described (a description of 'random' or
'randomised' is insufficient), N/A – if only 1 index test
was evaluated or all participants received all tests
For C)
Yes – if appropriate methods of allocation concealment
are described, No – if appropriate methods of allocation
concealment are not described, Unclear – if the method
of allocation concealment is not described (sufficient
detail to allow a definite judgement is required), N/A – if
only 1 index test was evaluated
 
Could the selection of participants have introduced bias?
For non-comparative and within-person comparative studies
If answers to all of questions 1), 2), and 3) 'Yes':1.
If answers to any 1 of questions 1), 2), or 3) 'No':2.
If answers to any 1 of questions 1), 2), or 3) 'Unclear':3.
For between-person comparative studies
If answers to all of questions 1), 2), 3), and 4) 'Yes':1.
If answers to any 1 of questions 1), 2), 3), or 4) 'No':2.
If answers to any 1 of questions 1), 2), 3), or 4) 'Unclear':3.
For non-comparative and within-person comparative
studies
Risk is low1.
Risk is high2.
Risk unclear3.
For between-person comparative studies
Risk is low1.
Risk is high2.
Risk unclear3.
PARTICIPANT SELECTION (1) - CONCERNS REGARDING APPLICABILITY
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Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
 
1) Are the included participants and chosen study setting
appropriate to answer the review question, i.e., are the study
results generalisable?
This item is not asking whether exclusion of certain
participant groups might bias the study's results (as in Risk
of Bias above), but is asking whether the chosen study
participants and setting are appropriate to answer our review
question. Because we are looking to establish test accuracy
in both primary presentation and referred participants, a
study could be appropriate for 1 setting and not for the other,
or it could be unclear as to whether the study can
appropriately answer either question
For each study assessed, please consider whether it is more
relevant for A) participants with a primary presentation of a
skin lesion or B) referred participants, and respond to the
questions in either A) or B) accordingly. If the study gives
insufficient details, please respond Unclear to both parts of
the question
 
A) For studies that will contribute to the analysis of
participants with a primary presentation of a skin lesion (i.e.,
test naive)
Yes – if participants included in the study appear to be
generally representative of those who might present in a
usual practice setting
No – if study participants appear to be unrepresentative of
usual practice, e.g., in terms of severity of disease,
demographic features, presence of differential diagnosis or
co-morbidity, setting of the study, and previous testing
protocols
Unclear – if insufficient details are provided to determine the
generalisability of study participants
B) For studies that will contribute to the analysis of referred
participants (i.e., who have already undergone some form
of testing)
Yes – if study participants appear to be representative of
those who might be referred for further investigation. If the
study focuses only on those with equivocal lesions, for
example, we would suggest that this is not representative of
the wider referred population
No – if study participants appear to be unrepresentative of
usual practice, e.g., if a particularly high proportion of
participants have been self-referred or referred for cosmetic
reasons. Other factors to consider include severity of
disease, demographic features, presence of differential
diagnosis or co-morbidity, setting of the study, and previous
testing protocols
Unclear – if insufficient details are provided to determine the
generalisability of study participants
2) Did the study avoid including participants with multiple
lesions?
Yes – if the difference between the number of included
lesions and number of included participants is less than 5%
No – if the difference between the number of included
lesions and number of included participants is greater than
5%
Unclear – if it is not possible to assess
 
Is there concern that the included participants do not match the
review question?
If the answer to question 1) or 2) 'Yes':1.
If the answer to question 1) or 2) 'No':2.
If the answer to question 1) or 2) 'Unclear':3.
 
Concern is low1.
Concern is high2.
Concern is unclear3.
INDEX TEST (2) - RISK OF BIAS (to be completed per test evaluated)
1) Was the index test or testing strategy result interpreted
without knowledge of the results of the reference standard?
Yes – if index test described as interpreted without
knowledge of reference standard result or, for prospective
studies, if index test is always conducted and interpreted
prior to the reference standard
No – if index test described as interpreted in knowledge of
reference standard result
Unclear – if index test blinding is not described
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Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
2) Was the diagnostic threshold at which the test was
considered positive (i.e., BCC or cSCC present) prespecified?
Yes – if threshold was prespecified (i.e., prior to analysing
study results)
No – if threshold was not prespecified
Unclear – if not possible to tell whether or not diagnostic
threshold was prespecified
3) For within-person comparisons of index tests or testing
strategies (i.e., > 1 index test applied per participant): was each
index test result interpreted without knowledge of the results of
other index tests or testing strategies?
Yes – if all index tests were described as interpreted without
knowledge of the results of the others
No – if the index tests were described as interpreted in the
knowledge of the results of the others
Unclear – if it is not possible to tell whether knowledge of
other index tests could have influenced test interpretation
N/A – if only 1 index test was evaluated
 
Could the conduct or interpretation of the index test have
introduced bias?
For non-comparative and between-person comparison studies
If answers to questions 1) and 2) 'Yes':1.
If answers to either questions 1) or 2) 'No':2.
If answers to either questions 1) or 2) 'Unclear':3.
For within-person comparative studies
If answers to all questions 1), 2), and 3) for any index test1.
'Yes':
If answers to any 1 of questions 1), 2), or 3) for any index2.
test 'No':
If answers to any 1 of questions 1), 2), or 3) for any index3.
test 'Unclear':
 
For non-comparative and between-person comparison
studies
Risk is low1.
Risk is high2.
Risk is unclear3.
For within-person comparative studies
Risk is low1.
Risk is high2.
Risk is unclear3.
INDEX TEST (2) - CONCERN ABOUT APPLICABILITY
 
1) Was the diagnostic threshold to determine presence or
absence of disease established in a previously published
study?
E.g., previously evaluated/established
algorithm/checklist used
lesion characteristics indicative of BCC or cSCC used
objective (usually numerical) threshold used
Yes – if a previously evaluated/established tool to aid
diagnosis of BCC or cSCC was used or if the diagnostic
threshold used was established in a previously published
study
No – if an unfamiliar/new tool to aid diagnosis of BCC or
cSCC was used, if no particular algorithm was used, or if
the objective threshold reported was chosen based on
results in the current study
Unclear – if insufficient information was reported
 
2) Were thresholds or criteria for diagnosis reported in sufficient
detail to allow replication?
Study results can only be reproduced if the diagnostic threshold
is described in sufficient detail. This item applies equally to
studies using pattern recognition and those using checklists or
algorithms to aid test interpretation
Yes – if the criteria for diagnosis of BCC or cSCC were
reported in sufficient detail to allow replication
No – if the criteria for diagnosis of BCC or cSCC were not
reported in sufficient detail to allow replication
Unclear – if some but not sufficient information on criteria
for diagnosis to allow replication were provided
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Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
3) Was the test interpretation carried out by an experienced
examiner?
Yes – if the test was interpreted by 1 or more speciality-
accredited dermatologists, or by examiners of any clinical
background with special interest in dermatology and with
any formal training in the use of the test
No – if the test was not interpreted by an experienced
examiner (see above)
Unclear – if the experience of the examiner(s) was not
reported in sufficient detail to judge or if examiners
described as 'Expert' with no further detail given
N/A – if system-based diagnosis, i.e., no observer
interpretation
 
Is there concern that the index test, its conduct, or
interpretation differ from the review question?
If answers to questions 1), 2), and 3) 'Yes':1.
If answers to questions 1), 2), or 3) 'No':2.
If answers to questions 1), 2), or 3) 'Unclear':3.
 
Concern is low1.
Concern is high2.
Concern is unclear3.
REFERENCE STANDARD (3) - RISK OF BIAS
 
1) Is the reference standard likely to correctly classify the target
condition?
A) Disease-positive - 1 or more of the following:
histological confirmation of BCC or cSCC following biopsy or
lesion excision
clinical follow-up of benign-appearing lesions for at least 6
(or 3 for cSCC) months following the application of the index
test, leading to a histological diagnosis of BCC or cSCC
B) Disease-negative - 1 or more of the following:
histological confirmation of absence of BCC or cSCC
following biopsy or lesion excision in at least 80% of
disease-negative participants
clinical follow-up of benign-appearing lesions for a minimum
of 6 months (or 3 for cSCC) following the index test in up to
20% of disease-negative participants
 
A) Disease-positive
Yes – if all participants with a final diagnosis of BCC or
cSCC underwent 1 of the listed reference standards
No – if a final diagnosis of BCC or cSCC for any participant
was reached without histopathology
Unclear – if the method of final diagnosis was not reported
for any participant with a final diagnosis of BCC or cSCC or
if the length of clinical follow-up used was not clear or if a
clinical follow-up reference standard was reported in
combination with a participant-based analysis and it was
not possible to determine whether the detection of a
malignant lesion during follow-up is the same lesion that
originally tested negative on the index test
B) Disease-negative
Yes – if at least 80% of benign diagnoses were reached by
histology and up to 20% were reached by clinical follow-up
for a minimum of 6 (or 3) months following the index test
No – if more than 20% of benign diagnoses were reached
by clinical follow-up for a minimum of 6 (or 3) months
following the index test or if clinical follow-up period was
less than 6 (or 3) months
Unclear – if the method of final diagnosis was not reported
for any participant with benign diagnosis
 
2) Were the reference standard results interpreted without
knowledge of the results of the index test?
Please score this item for all studies even though
histopathology interpretation is usually conducted with
knowledge of the clinical diagnosis (from visual inspection or
dermoscopy or both). We will deal with this by not including the
response to this item in the 'Risk of bias' assessment for these
tests. For reviews of all other tests, this item will be retained
Yes – if the reference standard diagnosis was reached
blinded to the index test result
No – if the reference standard diagnosis was reached with
knowledge of the index test result
Unclear – if blinded reference test interpretation was not
clearly reported
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Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
 
Could the reference standard, its conduct, or its interpretation
have introduced bias?
For visual inspection/dermoscopy evaluations
If answer to question 1) 'Yes':1.
If answer to question 1) 'No':2.
If answer to question 1) 'Unclear':3.
For all other tests
If answers to questions 1) and 2) 'Yes':1.
If answers to questions 1) or 2) 'No':2.
If answers to questions 1) or 2) 'Unclear':3.
For visual inspection/dermoscopy evaluations
Risk is low1.
Risk is high2.
Risk is unclear3.
For all other tests
Risk is low1.
Risk is high2.
Risk is unclear3.
REFERENCE STANDARD (3) - CONCERN ABOUT APPLICABILITY
1) Are index test results presented separately for each
component of the target condition (i.e., separate results
presented for those with invasive melanoma, melanoma in situ,
lentigo maligna, severe dysplasia, BCC, and cSCC)?
Yes – if index test results for each component of the target
condition can be disaggregated
No – if index test results for the different components of the
target condition cannot be disaggregated
Unclear – if not clearly reported
 
2) Expert opinion (with no histological confirmation) was not
used as a reference standard
'Expert opinion' means diagnosis based on the standard clinical
examination, with no histology or lesion follow-up
***do not complete this item for teledermatology studies
Yes – if expert opinion was not used as a reference
standard for any participant
No – if expert opinion was used as a reference standard for
any participant
Unclear – if not clearly reported
3) Was histology interpretation carried out by an experienced
histopathologist or by a dermatopathologist?
Yes – if histology interpretation was reported to be carried
out by an experienced histopathologist or
dermatopathologist
No – if histology interpretation was reported to be carried
out by a less experienced histopathologist
Unclear – if the experience/qualifications of the pathologist
were not reported
 
Is there concern that the target condition as defined by the
reference standard does not match the review question?
If answers to all questions 1), 2), and 3) 'Yes':1.
If answers to any 1 of questions 1), 2), or 3) 'No':2.
If answers to any 1 of questions 1), 2), or 3) 'Unclear':3.
***For teledermatology studies only
If answers to all questions 1) and 3) 'Yes':1.
If answers to questions 1) or 3) 'No':2.
If answers to questions 1) or 3) 'Unclear':3.
Concern is low1.
Concern is high2.
Concern is unclear3.
***For teledermatology studies only
Concern is low1.
Concern is high2.
Concern is unclear3.
FLOW AND TIMING (4): RISK OF BIAS
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Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
 
1) Was there an appropriate interval between index test and
reference standard?
A) For histopathological reference standard, was the interval
between index test and reference standard ≤ 1 month?
B) If the reference standard includes clinical follow-up of
borderline/benign-appearing lesions, was there at least 6 (or 3)
months' follow-up following application of index test(s) for
studies of BCC (or cSCC)?
 
A)
Yes – if study reports ≤ 1 month between index and
reference standard
No – if study reports > 1 month between index and
reference standard
Unclear – if study does not report interval between index
and reference standard
B)
Yes – if study reports ≥ 6 (or 3 for cSCC) months' follow-up
No – if study reports < 6 (or 3 for cSCC) months' follow-up
Unclear – if study does not report length of clinical follow-up
2) Did all participants receive the same reference standard? Yes – if all participants underwent the same reference
standard
No – if more than 1 reference standard was used
Unclear – if not clearly reported
3) Were all participants included in the analysis? Yes – if all participants were included in the analysis
No – if some participants were excluded from the analysis
Unclear– if not clearly reported
 
4) For within-person comparisons of index tests
Was the interval between application of index tests ≤ 1 month?
Yes – if study reports ≤ 1 month between index tests
No – if study reports > 1 month between index tests
Unclear – if study does not report interval between index
tests
 
Could the participant flow have introduced bias?
For non-comparative and between-person comparison studies
If answers to questions 1), 2), and 3) 'Yes':1.
If answers to any 1 of questions 1), 2), or 3) 'No':2.
If answers to any 1 of questions 1), 2), or 3) 'Unclear':3.
For within-person comparative studies
If answers to all questions 1), 2), 3), and 4) 'Yes':1.
If answers to any 1 of questions 1), 2), 3), or 4) 'No':2.
If answers to any 1 of questions 1), 2), 3), or 4) is 'Unclear':3.
For non-comparative and between-person comparison
studies
Risk is low1.
Risk is high2.
Risk is unclear3.
For within-person comparative studies
Risk is low1.
Risk is high2.
Risk is unclear3.
BCC = basal cell carcinoma; cSCC = cutaneous squamous cell carcinoma.
7 Summary of tests and target conditions evaluated per study
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  In-person Image-based Other tests
evaluated in
study
Target conditions
reported
Appears in
melanoma
reviewVisual
inspection
Dermoscopy
added to VI
Visual
inspection
Dermoscopic
images
BCC SCC KER
Altamura 2010 - - - X - X - - -
Amirnia 2016 - X - - - X - - -
Argenziano
2006
X X - - - - - X X
Carli 2002a X X - X - X - - X
Carli 2002b - - X X - X - X X
Chang 2013 X - - - - - - X X
Cooper 2002 X - - - - X X X  
Durdu 2011 - X - - Exfoliative
cytology
X - X X
Ek 2005 X - - - - X X X X
Gokdemir 2011 - X - - - X - - X
Hacioglu 2013 X - - X CAD - - X -
Lorentzen 1999 - - X - - X - - X
Lorentzen 2008 - - - X - X - - X
Markowitz 2015 X X - - OCT X - - -
Menzies 2000 - - - X - X - X -
Navarrete
Dechent 2016
- - - X - X X X -
Nori 2004 - - X - - X - - -
Rosendahl 2011 - - X X - X - X X
Schwartzberg
2005
X - - - - X - - -
Stanganelli 2000 X X - - - X - - X
Steiner 1987 X - - - - X - - X
Ulrich 2015 X X - - OCT X - - -
Witkowski 2016 - - - X RCM X X X -
Zalaudek 2006 - - - X - X - - X
 
Footnotes:
VI - visual inspection; BCC – basal cell carcinoma; cSCC – cutaneous squamous cell carcinoma; KER - any skin cancer;
RCM – reflectance confocal microscopy; CAD – computer-assisted diagnosis; OCT - optical coherence tomography
8 Summary study details
 
Study author
Outcomes
reported
Pathway
Study type
Country
Setting
Inclusion
criteria
 
Index tests
(algorithm)
Diagnostic
approach
Threshold Observer qual.
(n)
Experience
 
Reference
standard
Final diagnoses
Prevalence
(Any)
 
Exclusions
Comments
(marked *)
 
In-person evaluations            
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Amirnia 2016
BCC
Referred
(selected on
reference) (c)
 
NC
NR-CS
Iran
Secondary
61 / 61
Patients
suspected of
BCC or
melanocytic
nevi of the face
who were
referred to
dermatology
clinic
 
Dermoscopy
(3 point
checklist plus
dermatoscopic
criteria of
melanocytic
nevi and BCC)
In person
 
>= 2 chars
present;
diagnosis of
BCC
 
Dermatologist
(assumed) (n =
NR.; exp NR)
Single observer
 
Histology
BCC 27
Benign 28
27/61; 44%
 
 
 
Argenziano
2006
Any
Limited prior
testing;
selected on
refererence
standard (c)
 
BPC
RCT
Italy,
Spain
Primary
NR / 85
[Full
sample
1203
lesions*]
Patients asking
for screening or
exhibiting one
or more skin
tumours as
seen during
routine physical
examination
(patient-finding
screening).
Participating
PCPs
randomised to
either visual
inspection
alone or visual
inspection plus
dermoscopy;
only excised
lesions can be
included for
each arm.
VI (ABCD)
Dermoscopy
(3-point
checklist)
In person
Subjective
impression; dx
of malignancy
 
GPs (n = 37)
All trained in
ABCD rule
Single observer
Histology
MEL 6
BCC 37; SCC
10
Benign 32
53/85; 62%
*Only those
patients who
were
considered to
have lesions
suggestive of
skin cancer
had histology
and could be
included; rest
had expert
diagnosis
(making full
dataset
ineligible for
this review)
 
 
Carli 2002a
BCC
[MM+MiS]
Referred
(selected on
reference) (u)
 
WPC
NR-CS
Italy
Secondary
NR / 256
Clinically
equivocal or
suspicious PSL
subjected to
excisional
biopsy at the
Institute of
Dermatology
 
1. VI (no
algorithm)
2.
Dermoscopy
(pattern)
In-person
(Dermoscopy
– image-
based)
Subjective
impression
 
Dermatologist (n
= 2; High exp –
“extensive
experience in
both clinical and
dermoscopic
diagnosis”)
Consensus of 2
 
Histology
MM 40; MiS 14
BCC 5
BN 177; SN 16;
SK 4
BCC: 5/256; 2%
 
None reported
BCC (VI): 2
MMS were FP
BCC (Derm –
pattern): all MM
TN
 
 
Chang 2013
Any
Referred
(selected on
reference) (u)
 
NC
R-CS
Taiwan
Secondary
676 / 769
Potentially
malignant
biopsied or
excised skin
lesions
(nontumour
specimens
excluded)
 
VI (no
algorithm)
In person
Subjective
impression ;
definitely
malignant
 
Dermatologists;
n = 25
Board-certified
Single observer
 
Histology
MM 4; MiS 4
BCC: 110;
cSCC: 20
'Benign'
diagnoses: 595
152/769; 20%
 
Poor
quality
index test
image?mis-
registered or
poor quality
images
(unfocused or
containing a
motion artifact)
 
#165 Visual examination and dermoscopy, alone or in combination, for the diagnosis of keratinocyte skin cancers in ad...
216 / 231
 
Cooper 2002
BCC
cSCC
Any
Follow-up (c)
 
NC
P-CS
UK
Spec.
clinic
NR / 102
Patients
attending the
open access
dermatology
renal transplant
clinic with
suspicious
lesions
VI (No
algorithm)
In person
 
NR; correct
diagnosis of
malignancy
 
Mixed (n = 2;
exp NR)
Single observer
 
Histology
BCC 12; cSCC
21
KA 2; BD 19;
Solar 16; viral
warts 7; other
25
BCC: 12/102;
12%
SCC: 21/102;
21%
BCC: 3 SCCs
were FP
 
 
Durdu 2011
BCC
Any
[MM+MiS]
Referred
(selected on
reference) (u)
 
WPC
P-CS
Secondary
Turkey
176/200
PSL that could
not be
diagnosed with
only
dermatologic
physical
examination;
2x2 included for
melanocytic
subset
 
Dermoscopy
(No algorithm
(ABCD for
diagnosis of
melanoma
only)
[Also
evaluated
exfoliative
cytology]
In person
 
NR
Dermatologist (n
= 1; exp NR)
Single observer
Histology
MM+MiS 10;
BCC: 34; Other
malignant 2
SK 24; BN 100;
DF 12; Warts
16; Dirt 1; Other
1
BCC: 34/200;
17%
-
 
 
Ek 2005
BCC
cSCC
Any
[MM+MiS]
Referred
(selected on
reference) (c)
 
NC
P-CS
Aus.
Specialist
clinic
1223 /
2582
Lesions excised
for which
malignancy
could not be
excluded
VI (no
algorithm)
In-person
Subjective
impression
Plastic surgeon
(n = 4 or 5;
mixed
experience; 3
consultants, 1
plastic surgery
trainee (usually
1st year, on 6
month rotation)
and a clinical
assistant)
Unclear
Histology
MEL 23
BCC 1214; SCC
517; BD 188;
SK 63; 577
other benign
(incl 330 solar
keratosis)
BCC:
1214/2582; 47%
SCC: 517/2582;
20%
 
Incomplete or
incorrectly
entered
proformas were
excluded – 79
patients with 96
lesions
BCC:202 SCC
and 6 MM were
FPs
 
 
Gokdemir
2011
BCC
[MM+MiS]
Referred
(selected on
reference) (u)
 
NC
NR-CS
Secondary
Turkey
362 / 449
Patients with
melanocytic
and non-
melanocytic
skin lesions
with
dermoscopic
and histologic
diagnoses.
Dermoscopy
(no algorithm)
Unclear if in-
person or
image-based
Subjective
assessment
(dx of MM)
Dermatologist (n
= NR; exp High
“at least 2 years’
experience with
Molemax II”)
Unclear obs
interp
Histology
MM+MiS 13;
BCC: 45
Benign: 390
BCC: 45/448;
10%
BCC: 1 MM
was FP
 
Hacioglu
2013
Any
Referred
(selected on
reference) (u)
 
WPC
NR-CS
Turkey
Secondary
76 / 80
Patients with
skin lesions <12
mm diameter
suspicious for
malignancy;
lesions that had
a crusted or
rough surface
were excluded.
NB aim is
diagnose non
melanoma skin
cancers
VI (no
algorithm)
In-person
[Also
evaluates
image-based
dermoscopy
and CAD]
Subjective
impression;
diagnosis of
BCC/cSCC
 
Dermatologist
(assumed) (n =
1; exp NR)
Single observer
Histology
MM 3; BCC 24;
cSCC 3;
basosquamous
2
SK 19; AK 8;
intradermal
nevus 4; DF 3;
KA 2; Other 12
29/80; 36%
 
Study reports 0
excluded from
analysis after
histopathology
results
*3 MM
considered
disease
negative by
authors; cannot
be
disaggregated
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Markowitz
2015
BCC
Equivocal
lesions
(selected on
reference) (u)
 
WPC
P-CS
US
Secondary
100 / 115
Adults with <= 3
suspicious
lesions, if they
had >= 1
clinically
challenging pink
lesion, on the
head or neck,
that was
suspicious for
BCC, and to be
biopsied to rule
BCC in or out,
and if they were
eligible for
Mohs surgery.
 
VI (no
algorithm)
Dermoscopy
(two-step
algorithm
Marghoob
2010)
In-person
[Also
evaluates
OCT]
Possible BCC Dermatologist
(assumed) (n =
NR; exp NR)
Unclear
 
Histology
BCC 70
Benign 45
BCC: 70/115;
61%
None reported
 
Schwartzberg
2005
BCC
Referred
(selected on
reference) (u)
 
WPC-algs
P-CS
US
Secondary
141 / 141
Patients with
suspected BCC
undergoing
biopsy
 
VI (no
algorithm; own
new algorithm)
In-person
BCC certain
or likely
(Confidence
level 1 or 2)
Dermatologist
(assumed) (n =
17; exp NR)
Single
 
Histology
BCC 82
Benign 59
BCC: 82/141;
58%
-
 
 
Stanganelli
2000
BCC
Any
[MM+MiS]
Referred
(unselected
on reference)
(u)
 
WPC
R-CS
Italy
Specialist
clinic
NR / 3372
PSL referred by
dermatologists
and general
practitioners
either for pre-
surgical
assessment or
consultation
1. VI (ABCD)
2.
Dermoscopy
(pattern
analysis)
In person
NR
Subjective
impression
 
NR (assumed
dermatologist -
described as one
of the co-
authors; n = 1)
Single observer
Histology /
Registry FU
MEL 55
BCC 43; Benign
3274
43/3372; 1%
 
None reported
BCC: all MMs
were TN for VI
and for
dermoscopy  
 
Steiner 1987
BCC
Any
[MM+MiS]
Equivocal
(selected on
reference) (u)
 
WPC
P-CS
Austria
Spec.
clinic
NR / 318
 
Small (< 10
mm)
diagnostically
equivocal PSL;
no absolute
agreement on
clinical
diagnosis
among
investigating
clinicians at a
pigmented
lesion clinic.
 
1. VI (no
algorithm)
In-person
[also
evaluated
dermoscopy]
Subjective
impression
 
Dermatologists
(n = 3; High exp
- "experienced
dermatologists")
Consensus of 3
observers
 
Histology
MM 49; MiS 24
BCC 20
BN 143; SK 20;
lentigo simplex
and nevoid
lentigo 19;
Other 15
BCC: 20/318;
9%
 
None reported
Dermoscopy
data excluded
as no
breakdown of
incorrect
diagnoses
BCC (VI): 3
MMs were FP
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Ulrich 2015
BCC
Equivocal
(selected on
reference) (u)
 
WPC
P-CS
Germany
Secondary
155 / 231
Patients with
non-pigmented
pink lesions
with clinical
suspicion of
BCC requiring
biopsy for
diagnostic
confirmation.
Pink lesions
defined as
clinically
unclear
erythematous
papule or
plaque; either
reddish
macules,
patches or
small papules
with or without
scale.
 
VI (no
algorithm)
Dermoscopy
(two-step
algorithm
Marghoob
2012)
In-person
[Also
evaluates
OCT]
 
Clinical
characteristics
of BCC
 
Dermatologist
(assumed) (n =
NR; exp NR)
Single observer
 
Histology
*BCC 141
Benign 94
BCC:141/235;
60%
 
Histology was
missing for 21
lesions, and
one case was
found to have a
combination of
both BCC and
SK or AK,
leaving 235
lesions for
analysis
*231 diagnoses
available for VI
(140 BCC) and
231 for
dermoscopy
(139 BCCs)
 
Image-based evaluations  
 
Altamura
2010
BCC
Referred
(selected on
reference) (c)
 
NC
RP-CCS
Secondary
Italy; Aus;
Austria
NR / 300
Skin lesions
randomly
selected from
digital
databases at
dermatology
departments
and tertiary
referral centre;
all excised
 
Dermoscopy
(Menzies for
BCC (rev))
Image based
(none)
 
Diagnosis of
BCC
 
Dermatologist
(assumed) (n =
3; exp High)
observers
experienced in
dermatoscopic
evaluation
Single observer
Histology
MM 40; MiS 10;
BCC 150; cSCC
2
BN 50; SK 20;
AK 12; DF 10;
Other 6
BCC: 150/300;
50%
MM and cSCC
results not
disaggregated
from Dis neg
group  
 
Carli 2002a
BCC
[MM+MiS]
Referred
(selected on
reference) (u)
 
WPC
R-CS
Italy
Secondary
NR / 256
Clinically
equivocal or
suspicious PSL
subjected to
excisional
biopsy at the
Institute of
Dermatology
 
(Dermoscopy
– image-
based)
In-person
[Also
evaluates in-
person VI and
dermoscopy
(see above)]
Subjective
impression
 
Dermatologist (n
= 2; High exp –
“extensive
experience in
both clinical and
dermoscopic
diagnosis”)
Consensus of 2
 
Histology
MM 40; MiS 14
BCC 5
BN 177; SN 16;
SK 4
BCC: 5/256; 2%
 
None reported
BCC: all
MM+MiS test
negative  
 
Carli 2002b
BCC
Any
[MM+MiS]
Referred
(selected on
reference) (u)
 
WPC
R-CS
Italy
Secondary
NR / 57
Clinically
suspicious or
equivocal PSL
undergoing
excision for
diagnostic
purposes; all <=
14mm diameter
 
1. VI (NR)
2.
Dermoscopy
(NR)
Image-based
(blinded)
NR Dermatologists
(n = 2)
High exp ('with
experience in the
field of ');
consensus of 2
 
Histology
MM 6, MiS 5
BCC 10
BN 31, SK 1;
Other 4
10/57; 18%
4 ‘not
evaluables’
excluded (NB
these differ
between
clinical images
and
dermoscopic
images (1 MM
excluded from
VI analysis)
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Hacioglu
2013
Any
Referred
(selected on
reference) (u)
 
WPC
NR-CS
Turkey
Secondary
76 / 80
Patients with
skin lesions <
12 mm
diameter
suspicious for
malignancy;
lesions that had
a crusted or
rough surface
were excluded.
NB aim is
diagnose non
melanoma skin
cancers
Dermoscopy
(no algorithm)
Image based
(blinded)
[Also
evaluates in-
person VI and
CAD]
Subjective
impression;
diagnosis of
BCC/cSCC
 
Dermatologist
(assumed) (n =
1; exp NR)
Single observer
Histology
MM 3; BCC 24;
cSCC 3;
basosquamous
2
SK 19; AK 8;
intradermal
nevus 4; DF 3;
KA 2; Other 12
29/80; 36%
 
Study reports 0
excluded from
analysis after
histopathology
results
*3 MM
considered
disease
negative by
authors; cannot
be
disaggregated
 
 
Lorentzen
1999
BCC
[MM]
Referred
(selected on
reference) (c)
WPC
P-CS
Specialist
clinic
Denmark
232 / 232
Patients with
lesions
suspicious for
CMM referred
to outpatients
clinic
1. VI (no
algorithm)
2.
Dermoscopy
(no algorithm)
Image based
(clinical image)
subjective
impression;
correct dx of
M
Mixed:
Dermatologist (n
= 4; exp High
(4-5 years daily
experience) &
'non-expert
dermatology
residents' (n = 5;
1-2 years
interest and
formal training in
dermatoscopy)
Average
Histology
MM 49; BCC 16
SK 12; BN 137
Other: 18 (SN,
BD plus others)
BCC: 16/232;
7%
Poor quality
index test image
10 cases
excluded
BCC: MM results
not
disaggregated
 
Lorentzen
2008
BCC
MM
Any
Referred
(selected on
reference) (c)
WPC
NR-CS
Specialist
clinic
Denmark
119 / 119
Patients
referred to the
specialist
naevus clinic;
compared
classic
dermoscopy to
acrylic globe
magnifer
Dermoscopy
(Kenet risk
stratification)
Image based
(blinded)
NR Dermatologist (n
= NR)
Average
Histology
MM 24; BCC 13
BN 69;
Mild//moderate
dysplasia 2; SK
9; Other 2
BCC: 13/119;
11%
1
dermatofibroma
 
Menzies
2000
BCC
Any
[MM-excl]
Referred
(selected on
reference) (u)
 
NC
RP-CCS
Spec.
clinic
Aus; US
Test set:
NR / 213
[Full
sample
426]
 
PSL with
dermoscopic
images and
histological
diagnoses
Dermoscopy
(Menzies for
BCC (new))
Image based
(none)
absence of
pigment
network and
>= 1 other
char present;
Dx
Dermatologist
(assumed) (n =
2; exp NR) NR
 
Histology
MM 71; BCC 71
BN 59; SK 5;
Solar 3; DF 1;
Other 3
BCC: 71/213;
33%
*Included 142
BCCs, 142
invasive
melanomas
and 142
randomly
sampled
benign
BCC: 5 MM
classed as FP
 
#165 Visual examination and dermoscopy, alone or in combination, for the diagnosis of keratinocyte skin cancers in ad...
220 / 231
 
Navarrete
Dechent
2016
BCC
cSCC
Any
[MM+MiS
excl]
Referred
(selected on
reference) (u)
 
NC
RP-CS
Spec clinic
US
NR / 457
Consecutively
excised
nonpigmented
lesions; no
discernible
pigment on
clinical or
dermoscopic
images.
Dermoscopy
(Shiny white
blotches and
strands (new))
Image based
(blinded)
>= 1 char
present
Dermatologist
(assumed) and
medical student
(n = 2; exp NR)
Consensus of 2
Histology
MEL 21; BCC
287; cSCC 106
lichen
planus–like
keratosis 39;
Nevus 4
BCC: 287/457;
63%
cSCC: 106/457;
23%
BCC: 9 MM
and 44 cSCC
were FP
 
 
Nori 2004
BCC
Referred
(selected on
reference) (u)
 
WPC
RP-NR
Secondary
US;Spain
105 (VI)
Full
sample:
145 / 152
Biopsy
confirmed BCC
and
convenience
sample of non-
BCC with 'range
of common
diagnoses';
lesions with
superior clinical
image quality
selected for VI
VI (no
algorithm)
Image based
(blinded)
[Also
evaluates
RCM]
Subjective
impression:
High/Med
probability of
BCC
Dermatologist (n
= 2; exp NR)
Single observer
Histology and
Expert opinion*
BCC 58
Benign 47
[Full sample
includes 83
BCC; 4 SCC; 65
benign]
BCC: 58/105;
55%
 
*15 lesions not
biopsied
because the
clinical
diagnosis was
considered
diagnostic
(e.g.SK)
cSCC results
not
disaggregated
 
 
Rosendahl
2011
BCC
Any
[MM+MiS]
Limited prior
test (selected
on reference)
(u)
 
WPC-algs
R-CS
Aus.
Primary
389 / 463
PSL submitted
for histology
from the
primary care
skin cancer
practice of one
author
 
1. VI (no
algorithm)
2.
Dermoscopy
(pattern; chaos
and clues)
1. subjective
impression
2. NR; both
chars present
 
Dermatologist (n
= 1)
High exp
(confirmed by
author); Single
obs
 
Histology
MM 9; MiS 20
BCC 72; SCC 5
BN 217; BD 18;
AK 14*; BNM
140
* considered
malignant by
study authors
72/463; 16%
 
3 poor quality
images
excluded
BCC (VI): 3
MM were FP
BCC (Derm
chaos/clues):
23 MM/MiS
were FPs
BCC (Pattern):
1 MM was FP
 
 
Witkowski
2016
BCC
cSCC
Any
[MM+MiS
excl]
Equivocal
(selected on
reference) (u)
 
WPC
RP-CS
Secondary
Italy
NR. / 260
Consecutive
clinically
equivocal ‘pink’
cutaneous
lesions with
absent
pigmentation or
containing less
than 10%
pigment and
absence of
pigment
network.
All lesions were
excised at first
visit or follow-up
video
dermoscopy
control visit
 
Dermoscopy
(No algorithm)
Image based
(blinded)
[Also
evaluates
RCM]
 
NR
 
Dermatologist
(assumed) (n =
NR; exp NR)
Single
Histology
MEL 12; BCC
114; cSCC 13;
Other malig 1
BN 47; SN 6;
SL/SK/LPLK/AK
25; DF 18 Other
24
BCC: 114/260;
44%
cSCC: 13/260;
5%
BCC: 1 MM
and 1 cSCC
were FP
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Zalaudek
2006
BCC
Any
[MM+MiS]
Referred
(selected on
reference) (u)
 
NC
R-CS
Specialist
clinic
Italy
NR / 165
Random
sample of
excised,
equivocal and
nonequivocal,
PSL and and
non-PSLs with
melanin or
haemoglobin
pigmentation in
all or part of the
lesion.
 
Dermoscopy
(3PCL)
Image-based
(age, site,
gender)
 
>= 2 chars
present
 
Mixed (n = 150;
exp NR)
Average result
 
Histology
Full sample:
MM 18; MiS 11
BCC: 18
79 BN; 26 SK; 8
vascular; 3 DF
BCC: 18/150;
12%
 
15 used for
training
purposes
BCC: 7 MM
were FP  
Footnotes:
1 Test naïve; 2 Limited prior testing; 3 Limited prior testing (with selection on reference standard); 3* Limited prior testing
(with selection on reference standard and equivocal nature of lesions); 4 Referred for further assessment; 5 Referred for
further assessment (with selection on reference standard); 5* Referred for further assessment (with selection on reference
standard and equivocal nature); 6 Referred for further assessment (equivocal on specialist review); 7 Lesions that have
been undergoing follow-up
c- clearly positioned on clinical pathway; u – unclear position on clinical pathway; NR – not reported; PSL – pigmented skin
lesion; PLC – pigmented lesion clinic; MM – malignant melanoma; MiS – melanoma in situ (or lentigo maligna); BCC –
basal cell carcinoma; cSCC – cutaneous squamous cell carcinoma; LS – lentigo simplex; SK – seborrheic keratosis; SN –
Spitz nevi; AK – actinic keratosis; BN – benign naevi; BD – Bowen’s disease; DF – dermatofibroma; FU – follow-up; R
–retrospective; P – prospective; CS – case series; CCS – case control study; WPC – within person comparison (of tests);
BPC – between person comparison (of tests); NC – non comparative; RCM – reflectance confocal microscopy; CAD –
computer-assisted diagnosis; 7PCL - seven point checklist; 3PCL - three point checklist
 
9 Content of algorithms for BCC
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Menzies algorithm for pigmented
BCC
Menzies 2000
 
Menzies (revised;
pigmented and non-
pigmented BCC)
Altamura 2010
 
Two-step
algorithm
(Marghoob 2010);
non-pigmented
BCC
Markowitz 2015
 
3-point checklist
plus dermoscopic
criteria (pigmented
BCC)
Amirnia 2016
 
Shiny White Structures
(SWSs); non-pigmented
BCC
Navarrete Dechent 2016
No pigment network (Negative
feature absent)
> 1 positive feature present
1. Spoke wheel areas (well-
circumscribed radial projections)
2. Large gray-blue ovoid nests
(well circumscribed, confluent or
near confluent pigmented ovoid
or elongated areas, larger than
globules, not intimately
connected to a pigmented tumor
body
3. Arborizing telangiectasia
(telangiectasia with distinct
treelike branching)
4. Multiple gray-blue globules
(as opposed to multiple gray-
blue dots)
5. Maple leaflike areas (brown to
gray-blue discrete bulbous
extensions forming leaflike
pattern
6. Ulceration (absence of
epidermis often associated with
congealed blood; not due to
recent trauma).
 
'Classic'
BCC
patterns for
pigmented
BCC (Menzies 2000)
1. ulceration,
2. multiple blue/gray
globules,
3. leaflike areas,
4. large blue/gray
ovoid nests,
5. spoke-wheel
areas,
6. arborizing
telangiectasia
Plus 'Non-classic'
patterns
short fine
superficial
telangiectasia,
multiple small
erosions,
concentric
structures,
multiple in-focus
blue/gray dots
 
Dermoscopic
features consistent
with BCC:
arborized
vessels,
pink white shiny
background,
blue/grey ovoid
nests,
ash leaf pattern,
dot-globular-like
pattern,
spoke wheel,
and
crystalline-like
structures
 
1. Asymmetry in
colour or structure
in one or two
orthogonal axis
asymmetric
2. Pigment network
with irregular holes
and thick lines
atypical network
3. Any kind of blue
or white colour
Blue - white
structures
Dermoscopic
criteria of BCC
tree-like arteries
blue-grey points
 
SWSs were classified as
1. blotches (clods; discrete,
small or large structure-less
areas);
2. strands (long thick or thin
lines, randomly distributed or
parallel, not orthogonally
oriented);
3. rosettes (cluster of 4 white
dots in a 4-leaf clover–like
arrangement); and
4. short white lines
(crystalline structures and
chrysalis; fine lines that
intersect or are oriented
orthogonally to each other)
5. non-specified.
All lesions also evaluated for
Menzies 2000 criteria;
‘featureless’ lesions further
evaluated for:
short fine telangiectasias;
multiple in-focus, blue-
gray dots;
multiple small erosions;
and
concentric structures
BCC - basal cell carcinoma
10 Forest plots for covariate investigations by prevalence and use of an algorithm
Figure 23; Figure 24
Graphs
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